<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003039.pub2" GROUP_ID="GYNAECA" ID="916900071216091247" MERGED_FROM="" MODIFIED="2016-07-27 10:45:50 +0100" MODIFIED_BY="Clare Jess" REVIEW_NO="D009" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2016-07-27 10:45:37 +0100" MODIFIED_BY="Clare Jess">
<TITLE MODIFIED="2014-06-18 16:57:06 +0100" MODIFIED_BY="[Empty name]">Colony-stimulating factors for chemotherapy-induced febrile neutropenia</TITLE>
<CONTACT MODIFIED="2016-07-27 10:45:37 +0100" MODIFIED_BY="Clare Jess"><PERSON ID="13680" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Otavio</FIRST_NAME><MIDDLE_INITIALS>Augusto Camara</MIDDLE_INITIALS><LAST_NAME>Clark</LAST_NAME><POSITION>CEO</POSITION><EMAIL_1>otavio.clark@evidencias.com.br</EMAIL_1><EMAIL_2>otavioclark@uol.com.br</EMAIL_2><ADDRESS><ORGANISATION>Evidências- A Kantar Health Company</ORGANISATION><ADDRESS_1>R Tranquillo Prosperi, 143</ADDRESS_1><ADDRESS_2>Campinas</ADDRESS_2><CITY>São Paulo</CITY><ZIP>13084-778</ZIP><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 193 287 8310</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2016-07-27 10:45:37 +0100" MODIFIED_BY="Clare Jess"><PERSON ID="44145014117833128947091001144555" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Rahul</FIRST_NAME><LAST_NAME>Mhaskar</LAST_NAME><EMAIL_1>rmhaskar@health.usf.edu</EMAIL_1><ADDRESS><DEPARTMENT>Center for Evidence Based Medicine and Health Outcomes Research</DEPARTMENT><ORGANISATION>University of South Florida</ORGANISATION><CITY>Tampa</CITY><REGION>Florida</REGION><COUNTRY CODE="US">USA</COUNTRY></ADDRESS></PERSON><PERSON ID="13680" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Otavio</FIRST_NAME><MIDDLE_INITIALS>Augusto Camara</MIDDLE_INITIALS><LAST_NAME>Clark</LAST_NAME><POSITION>CEO</POSITION><EMAIL_1>otavio.clark@evidencias.com.br</EMAIL_1><EMAIL_2>otavioclark@uol.com.br</EMAIL_2><ADDRESS><ORGANISATION>Evidências- A Kantar Health Company</ORGANISATION><ADDRESS_1>R Tranquillo Prosperi, 143</ADDRESS_1><ADDRESS_2>Campinas</ADDRESS_2><CITY>São Paulo</CITY><ZIP>13084-778</ZIP><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 193 287 8310</PHONE_1></ADDRESS></PERSON><PERSON ID="13706" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Gary</FIRST_NAME><LAST_NAME>Lyman</LAST_NAME><POSITION>Professor of Medicine and Co-Director HICOR</POSITION><EMAIL_1>glyman@fhcrc.org</EMAIL_1><ADDRESS><DEPARTMENT>University of Washington</DEPARTMENT><ORGANISATION>Fred Hutchinson Cancer Research Center</ORGANISATION><ADDRESS_1>1100 Fairview Ave  N</ADDRESS_1><ADDRESS_2>M3-B232</ADDRESS_2><CITY>Seattle</CITY><ZIP>98109-1024</ZIP><REGION>WA</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 206 667 6670</PHONE_1><PHONE_2>+1 919 724 0038</PHONE_2><FAX_1>+1 216 667 5977</FAX_1></ADDRESS></PERSON><PERSON ID="z1305301055215376084561126017937" ROLE="AUTHOR"><FIRST_NAME>Tobias</FIRST_NAME><LAST_NAME>Engel Ayer Botrel</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Oncologist and Evidence Based Medicine Consultant</POSITION><EMAIL_1>tobias.engel@evidencias.com.br</EMAIL_1><ADDRESS><ORGANISATION>Evidence Based Medicine Consultancy</ORGANISATION><ADDRESS_1>Rua Santo Antônio, apt 902</ADDRESS_1><ADDRESS_2>Poços de Caldas</ADDRESS_2><CITY>Minas Gerais</CITY><ZIP>37701-036</ZIP><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 35 9140 0067</PHONE_1></ADDRESS></PERSON><PERSON ID="z1305151024054703791107539907592" ROLE="AUTHOR"><FIRST_NAME>Luciano</FIRST_NAME><LAST_NAME>Morganti Paladini</LAST_NAME><POSITION>Health Technology Assessment</POSITION><EMAIL_1>luciano.paladini@evidencias.com.br</EMAIL_1><ADDRESS><DEPARTMENT>HTA</DEPARTMENT><ORGANISATION>Evidências</ORGANISATION><ADDRESS_1>Rua dos Pica Paus 1750 ? Al dos Acaris 355</ADDRESS_1><ADDRESS_2>Nova Uberlândia</ADDRESS_2><CITY>Uberlândia</CITY><ZIP>38412-641</ZIP><REGION>Minas Gerais</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>55-34-3224 5791</PHONE_1></ADDRESS></PERSON><PERSON ID="30139973236749609469101201140340" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Benjamin</FIRST_NAME><LAST_NAME>Djulbegovic</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>Distinguished Professor</POSITION><EMAIL_1>bdjulbeg@health.usf.edu</EMAIL_1><EMAIL_2>benjamin.djulbegovic@moffitt.org</EMAIL_2><URL>www.hsc.usf.edu/</URL><ADDRESS><DEPARTMENT>USF Program for Comparative Effectiveness Research &amp; Dpt of Hematology, Moffitt Cancer Ctr</DEPARTMENT><ORGANISATION>University of South Florida &amp; Mofftt Cancer Center</ORGANISATION><CITY>Tampa</CITY><REGION>Florida</REGION><COUNTRY CODE="US">USA</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-10-30 16:12:57 +0000" MODIFIED_BY="Clare Jess">
<UP_TO_DATE>
<DATE DAY="25" MONTH="3" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="25" MONTH="3" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="3" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2003"/>
<LAST_CITATION_ISSUE ISSUE="10" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2016-07-27 10:42:50 +0100" MODIFIED_BY="Clare Jess">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-07-27 10:42:50 +0100" MODIFIED_BY="Clare Jess">
<DATE DAY="27" MONTH="7" YEAR="2016"/>
<DESCRIPTION>
<P>Brief Economic Commentary added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-02-11 12:38:00 +0000" MODIFIED_BY="Tracey Bishop">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-02-11 12:38:00 +0000" MODIFIED_BY="Tracey Bishop">
<DATE DAY="30" MONTH="10" YEAR="2014"/>
<DESCRIPTION>
<P>Minor text amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-10-30 16:13:03 +0000" MODIFIED_BY="Clare Jess">
<DATE DAY="23" MONTH="4" YEAR="2013"/>
<DESCRIPTION>
<P>Review text updated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-10-30 16:13:06 +0000" MODIFIED_BY="Clare Jess">
<DATE DAY="23" MONTH="4" YEAR="2013"/>
<DESCRIPTION>
<P>New search identified one additional study for inclusion. Conclusions unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-02-05 13:56:45 +0000" MODIFIED_BY="Clare Jess">
<DATE DAY="13" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="12" MONTH="7" YEAR="2000"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2012-11-28 16:13:36 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2012-11-28 16:13:36 +0000" MODIFIED_BY="[Empty name]">
<SOURCE>
<NAME>H Lee Moffitt Cancer Center</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2012-11-28 16:13:36 +0000" MODIFIED_BY="[Empty name]">
<NAME>Center for Evidence based Medicine and Health Outcomes Research, University of South Florida</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-07-27 10:43:36 +0100" MODIFIED_BY="Clare Jess">
<SUMMARY MODIFIED="2016-07-27 10:43:36 +0100" MODIFIED_BY="Clare Jess">
<TITLE MODIFIED="2014-07-14 19:53:42 +0100" MODIFIED_BY="[Empty name]">Does administering colony-stimulating factors plus antibiotics in people with fever and low white cell count reduce hospitalization?</TITLE>
<SUMMARY_BODY MODIFIED="2016-07-27 10:43:36 +0100" MODIFIED_BY="Clare Jess">
<P>
<B>Background: </B>People undergoing chemotherapy often experience febrile neutropenia, characterized by a high temperature combined with a low white blood cell count. Febrile neutropenia is a potentially life-threatening condition and requires prompt medical intervention. The standard treatment for febrile neutropenia includes supportive care of fluids, electrolytes (any substance that contains free ions that can conduct electricity given either intravenously or orally) and antibiotics given either orally or intravenously.<B>
<BR/>Review question: </B>Whether colony-stimulating factors (CSFs) (hormones that stimulate the production of white blood cells) added to antibiotics are better than antibiotics alone in the treatment of febrile neutropenia caused by cancer chemotherapy?<BR/>
<B>Literature</B> <B>search date:</B> March 2014 and May 2015 for the economic evaluation. <B>
<BR/>Main findings: </B>We identified 14 randomized controlled trials (RCTs) enrolling a total of 1553 participants. Six trials were funded by industry alone and 3 trials were jointly funded by industry and public sources and only 1 trial was funded by public sources alone. Our study shows that although CSFs do not appear to improve survival, they shorten the amount of time a person spends in hospital and increase their chances that white blood cells will recover to normal levels. It is not clear whether the use of a CSF reduces the number of people who die due to infection. Our study shows that CSFs shorten the time taken for the white blood cells to return to normal levels, recovery from fever and stopping antibiotics. The number of patients suffering from treatment related harms such as blood clots in the veins were similar between patients receiving CSF and antibiotics and antibiotics alone. The number of patients experiencing bone or joint pain or flu-like symptoms was higher among individuals receiving CSF and antibiotics compared with individuals receiving antibiotics alone. No economic evaluations were identified. Several of the included RCTs identified economic benefits regarding a reduction in overall length of stay attributable to the use of CSF plus antibiotics, however they fell short of undertaking a full economic evaluation. <B>
<BR/>Quality of the evidence: </B>The overall methodological quality of included studies was moderate to low.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-07-27 10:43:36 +0100" MODIFIED_BY="Clare Jess">
<ABS_BACKGROUND MODIFIED="2014-06-23 15:12:02 +0100" MODIFIED_BY="Clare Jess">
<P>Febrile neutropenia is a frequent adverse event experienced by people with cancer who are undergoing chemotherapy, and is a potentially life-threatening situation. The current treatment is supportive care plus antibiotics. Colony-stimulating factors (CSFs), such as granulocyte-CSF (G-CSF) and granulocyte-macrophage CSF (GM-CSF), are cytokines that stimulate and accelerate the production of one or more cell lines in the bone marrow. Clinical trials have addressed the question of whether the addition of a CSF to antibiotics could improve outcomes in individuals diagnosed with febrile neutropenia. However, the results of these trials are conflicting.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-06-23 15:12:20 +0100" MODIFIED_BY="Clare Jess">
<P>To evaluate the safety and efficacy of adding G-CSF or GM-CSF to standard treatment (antibiotics) when treating chemotherapy-induced febrile neutropenia in individuals diagnosed with cancer.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-07-27 10:43:36 +0100" MODIFIED_BY="Clare Jess">
<P>We conducted the search in March 2014 and covered the major electronic databases: the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, LILACS, and SCI. We contacted experts in hematology and oncology and also scanned the citations from the relevant articles. In addition, we also searched for economic evaluations via MEDLINE(R) In-Process &amp; Other Non-Indexed Citations, Embase, CENTRAL and NHS Economic Evaluation Database in May 2015 to support a Brief Economic Commentary (BEC).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2016-07-27 10:43:36 +0100" MODIFIED_BY="Clare Jess">
<P>We searched for randomized controlled trials (RCTs) and economic evaluations that compared CSF plus antibiotics versus antibiotics alone for the treatment of chemotherapy-induced febrile neutropenia in adults and children.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-07-18 15:24:06 +0100" MODIFIED_BY="[Empty name]">
<P>We used the standard methodological procedures expected by The Cochrane Collaboration. We performed meta-analysis of the selected studies using Review Manager 5 software.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-07-27 10:43:36 +0100" MODIFIED_BY="Clare Jess">
<P>Fourteen RCTs (15 comparisons) including a total of 1553 participants addressing the role of CSF plus antibiotics in febrile neutropenia were included. Overall mortality was not improved by the use of CSF plus antibiotics versus antibiotics alone (hazard ratio (HR) 0.74 (95% confidence interval (CI) 0.47 to 1.16) P = 0.19; 13 RCTs; 1335 participants; low quality evidence). A similar finding was seen for infection-related mortality (HR 0.75 (95% CI 0.47 to 1.20) P = 0.23; 10 RCTs; 897 participants; low quality evidence). Individuals who received CSF plus antibiotics were less likely to be hospitalized for more than 10 days (risk ratio (RR) 0.65 (95% CI 0.44 to 0.95) P = 0.03; 8 RCTs; 1221 participants; low quality evidence) and had more number of participants with a more faster neutrophil recovery (RR 0.52 (95% CI 0.34 to 0.81) P = 0.004; 5 RCTs; 794 participants; moderate quality evidence) than those treated with antibiotics alone. Similarly, participants receiving CSF plus antibiotics had shorter duration of neutropenia (standardized mean difference (SMD) -1.70 (95% CI -2.65 to -0.76) P = 0.0004; 9 RCTs; 1135 participants; moderate quality evidence), faster recovery from fever (SMD -0.49 (95% CI -0.90 to -0.09) P value = 0.02; 9 RCTs; 966 participants; moderate quality evidence) and shorter duration of antibiotics use (SMD -1.50 (95% CI -2.83 to -0.18) P = 0.03; 3 RCTs; 457 participants; low quality evidence) compared with participants receiving antibiotics alone. We found no significant difference in the incidence of deep venous thromboembolism (RR 1.68 (95% CI 0.72 to 3.93) P = 0.23; 4 RCTs; 389 participants; low quality evidence) in individuals treated with CSF plus antibiotics compared with those treated with antibiotics alone. We found higher incidence of bone or joint pain or flu-like symptoms (RR 1.59 (95% CI 1.04 to 2.42) P = 0.03; 6 RCTs; 622 participants; low quality evidence) in individuals treated with CSF plus antibiotics compared with those treated with antibiotics alone. Overall, the methodological quality of studies was moderate to low across different outcomes. The main reasons to downgrade the quality of evidence were inconsistency across the included studies and imprecision of results. No full economic evaluations were identified. Several of the included RCTs identified economic benefits regarding a reduction in overall length of stay attributable to the use of CSF plus antibiotics, however they fell short of undertaking a full economic evaluation.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-07-27 10:43:36 +0100" MODIFIED_BY="Clare Jess">
<P>The use of a CSF plus antibiotics in individuals with chemotherapy-induced febrile neutropenia had no effect on overall mortality, but reduced the amount of time participants spent in hospital and improved their ability to achieve neutrophil recovery. It was not clear whether CSF plus antibiotics had an effect on infection-related mortality. Participants receiving CSFs had shorter duration of neutropenia, faster recovery from fever and shorter duration of antibiotics use. The current scarcity of relevant economic evaluations highlights an evidence gap and the need for further research fully explore the cost-effectiveness of these treatment alternatives.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-07-27 10:43:36 +0100" MODIFIED_BY="Clare Jess">
<BACKGROUND MODIFIED="2016-07-27 10:43:36 +0100" MODIFIED_BY="Clare Jess">
<CONDITION MODIFIED="2016-07-27 10:43:36 +0100" MODIFIED_BY="Clare Jess">
<P>Febrile neutropenia is a relatively frequent event in people with cancer receiving chemotherapy. It is a potentially life-threatening condition and requires prompt medical intervention (<LINK REF="REF-Pizzo-1999" TYPE="REFERENCE">Pizzo 1999</LINK>). Febrile neutropenia is one of the most concerning complications of cancer chemotherapy and is a major cause of morbidity, healthcare resource use and compromised efficacy resulting from delays and dose reductions in chemotherapy. Mortality from febrile neutropenia has diminished steadily but remains significant. Overall mortality rates are around 5% in people with solid tumours (1% in low-risk people) and as high as 11% in people diagnosed with some hematological malignancies. Prognosis is worst in people with proven bacteremia, with mortality rates of 18% and 5% reported in people with Gram-negative and Gram-positive bacteremia, respectively. Elderly people are at a higher risk of febrile neutropenia following chemotherapy, with worse morbidity and mortality rates (<LINK REF="REF-de-Naurois-2010" TYPE="REFERENCE">de Naurois 2010</LINK>).</P>
<P>Chemotherapy-induced febrile neutropenia is a potentially life-threatening complication for which the incidence and mortality varies according to cancer type and chemotherapy regimen. The economic burden of the complication has been estimated in the literature, however, estimated costs are variable. One study suggests that for solid tumour patients within a routine oncology hospital setting the average cost per episode is $3855<SUP>*</SUP> (2013 US$) (<SUP>*</SUP>adjusted from 2007 GBP to 2014 US$ using CCEMG-EPPI cost conversion tool (<A HREF="http://eppi.ioe.ac.uk/costconversion/default.aspx">http://eppi.ioe.ac.uk/costconversion/default.aspx</A>) (<LINK REF="REF-Schelenz-2012" TYPE="REFERENCE">Schelenz 2012</LINK>) whilst a review of cost-of-illness studies in lymphoma patients experiencing febrile neutropenia found large variation in the cost estimates ranging from $5819 to $34,756 (2013 US$) per episode (<LINK REF="REF-Wang-2015" TYPE="REFERENCE">Wang 2015</LINK>) </P>
</CONDITION>
<INTERVENTION MODIFIED="2014-06-23 15:14:00 +0100" MODIFIED_BY="Clare Jess">
<P>The standard treatment for febrile neutropenia includes supportive care plus broad-spectrum antibiotics (<LINK REF="REF-Pizzo-1999" TYPE="REFERENCE">Pizzo 1999</LINK>). There is no consensus in the literature as to which antibiotics or combination of antibiotics is ideal for the treatment for febrile neutropenia (<LINK REF="REF-Giamerellou-2001" TYPE="REFERENCE">Giamerellou 2001</LINK>). Hematopoietic growth-stimulating factors are a class of cytokines that regulate the proliferation, differentiation, and functions of hematopoietic cells (<LINK REF="REF-Griffin-2001" TYPE="REFERENCE">Griffin 2001</LINK>). More than 20 different types of stimulating factor have been identified (<LINK REF="REF-Griffin-2001" TYPE="REFERENCE">Griffin 2001</LINK>) and many have been tested in clinical studies for different applications (<LINK REF="REF-Griffin-2001" TYPE="REFERENCE">Griffin 2001</LINK>; <LINK REF="REF-Segal-2001" TYPE="REFERENCE">Segal 2001</LINK>). Among them, granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) have been studied in people with cancer because of their potential effect on neutropenia.</P>
</INTERVENTION>
<THEORY MODIFIED="2014-06-23 15:14:19 +0100" MODIFIED_BY="Clare Jess">
<P>G-CSF regulates the production of the neutrophil lineage. The administration of G-CSF to humans results in a dose-dependent increase in circulating neutrophils (<LINK REF="REF-Griffin-2001" TYPE="REFERENCE">Griffin 2001</LINK>; <LINK REF="REF-Petros-2001" TYPE="REFERENCE">Petros 2001</LINK>), due mainly to a reduction in transit time from stem cell to mature neutrophil (<LINK REF="REF-Griffin-2001" TYPE="REFERENCE">Griffin 2001</LINK>). GM-CSF stimulates the growth of granulocyte, macrophage and eosinophil colonies (<LINK REF="REF-Griffin-2001" TYPE="REFERENCE">Griffin 2001</LINK>; <LINK REF="REF-Petros-2001" TYPE="REFERENCE">Petros 2001</LINK>). The administration of GM-CSF to humans results in a dose-dependent increase in blood neutrophils, eosinophils, macrophages and sometimes lymphocytes (<LINK REF="REF-Griffin-2001" TYPE="REFERENCE">Griffin 2001</LINK>; <LINK REF="REF-Petros-2001" TYPE="REFERENCE">Petros 2001</LINK>). Different types of G-CSF and GM-CSF have been tested in clinical trials and are available. Among the most used G-CSFs are filgrastim and lenograstim, and among the most used GM-CSFs are sargramostim and molgramostim. Both G-CSFs and GM-CSFs have been demonstrated to be effective in reducing the incidence of febrile neutropenia when given immediately after chemotherapy (<LINK REF="REF-Freyer-1998" TYPE="REFERENCE">Freyer 1998</LINK>; <LINK REF="REF-Lyman-2002" TYPE="REFERENCE">Lyman 2002</LINK>) and as supportive therapy in people undergoing bone marrow transplantation (<LINK REF="REF-Griffin-2001" TYPE="REFERENCE">Griffin 2001</LINK>; <LINK REF="REF-Petros-2001" TYPE="REFERENCE">Petros 2001</LINK>). The known effect of G-CSF and GM-CSF in increasing the number of circulating neutrophils provided the background for clinical studies designed to assess their role as adjunct therapy to antibiotics in people diagnosed with febrile neutropenia.</P>
</THEORY>
<IMPORTANCE MODIFIED="2014-10-22 11:31:52 +0100" MODIFIED_BY="Clare Jess">
<P>The results of randomized controlled trials (RCTs) addressing the role of CSFs in the management of febrile neutropenia have not been clear and conflicting findings have been published. Whereas two studies found no significant effect of CSFs in the prevention of prolonged hospitalization (<LINK REF="STD-Anaissie-1996" TYPE="STUDY">Anaissie 1996</LINK>; <LINK REF="STD-Maher-1994" TYPE="STUDY">Maher 1994</LINK>), Another reported CSFs to have a significant impact on length of hospitalization (<LINK REF="STD-Riikonen-1994" TYPE="STUDY">Riikonen 1994</LINK>). Time to recovery from fever was favorably affected by CSF in two studies (<LINK REF="STD-Mayordomo-1995" TYPE="STUDY">Mayordomo 1995</LINK>; <LINK REF="STD-Ravaud-1998" TYPE="STUDY">Ravaud 1998</LINK>) but not in another (<LINK REF="STD-Vellenga-1996" TYPE="STUDY">Vellenga 1996</LINK>). Also, different results regarding the use of CSFs have been reported in people classified as having a low or high baseline risk of developing a life-threatening complication (<LINK REF="STD-Ravaud-1998" TYPE="STUDY">Ravaud 1998</LINK>). Individually, these studies included fewer than 220 participants, and this factor, in addition to reported low rates of clinical events such as death, means that they may have been underpowered to detect a difference between the treated groups. Conflicting results obtained from small studies demands the conduct of a systematic review of the literature (<LINK REF="REF-Egger-2001" TYPE="REFERENCE">Egger 2001</LINK>) in order to extend the totality of evidence to allow informed medical decision. Accordingly, in 2000, we conducted and published a Cochrane systematic review addressing the role of CSF plus antibiotics versus antibiotics alone in individuals with chemotherapy-induced febrile neutropenia (<LINK REF="REF-Clark-2000" TYPE="REFERENCE">Clark 2000</LINK>). However, since the publication of this review, further RCTs in this area have been published. This gave us an impetus to update our previous systematic review.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-06-23 15:15:12 +0100" MODIFIED_BY="Clare Jess">
<P>To evaluate the safety and efficacy of adding G-CSF or GM-CSF to standard treatment (antibiotics) when treating chemotherapy-induced febrile neutropenia in individuals diagnosed with cancer.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-07-27 10:43:36 +0100" MODIFIED_BY="Clare Jess">
<SELECTION_CRITERIA MODIFIED="2016-07-27 10:43:36 +0100" MODIFIED_BY="Clare Jess">
<CRIT_STUDIES MODIFIED="2016-07-27 10:43:36 +0100" MODIFIED_BY="Clare Jess">
<P>We included all randomized controlled trials (RCTs) with a parallel design that compared the use of a CSF plus antibiotics versus antibiotics alone for the treatment of individuals with established chemotherapy-induced febrile neutropenia. We also looked for full economic evaluations.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-10-20 13:06:19 +0100" MODIFIED_BY="Clare Jess">
<P>Individuals undergoing chemotherapy for cancer who experienced neutropenia (absolute neutrophil count (ANC) less than 1 x 10<SUP>9</SUP>/L (1000/mm<SUP>3</SUP>)) and fever (body temperature higher than 38.5°C on one occasion or higher than 38°C on two or more occasions).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-06-23 15:21:18 +0100" MODIFIED_BY="Clare Jess">
<P>Intervention group: G-CSF or GM-CSF plus antibiotics</P>
<P>Control group: antibiotics plus no further treatment or placebo</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-10-10 17:24:08 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2012-10-31 14:26:09 +0000" MODIFIED_BY="Clare Jess">
<UL>
<LI>Overall mortality</LI>
<LI>Infection-related mortality</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-10-10 17:24:08 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Number of people hospitalized for more than 10 days</LI>
<LI>Time to neutrophil recovery (number of people with neutropenia (ANC &lt; 1000/mm<SUP>3</SUP>) for more than 5 to 10 days)</LI>
<LI>Duration (measured in days) of grade IV neutropenia (ANC &lt; 500/mm<SUP>3</SUP>)</LI>
<LI>Time to recovery from fever</LI>
<LI>Time to withdrawal from antibiotics</LI>
<LI>Time to defervescence (the abatement of a fever due to a decrease in body temperature)</LI>
<LI>Treatment-related harms, including deep vein thrombosis (DVT) and bone, joint pain or flu like symptoms</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-07-27 10:43:36 +0100" MODIFIED_BY="Clare Jess">
<ELECTRONIC_SEARCHES MODIFIED="2016-07-27 10:43:36 +0100" MODIFIED_BY="Clare Jess">
<P>We performed a wide search on the main computerized databases of interest. For the original review, the search dates were: the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 1, 2003), MEDLINE (1966 to 2002), EMBASE (1974 to 2001), LILACS (1980 to 2003), CANCERLIT (1975 to 2002), and SCI (1974 to 2001).</P>
<P>For this update, we extended the searches to: CENTRAL (Issue 3 of 12, March 2014; searched 25 March 2014), MEDLINE (2002 to 2014; searched 25 March 2014), EMBASE (2001 to 2014), LILACS (2014), CANCERLIT (2002 to 2004; now incorporated into MEDLINE), and SCI (2001 to 2014).</P>
<P>For MEDLINE, we used the methodological search strategy for RCTs (<LINK REF="REF-Dickersin-1994" TYPE="REFERENCE">Dickersin 1994</LINK>) recommended by The Cochrane Collaboration (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>). For EMBASE, we used adaptations of this same strategy and for LILACS we used the methodological search strategy reported by <LINK REF="REF-Castro-1999" TYPE="REFERENCE">Castro 1999</LINK>. We performed an additional search of the SCI database to look for studies that had cited the included studies (see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>; <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>; <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>; <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>; <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>; <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for the respective search strategies).</P>
<P>The search strategies used have been developed and executed by the author team.</P>
<P>For economic evaluations we used the non-methodological portion of the original search strategies in combination with a economic evaluation filter (<LINK REF="APP-07" TYPE="APPENDIX">Appendix 7</LINK>) for all databases except NHS EED since this database only contains economic evaluation citations.The following databases were searched: Ovid MEDLINE(R) In-Process &amp; Other Non-Indexed Citations and Ovid MEDLINE(R)1946 to May 2015, Embase 1974 to 2015 Week 24, EBM Reviews - Cochrane Central Register of Controlled Trials May 2015 and EBM Reviews - NHS Economic Evaluation Database 2nd Quarter 2015.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-06-23 15:22:57 +0100" MODIFIED_BY="Clare Jess">
<P>We scanned all the references of relevant articles and retrieved all additional articles of potential interest for further analysis.<BR/>We consulted experts in oncology and hematology about ongoing studies or studies that have not yet been published. We also scanned the personal collections of articles of two of the authors (GL and BD).</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-07-27 10:43:36 +0100" MODIFIED_BY="Clare Jess">
<STUDY_SELECTION MODIFIED="2014-10-22 11:48:27 +0100" MODIFIED_BY="Clare Jess">
<P>Two review authors (OACC and RM) independently scanned the retrieved titles and abstracts of all studies for their eligibility for inclusion in the systematic review. We resolved any disagreements in the selection of studies by consensus (<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>). At every stage of searching and screening, we documented the overall number of studies identified, excluded, and included, with reasons, according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines, which we also used to create a flow diagram (<LINK REF="REF-Moher-2009" TYPE="REFERENCE">Moher 2009</LINK>).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-10-22 12:03:13 +0100" MODIFIED_BY="Clare Jess">
<P>Two review authors (OACC and RM) independently extracted data using a standardized data extraction form. From each relevant trial, we retrieved data on the selected clinical outcomes, methodological characteristics, and types of participants in each study. Specifically we extracted data on the following.</P>
<SUBSECTION>
<HEADING LEVEL="4">Clinical outcomes</HEADING>
<UL>
<LI>Mortality - overall and infection related</LI>
<LI>Number of people hospitalized for more than 10 days</LI>
<LI>Time to neutrophil recovery (number of people with neutropenia (ANC &lt; 1000/mm<SUP>3</SUP>) for more than 5 to 10 days)</LI>
<LI>Duration of grade IV neutropenia (Data reported in individual studies as either median days to recovery to ANC &gt; 500/mm<SUP>3 </SUP>or median days of grade IV neutropenia: ANC &lt; 500/mm<SUP>3</SUP>)</LI>
<LI>Time to recovery from fever</LI>
<LI>Time to withdrawal from antibiotics</LI>
<LI>Time to defervescence (the abatement of a fever due to a decrease in body temperature)</LI>
<LI>Treatment-related harms, including deep DVT and bone, joint pain or flu like symptoms</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Additional data</HEADING>
<UL>
<LI>General information on the study: authors, date of publication, title, publication type (full text, abstract, unpublished), number of centers involved, and funding source</LI>
<LI>Study characteristics: inclusion/exclusion criteria, length of follow up, diagnostic criteria for neutropenia (ANC), criteria for hospital discharge</LI>
<LI>Participant characteristics: age, adults versus children, gender, number of participants recruited/allocated/evaluated, participants lost to follow up, type of tumour (solid versus hematological)</LI>
<LI>Intervention: detailed description of both the intervention and standard treatment in terms of:</LI>
<UL>
<LI>type of CSF used with dosage and duration;</LI>
<LI>type of antibiotics used with dosage and duration</LI>
</UL>
</UL>
<P>Studies reported data for the outcome of time to neutrophil recovery in the form of number of participants with neutropenia for more than 5 to 10 days. Accordingly, we extracted data in the form of number of participants with neutropenia for 5 to 10 days in both the experimental and control arms and have reported risk ratio (RR) and 95% confidence intervals (CIs).</P>
<P>Studies reported data for the outcome of duration of grade IV neutropenia in the form of median days to recovery to ANC &gt; 500/mm<SUP>3 </SUP>or median days of grade IV neutropenia: ANC &lt; 500/mm<SUP>3</SUP>. Accordingly, we extracted data in the form of mean and standard deviation of duration of neutropenia in both the experimental and control arms and have reported standardized mean difference (SMD) and 95%CIs.</P>
<P>When time-to-event data were not available for direct extraction, we extracted data according to the methods described by Tierney et al (<LINK REF="REF-Tierney-2007" TYPE="REFERENCE">Tierney 2007</LINK>). These methods allow the calculation of the hazard ratio (HR) and associated statistics using indirect calculation of the variance and the number of observed minus expected events, based on parameters reported in the included studies (e.g. P values, log-rank statistics, or survival curves).</P>
<P>We extracted details regarding the main methodological dimensions empirically linked to bias (<LINK REF="REF-Egger-2001" TYPE="REFERENCE">Egger 2001</LINK>) and two review authors assessed the methodological quality of each selected trial. We gave special attention to the generation of randomization sequence, allocation concealment, blinding, use of intention-to-treat (ITT) versus per-protocol analyses, and source of funding. We used these data in sensitivity analyses to test the robustness of our findings.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Data management</HEADING>
<P>Two review authors manually extracted data from publications into a standardized data extraction form. A third review author validated the extracted data. We resolved all disagreements at each step by consensus or, where necessary, by consulting a third reviewer. One review author entered data into Review Manager (<LINK REF="REF-Review-Manager-5.3" TYPE="REFERENCE">Review Manager 5.3</LINK>) and another checked the entries for accuracy, consistency, and completeness. Senior review authors randomly reviewed 15% of the data for accuracy.</P>
</SUBSECTION>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-10-22 11:48:21 +0100" MODIFIED_BY="Clare Jess">
<P>Two review authors independently assessed all eligible studies for their risk of bias (assessment of methodological quality) using methods suggested in Chapter 8 of the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011c" TYPE="REFERENCE">Higgins 2011c</LINK>). The summary judgment of the review authors comprised an answer for each risk criterion, based on the following three-point scale:</P>
<UL>
<UL>
<LI>yes (low risk of bias: plausible bias unlikely to seriously alter the results if all criteria were met);</LI>
<LI>no (high risk of bias: plausible bias that seriously weakens confidence in the results if one or more criteria were not met);</LI>
<LI>unclear (uncertain risk of bias: plausible bias that raises some doubt about the results if one or more criteria were assessed as unclear).</LI>
</UL>
</UL>
<P>The following items were included in the assessment of risk of bias:</P>
<UL>
<LI>sequence generation (whether allocation sequence was adequately generated);</LI>
<LI>allocation concealment (whether allocation was adequately concealed);</LI>
<LI>masking/blinding (whether the knowledge of the allocated intervention was adequately prevented during the study; i.e. we extracted data regarding who (participants, personnel, outcome assessors, data analysts) was blinded);</LI>
<LI>incomplete outcome data (whether incomplete outcome data were adequately addressed);</LI>
<LI>selective outcome reporting (whether reports of the study were free of selective outcome reporting);</LI>
<LI>other sources of bias (whether reports of the study included pre specification of the expected difference in the primary outcome (delta), alpha error, beta error or sample size calculation);</LI>
<LI>ITT analysis (whether ITT analysis was undertaken in the study).</LI>
</UL>
<P>In addition, we assessed whether domains related to random error and sample size were specified <I>a priori</I> in each trial.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2014-07-25 20:39:20 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>For dichotomous outcomes (e.g. treatment-related harms), data were summarized as RR with 95% CIs for each trial</LI>
<LI>For time-to-event outcome (e.g. overall mortality), data were summarized as HRs and 95% CIs</LI>
<LI>For continuous outcomes (e.g. time to withdrawal from antibiotics), data were summarized as means and standard deviations for each trial. Where data were reported as median and range, we converted these data into mean and standard deviation using the method by Hozo et al (<LINK REF="REF-Hozo-2005" TYPE="REFERENCE">Hozo 2005</LINK>).</LI>
</UL>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2014-10-22 11:48:08 +0100" MODIFIED_BY="Clare Jess">
<P>The unit of analysis was a study from which aggregate data were extracted as follows: for dichotomous variables, the number of participants in the 'CSF plus antibiotics' arm (intervention group) and the number of participants in the 'antibiotics alone' arm (control group). For continuous variables, the means, standard deviations, and the numbers of participants in the intervention and control groups were used. For studies with multiple intervention groups, we included each pair-wise comparison separately. Hence, for dichotomous outcomes, both the number of events and the total number of participants were divided for the control arm (ATB alone). Similarly, for time-to-event outcomes, the number of events and the total number of participants were divided for the control arm and the variance and number of observed minus expected events were calculated separately for each comparison. For continuous outcomes, the total number of participants was divided for the control arm, and means and standard deviations were calculated separately for each comparison (<LINK REF="REF-Higgins-2011d" TYPE="REFERENCE">Higgins 2011d</LINK>).</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2014-06-23 15:24:33 +0100" MODIFIED_BY="Clare Jess">
<P>Where necessary outcome data were not available from the primary literature we requested missing data or complementary information from the first or corresponding authors of such publications.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2014-10-22 11:48:32 +0100" MODIFIED_BY="Clare Jess">
<P>We assessed heterogeneity among trials and between subgroups using a Chi<SUP>2</SUP> test with a P value of &lt; 0.10 as the level of significance. The degree of heterogeneity among trials and between subgroups was also assessed using the I² statistic. We used the following guide to the interpretation of the I² statistic: I² = 0% to 40%: heterogeneity that might not be important; I² = 30% to 60%: moderate heterogeneity; I² = 50% to 90%: substantial heterogeneity), I² = 75% to 100%: considerable heterogeneity (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>). The importance of the observed value of I<SUP>2</SUP> depends on (i) the magnitude and direction of effects and (ii) the strength of evidence for the heterogeneity (e.g. a P value from the Chi<SUP>2</SUP> test, or the I<SUP>2 </SUP>statistic). When heterogeneity was detected, we searched intensively for a possible explanation.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2014-10-22 11:48:32 +0100" MODIFIED_BY="Clare Jess">
<P>We assessed the possibility of publication bias by generating a funnel plot and by conducting a linear regression test using a P value of &lt; 0.1 as the level of significance (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>; <LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2016-07-27 10:43:36 +0100" MODIFIED_BY="Clare Jess">
<P>We conducted meta analyses using <LINK REF="REF-Review-Manager-5.3" TYPE="REFERENCE">Review Manager 5.3</LINK> software by the Cochrane Collaboration (<LINK REF="REF-Review-Manager-5.3" TYPE="REFERENCE">Review Manager 5.3</LINK>). For the outcomes of number of participants hospitalized for more than 10 days, time to neutrophil recovery (reported as number of people with neutropenia (ANC &lt; 1000/mm<SUP>3</SUP>) for more than 5 to 10 days), DVT and bone and joint pain, or flu-like symptoms we calculated the RRs with 95% CIs and pooled the data using the Mantel&#8211;Haenszel random-effects model. For the outcomes of overall mortality and infection-related mortality we calculated the observed minus expected log-rank statistics plus the variance, according to the methods described by Tierney et al (<LINK REF="REF-Tierney-2007" TYPE="REFERENCE">Tierney 2007</LINK>), and presented the results (pooled using a random effects model and inverse variance method) as HRs (<LINK REF="REF-Tierney-2007" TYPE="REFERENCE">Tierney 2007</LINK>). For the outcomes of duration of grade IV neutropenia, time to recovery from fever and time to withdrawal from antibiotics we calculated the standardized mean differences with 95% CIs and pooled the data using the random-effects model and inverse variance method. We provided a 'Summary of findings' table, produced using Grading of Recommendations Assessment, Development and Evaluation (GRADE) software (<LINK REF="REF-GRADEpro" TYPE="REFERENCE">GRADEpro</LINK>; <LINK REF="REF-Guyatt-2011" TYPE="REFERENCE">Guyatt 2011</LINK>; <LINK REF="REF-Guyatt-2011a" TYPE="REFERENCE">Guyatt 2011a</LINK>; <LINK REF="REF-Guyatt-2011b" TYPE="REFERENCE">Guyatt 2011b</LINK>; <LINK REF="REF-Guyatt-2011c" TYPE="REFERENCE">Guyatt 2011c</LINK>; <LINK REF="REF-Guyatt-2011d" TYPE="REFERENCE">Guyatt 2011d</LINK>; <LINK REF="REF-Guyatt-2011e" TYPE="REFERENCE">Guyatt 2011e</LINK>).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2014-07-18 17:03:54 +0100" MODIFIED_BY="[Empty name]">
<P>We performed subgroup analyses on the following clinical characteristics:</P>
<UL>
<LI>age group: use of CSF in children versus adults;</LI>
<LI>type of CSF used;</LI>
<LI>criteria for hospital discharge and</LI>
<LI>type of tumor: mix versus hematological versus solid tumors.</LI>
</UL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2014-06-23 15:24:33 +0100" MODIFIED_BY="Clare Jess">
<P>We assessed the robustness of our results by conducting a sensitivity analysis with respect to the methodological quality of the included RCTs.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-07-27 10:43:36 +0100" MODIFIED_BY="Clare Jess">
<STUDY_DESCRIPTION MODIFIED="2016-07-27 10:43:36 +0100" MODIFIED_BY="Clare Jess">
<P>Fourteen RCTs addressing the role of CSF in chemotherapy-induced febrile neutropenia, involving a total of 1553 participants, were included in the final analysis. See '(<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>)' and '(<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>)' tables for details. No full economic evaluations were identified.</P>
<SUBSECTION>
<HEADING LEVEL="3">Randomization of participants versus episodes of febrile neutropenia</HEADING>
<P>A particular difficulty with trials of febrile neutropenia is the problem of re-randomization (<LINK REF="REF-Paesmans-1998" TYPE="REFERENCE">Paesmans 1998</LINK>). This practice has the potential to bias the results of clinical trials because of the possible dependence of outcomes on previous events. People who have already developed one episode of febrile neutropenia are expected to be more prone to develop another, which in turn may violate the assumption that all events must be independent of each other to allow proper analysis of a trial as well as the pooling of data in meta-analysis (<LINK REF="REF-Hozo-2005a" TYPE="REFERENCE">Hozo 2005a</LINK>). Five included trials (<LINK REF="STD-Anaissie-1996" TYPE="STUDY">Anaissie 1996</LINK>; <LINK REF="STD-Lopez_x002d_Hernandez-2000" TYPE="STUDY">Lopez-Hernandez 2000</LINK>; <LINK REF="STD-Mitchell-1997" TYPE="STUDY">Mitchell 1997</LINK>; <LINK REF="STD-Riikonen-1994" TYPE="STUDY">Riikonen 1994</LINK>; <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>) allowed people to be entered in the study and randomized more than once. These trials analysed 419 episodes of febrile neutropenia and are responsible for about one-quarter of the total number of febrile neutropenia episodes and people included in this systematic review. It was impossible to extract data from these trials according to the number of people. As the practice of re-randomization is allowed by the Immunocompromised Host Society (<LINK REF="REF-IHS-1990" TYPE="REFERENCE">IHS 1990</LINK>), we included these trials in our analyses.</P>
</SUBSECTION>
<SEARCH_RESULTS MODIFIED="2014-10-20 13:34:45 +0100" MODIFIED_BY="Clare Jess">
<P>For this update we extended our search from the end of the search date in the original review to March 2014. We identified 1007 papers investigating G-CSF or GM-CSF in chemotherapy-induced febrile neutropenia in our updated search of electronic databases. We did not identify any studies through other search methods. We selected and retrieved 12 articles for full-text analysis. Of those identified, we excluded 11 for various reasons. We had excluded 21 studies in the original review process. Hence the total number of excluded studies from both reviews is 32 (<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). Thus, in addition to the 13 studies included in the original review, we included 1 new study (<LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>), bringing the included total to 14 (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> for details).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-06-23 15:24:33 +0100" MODIFIED_BY="Clare Jess">
<P>Seven articles described the effects of G-CSF (<LINK REF="STD-Aviles-1996" TYPE="STUDY">Aviles 1996</LINK>; <LINK REF="STD-Garcia_x002d_Carbonero-2001" TYPE="STUDY">Garcia-Carbonero 2001</LINK>; <LINK REF="STD-Lopez_x002d_Hernandez-2000" TYPE="STUDY">Lopez-Hernandez 2000</LINK>; <LINK REF="STD-Maher-1994" TYPE="STUDY">Maher 1994</LINK>; <LINK REF="STD-Mitchell-1997" TYPE="STUDY">Mitchell 1997</LINK>; <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK> <LINK REF="STD-Yoshida-1999" TYPE="STUDY">Yoshida 1999</LINK>), six described the effects of GM-CSF (<LINK REF="STD-Anaissie-1996" TYPE="STUDY">Anaissie 1996</LINK>; <LINK REF="STD-Arnberg-1998" TYPE="STUDY">Arnberg 1998</LINK>; <LINK REF="STD-Biesma-1990" TYPE="STUDY">Biesma 1990</LINK>; <LINK REF="STD-Ravaud-1998" TYPE="STUDY">Ravaud 1998</LINK>; <LINK REF="STD-Riikonen-1994" TYPE="STUDY">Riikonen 1994</LINK>; <LINK REF="STD-Vellenga-1996" TYPE="STUDY">Vellenga 1996</LINK>) and one was a three-arm study in which participants were randomized to G-CSF, GM-CSF or placebo (<LINK REF="STD-Mayordomo-1995" TYPE="STUDY">Mayordomo 1995</LINK>). Six articles included people with an ANC less than 1 x 10<SUP>9</SUP>/L (<LINK REF="STD-Anaissie-1996" TYPE="STUDY">Anaissie 1996</LINK>; <LINK REF="STD-Arnberg-1998" TYPE="STUDY">Arnberg 1998</LINK>; <LINK REF="STD-Biesma-1990" TYPE="STUDY">Biesma 1990</LINK>; <LINK REF="STD-Maher-1994" TYPE="STUDY">Maher 1994</LINK>; <LINK REF="STD-Ravaud-1998" TYPE="STUDY">Ravaud 1998</LINK>; <LINK REF="STD-Yoshida-1999" TYPE="STUDY">Yoshida 1999</LINK>), six included people with an ANC less than 0.5 x 10<SUP>9</SUP>/L (<LINK REF="STD-Garcia_x002d_Carbonero-2001" TYPE="STUDY">Garcia-Carbonero 2001</LINK>; <LINK REF="STD-Lopez_x002d_Hernandez-2000" TYPE="STUDY">Lopez-Hernandez 2000</LINK>; <LINK REF="STD-Mayordomo-1995" TYPE="STUDY">Mayordomo 1995</LINK>; <LINK REF="STD-Mitchell-1997" TYPE="STUDY">Mitchell 1997</LINK>; <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>; <LINK REF="STD-Vellenga-1996" TYPE="STUDY">Vellenga 1996</LINK>), one included those with an ANC less than 0.2 x 10<SUP>9</SUP>/L (<LINK REF="STD-Riikonen-1994" TYPE="STUDY">Riikonen 1994</LINK>) and one included participants with an ANC less than 0.1 x 10<SUP>9</SUP>/L (<LINK REF="STD-Aviles-1996" TYPE="STUDY">Aviles 1996</LINK>). Ten articles enrolled adults (<LINK REF="STD-Anaissie-1996" TYPE="STUDY">Anaissie 1996</LINK>; <LINK REF="STD-Arnberg-1998" TYPE="STUDY">Arnberg 1998</LINK>; <LINK REF="STD-Aviles-1996" TYPE="STUDY">Aviles 1996</LINK>; <LINK REF="STD-Biesma-1990" TYPE="STUDY">Biesma 1990</LINK>; <LINK REF="STD-Garcia_x002d_Carbonero-2001" TYPE="STUDY">Garcia-Carbonero 2001</LINK>; <LINK REF="STD-Maher-1994" TYPE="STUDY">Maher 1994</LINK>; <LINK REF="STD-Mayordomo-1995" TYPE="STUDY">Mayordomo 1995</LINK>; <LINK REF="STD-Ravaud-1998" TYPE="STUDY">Ravaud 1998</LINK>; <LINK REF="STD-Vellenga-1996" TYPE="STUDY">Vellenga 1996</LINK>; <LINK REF="STD-Yoshida-1999" TYPE="STUDY">Yoshida 1999</LINK>), three enrolled children (<LINK REF="STD-Mitchell-1997" TYPE="STUDY">Mitchell 1997</LINK>; <LINK REF="STD-Riikonen-1994" TYPE="STUDY">Riikonen 1994</LINK>; <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>) and one included both (<LINK REF="STD-Lopez_x002d_Hernandez-2000" TYPE="STUDY">Lopez-Hernandez 2000</LINK>). Three articles enrolled participants with hematological malignancies only (<LINK REF="STD-Aviles-1996" TYPE="STUDY">Aviles 1996</LINK>; <LINK REF="STD-Lopez_x002d_Hernandez-2000" TYPE="STUDY">Lopez-Hernandez 2000</LINK>; <LINK REF="STD-Yoshida-1999" TYPE="STUDY">Yoshida 1999</LINK>), one solid tumors only (<LINK REF="STD-Ravaud-1998" TYPE="STUDY">Ravaud 1998</LINK>) and ten articles included people with either type of malignancy (<LINK REF="STD-Anaissie-1996" TYPE="STUDY">Anaissie 1996</LINK>; <LINK REF="STD-Arnberg-1998" TYPE="STUDY">Arnberg 1998</LINK>; <LINK REF="STD-Biesma-1990" TYPE="STUDY">Biesma 1990</LINK>; <LINK REF="STD-Garcia_x002d_Carbonero-2001" TYPE="STUDY">Garcia-Carbonero 2001</LINK>; <LINK REF="STD-Maher-1994" TYPE="STUDY">Maher 1994</LINK>; <LINK REF="STD-Mayordomo-1995" TYPE="STUDY">Mayordomo 1995</LINK>; <LINK REF="STD-Mitchell-1997" TYPE="STUDY">Mitchell 1997</LINK>; <LINK REF="STD-Riikonen-1994" TYPE="STUDY">Riikonen 1994</LINK>; <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>; <LINK REF="STD-Vellenga-1996" TYPE="STUDY">Vellenga 1996</LINK>).</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-10-20 14:27:51 +0100" MODIFIED_BY="Clare Jess">
<P>A total of 21 studies were excluded after full text review in the original version of this review. Eight of these 21 excluded studies were duplicate reports (<LINK REF="STD-Bodey-1994" TYPE="STUDY">Bodey 1994</LINK>; <LINK REF="STD-Garcia_x002d_Carb-1999a" TYPE="STUDY">Garcia-Carb 1999a</LINK>; <LINK REF="STD-Garcia_x002d_Carb-1999b" TYPE="STUDY">Garcia-Carb 1999b</LINK>; <LINK REF="STD-Mayordomo-1992" TYPE="STUDY">Mayordomo 1992</LINK>; <LINK REF="STD-Mayordomo-1993" TYPE="STUDY">Mayordomo 1993</LINK>; <LINK REF="STD-Ravaud-1995" TYPE="STUDY">Ravaud 1995</LINK>; <LINK REF="STD-Uyl_x002d_de-Groot-1997" TYPE="STUDY">Uyl-de Groot 1997</LINK>; <LINK REF="STD-Vellenga-1996b" TYPE="STUDY">Vellenga 1996b</LINK>). In this update we excluded 11 studies after the full text review. The study by Montalar was published in abstract form only and no information on outcomes was available (<LINK REF="STD-Montalar-1998" TYPE="STUDY">Montalar 1998</LINK>). We tried to contact the authors of this abstract by e-mail, but received no answer. Therefore, this trial was excluded from our analysis. We excluded the trial by (<LINK REF="STD-Timmer_x002d_Bonte-2005" TYPE="STUDY">Timmer-Bonte 2005</LINK>) as it is a randomized trial addressing the prophylactic role of G-CSF.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-07-18 17:04:31 +0100" MODIFIED_BY="[Empty name]">
<P>Results of the 'Risk of bias' assessments are presented in (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). The overall methodological quality of included studies for the majority of outcomes we judged to be low according to GRADE methodology (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<ALLOCATION MODIFIED="2014-07-18 17:04:18 +0100" MODIFIED_BY="[Empty name]">
<P>Three of the included studies described an adequate method of randomization (<LINK REF="STD-Anaissie-1996" TYPE="STUDY">Anaissie 1996</LINK>; <LINK REF="STD-Garcia_x002d_Carbonero-2001" TYPE="STUDY">Garcia-Carbonero 2001</LINK>; <LINK REF="STD-Lopez_x002d_Hernandez-2000" TYPE="STUDY">Lopez-Hernandez 2000</LINK>) and five reported adequate concealment of the sequence of allocation (<LINK REF="STD-Aviles-1996" TYPE="STUDY">Aviles 1996</LINK>; <LINK REF="STD-Garcia_x002d_Carbonero-2001" TYPE="STUDY">Garcia-Carbonero 2001</LINK>; <LINK REF="STD-Maher-1994" TYPE="STUDY">Maher 1994</LINK>; <LINK REF="STD-Mayordomo-1995" TYPE="STUDY">Mayordomo 1995</LINK>; <LINK REF="STD-Mitchell-1997" TYPE="STUDY">Mitchell 1997</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2014-06-23 15:24:33 +0100" MODIFIED_BY="Clare Jess">
<P>Six trials were blinded (<LINK REF="STD-Arnberg-1998" TYPE="STUDY">Arnberg 1998</LINK>; <LINK REF="STD-Biesma-1990" TYPE="STUDY">Biesma 1990</LINK>; <LINK REF="STD-Maher-1994" TYPE="STUDY">Maher 1994</LINK>; <LINK REF="STD-Mitchell-1997" TYPE="STUDY">Mitchell 1997</LINK>; <LINK REF="STD-Riikonen-1994" TYPE="STUDY">Riikonen 1994</LINK>; <LINK REF="STD-Vellenga-1996" TYPE="STUDY">Vellenga 1996</LINK>). Eight trials did not employ blinding in the conduct of the trial (<LINK REF="STD-Anaissie-1996" TYPE="STUDY">Anaissie 1996</LINK>; <LINK REF="STD-Aviles-1996" TYPE="STUDY">Aviles 1996</LINK>; <LINK REF="STD-Garcia_x002d_Carbonero-2001" TYPE="STUDY">Garcia-Carbonero 2001</LINK>; <LINK REF="STD-Lopez_x002d_Hernandez-2000" TYPE="STUDY">Lopez-Hernandez 2000</LINK>; <LINK REF="STD-Mayordomo-1995" TYPE="STUDY">Mayordomo 1995</LINK>; <LINK REF="STD-Ravaud-1998" TYPE="STUDY">Ravaud 1998</LINK>; <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>; <LINK REF="STD-Yoshida-1999" TYPE="STUDY">Yoshida 1999</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2014-06-23 15:24:33 +0100" MODIFIED_BY="Clare Jess">
<P>An ITT analysis was performed in ten trials (<LINK REF="STD-Anaissie-1996" TYPE="STUDY">Anaissie 1996</LINK>; <LINK REF="STD-Arnberg-1998" TYPE="STUDY">Arnberg 1998</LINK>; <LINK REF="STD-Garcia_x002d_Carbonero-2001" TYPE="STUDY">Garcia-Carbonero 2001</LINK>; <LINK REF="STD-Maher-1994" TYPE="STUDY">Maher 1994</LINK>; <LINK REF="STD-Mayordomo-1995" TYPE="STUDY">Mayordomo 1995</LINK>; <LINK REF="STD-Mitchell-1997" TYPE="STUDY">Mitchell 1997</LINK>; <LINK REF="STD-Ravaud-1998" TYPE="STUDY">Ravaud 1998</LINK>; <LINK REF="STD-Vellenga-1996" TYPE="STUDY">Vellenga 1996</LINK>; <LINK REF="STD-Yoshida-1999" TYPE="STUDY">Yoshida 1999</LINK>; <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2014-07-18 17:04:31 +0100" MODIFIED_BY="[Empty name]">
<P>We did not have access to the trial protocols therefore we were unable to investigate the potential for selective reporting bias based only on trial publications.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2014-07-16 15:46:06 +0100" MODIFIED_BY="[Empty name]">
<P>Seven trials were placebo controlled (<LINK REF="STD-Arnberg-1998" TYPE="STUDY">Arnberg 1998</LINK>; <LINK REF="STD-Biesma-1990" TYPE="STUDY">Biesma 1990</LINK>; <LINK REF="STD-Maher-1994" TYPE="STUDY">Maher 1994</LINK>; <LINK REF="STD-Mayordomo-1995" TYPE="STUDY">Mayordomo 1995</LINK>; <LINK REF="STD-Mitchell-1997" TYPE="STUDY">Mitchell 1997</LINK>; <LINK REF="STD-Riikonen-1994" TYPE="STUDY">Riikonen 1994</LINK>; <LINK REF="STD-Vellenga-1996" TYPE="STUDY">Vellenga 1996</LINK>). A sample size was preplanned in seven (<LINK REF="STD-Garcia_x002d_Carbonero-2001" TYPE="STUDY">Garcia-Carbonero 2001</LINK>; <LINK REF="STD-Maher-1994" TYPE="STUDY">Maher 1994</LINK>; <LINK REF="STD-Mayordomo-1995" TYPE="STUDY">Mayordomo 1995</LINK>; <LINK REF="STD-Mitchell-1997" TYPE="STUDY">Mitchell 1997</LINK>; <LINK REF="STD-Ravaud-1998" TYPE="STUDY">Ravaud 1998</LINK>; <LINK REF="STD-Vellenga-1996" TYPE="STUDY">Vellenga 1996</LINK>; <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>), but the planned number was not reached in one trial (<LINK REF="STD-Ravaud-1998" TYPE="STUDY">Ravaud 1998</LINK>).</P>
<P>Seven trials were multicentric studies (<LINK REF="STD-Garcia_x002d_Carbonero-2001" TYPE="STUDY">Garcia-Carbonero 2001</LINK>; <LINK REF="STD-Maher-1994" TYPE="STUDY">Maher 1994</LINK>; <LINK REF="STD-Mitchell-1997" TYPE="STUDY">Mitchell 1997</LINK>; <LINK REF="STD-Ravaud-1998" TYPE="STUDY">Ravaud 1998</LINK>; <LINK REF="STD-Riikonen-1994" TYPE="STUDY">Riikonen 1994</LINK>; <LINK REF="STD-Vellenga-1996" TYPE="STUDY">Vellenga 1996</LINK>; <LINK REF="STD-Yoshida-1999" TYPE="STUDY">Yoshida 1999</LINK>).</P>
<P>We noted that one of the studies reported a much higher rate of mortality in the control group than in the intervention group (<LINK REF="STD-Aviles-1996" TYPE="STUDY">Aviles 1996</LINK>). Because of this, and because of a lack of description of important baseline characteristics of the people in both groups, concerns regarding the comparability of the study arms in this trial (<LINK REF="STD-Aviles-1996" TYPE="STUDY">Aviles 1996</LINK>) have been raised in the literature (<LINK REF="REF-Rubenstein-2000" TYPE="REFERENCE">Rubenstein 2000</LINK>).<BR/>
</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-10-30 14:27:12 +0000" MODIFIED_BY="[Empty name]">
<P>Our analysis included 14 trials (15 comparisons) involving a total of 1553 participants, 797 of whom were randomized to the intervention group and 756 to the control group. Not all trials provided data on all endpoints.</P>
<SUBSECTION>
<HEADING LEVEL="3">Overall mortality</HEADING>
<P>Data on overall mortality could be extracted from 13 trials (14 comparisons) with 1335 participants. The meta-analysis showed a statistically non significant trend of a benefit favoring the intervention group (HR 0.74, 95% CI 0.47 to 1.16; P = 0.19) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). No heterogeneity was detected in the analysis (P = 0.53, I<SUP>2 </SUP>= 0%). There were 35 deaths among 688 participants randomized to the intervention group and 45 among 647 randomized to the control group. However, it is important to note that 33% (15 of 45) of the events in the control group were reported in one study (<LINK REF="STD-Aviles-1996" TYPE="STUDY">Aviles 1996</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Infection-related mortality</HEADING>
<P>We could extract data on infection-related mortality from 10 trials (11 comparisons) with 897 participants. The meta-analysis showed a statistically non-significant trend in favor of CSF use (HR 0.75, 95% CI 0.47 to 1.20; P = 0.23) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). No heterogeneity was detected (P = 0.33, I<SUP>2 </SUP>= 12%). There were 15 infection-related deaths among the 471 participants randomized to the intervention group and 25 among 426 randomized to the control group. However, it is important to note that 60% (15 of 25) of the events in the control group were reported in one study (<LINK REF="STD-Aviles-1996" TYPE="STUDY">Aviles 1996</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Participants hospitalized for more than 10 days</HEADING>
<P>Data regarding the number of participants hospitalized for more than 10 days were extracted from eight trials (nine comparisons) that included 1221 participants. The pooled analysis showed a benefit in favor of the intervention group (RR 0.65, 95% CI 0.44 to 0.95; P = 0.03) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). Substantial heterogeneity was detected (P = 0.002, I<SUP>2 </SUP>= 69%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Time to neutrophil recovery (number of participants with neutropenia (ANC &lt; 1000/mm<SUP>3</SUP>) for more than 5 to 10 days)</HEADING>
<P>Data regarding the number of participants with neutropenia (ANC &lt; 1000/mm<SUP>3</SUP>) for more than 5 days were extracted from five trials (six comparisons) with a total of 794 participants. The pooled analysis revealed a significant effect of CSF plus antibiotics versus the antibiotics alone (RR 0.52, 95% CI 0.34 to 0.81; P = 0.004) for the outcome of time to neutrophil recovery (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). There was substantial heterogeneity among these trials (P = 0.006, I<SUP>2 </SUP>= 70%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Duration of grade IV neutropenia</HEADING>
<P>Data were extracted from nine trials (10 comparisons), with a total of 1135 participants, for the outcome of duration of grade IV neutropenia. A significant effect of CSF plus antibiotics was detected compared with the control group (SMD = -1.70, 95% CI -2.65 to -0.76; P = 0.0004) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). There was considerable heterogeneity among these trials (P &lt; 0.00001, I<SUP>2 </SUP>= 98%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Time to recovery from fever</HEADING>
<P>Data were extracted from nine trials (10 comparisons), with a total of 966 participants, for the outcome of time to recovery from fever. A significant effect of CSF plus antibiotics was detected compared with the control group (SMD -0.49, 95% CI -0.90 to -0.09; P = 0.02) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). There was considerable heterogeneity among these trials (P &lt; 0.00001, I<SUP>2 </SUP>= 89%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Time to withdrawal from antibiotics</HEADING>
<P>Data were extracted from three trials, with a total of 457 participants, for the outcome of time to withdrawal from antibiotics. A significant effect of CSF plus antibiotics was detected compared with antibiotics alone (SMD -1.50, 95% CI -2.83 to -0.18; P = 0.03) (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>). There was considerable heterogeneity among these trials (P &lt; 0.00001, I<SUP>2 </SUP>= 97%).</P>
<SUBSECTION>
<HEADING LEVEL="4">Treatment-related harms</HEADING>
<P>Treatment-related harms were poorly reported in the included studies. We could only extract data related to DVT, and bone pain, joint pain and flu-like symptoms from the included studies. Moreover, there was significant variation in the methods used by the authors to report treatment-related harms.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Deep vein thrombosis</HEADING>
<P>The number of participants developing DVT could be extracted from four studies with 389 participants. There were 9 cases of DVT among 194 participants randomized to the intervention group and 5 among 195 controls. The difference between the groups was not statistically significant (RR 1.68, 95% CI 0.72 to 3.93; P = 0.23) (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>). No heterogeneity was detected (P = 0.62, I<SUP>2 </SUP>= 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Bone and joint pain, and flu-like symptoms</HEADING>
<P>Data on these outcomes could be extracted from six studies (seven comparisons) with 622 participants. Forty-nine participants developed these symptoms from 328 participants randomized to the intervention group versus 25 of 294 randomized to the control group. The difference between the groups were statistically significant (RR 1.59, 95% CI 1.04 to 2.42; P = 0.03) indicating higher incidence of these events with use of CSF plus antibiotics compared with use of antibiotics alone (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>). No statistically significant heterogeneity was detected (P = 0.52, I<SUP>2 </SUP>= 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analyses</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Study population</HEADING>
<P>Our results did not change based on the study population (adults only versus children versus mixed) for any of the outcomes (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>; <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>). We noticed a statistically significant subgroup differences between trials with adult population (RR 0.45 (95% CI 0.29 to 0.70); 4 RCTs; 608 participants) (<LINK REF="STD-Garcia_x002d_Carbonero-2001" TYPE="STUDY">Garcia-Carbonero 2001</LINK>; <LINK REF="STD-Maher-1994" TYPE="STUDY">Maher 1994</LINK>; <LINK REF="STD-Mayordomo-1995" TYPE="STUDY">Mayordomo 1995</LINK>; <LINK REF="STD-Ravaud-1998" TYPE="STUDY">Ravaud 1998</LINK>) versus trial enrolling only children (RR 0.80 (95% CI 0.66 to 0.97); 1 RCT; 186 participants) (<LINK REF="STD-Mitchell-1997" TYPE="STUDY">Mitchell 1997</LINK>) for the outcome of time to neutrophil recovery with a stronger benefit for adults (test of interaction P = 0.02) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>). However, both trials (enrolling adults and children) favored use of antibiotics and CSF compared with antibiotics alone, but a stronger effect was seen among adult population.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Type of CSF</HEADING>
<P>Our results did not change based on the type of CSF (G-CSF and GM-CSF) for any of the outcomes (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>; <LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>; <LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>). We noticed a statistically significant subgroup differences between trials with G-CSF (SMD -2.73 (95% CI -4.43 to -1.04); 5 RCTs; 784 participants) (<LINK REF="STD-Aviles-1996" TYPE="STUDY">Aviles 1996</LINK>; <LINK REF="STD-Garcia_x002d_Carbonero-2001" TYPE="STUDY">Garcia-Carbonero 2001</LINK>; <LINK REF="STD-Maher-1994" TYPE="STUDY">Maher 1994</LINK>; <LINK REF="STD-Mayordomo-1995" TYPE="STUDY">Mayordomo 1995</LINK>; <LINK REF="STD-Mitchell-1997" TYPE="STUDY">Mitchell 1997</LINK>) versus trials with GM-CSF (SMD -0.67 (95% CI -1.12 to -0.22); 5 RCTs; 351 participants) (<LINK REF="STD-Biesma-1990" TYPE="STUDY">Biesma 1990</LINK>; <LINK REF="STD-Mayordomo-1995" TYPE="STUDY">Mayordomo 1995</LINK>; <LINK REF="STD-Ravaud-1998" TYPE="STUDY">Ravaud 1998</LINK>; <LINK REF="STD-Riikonen-1994" TYPE="STUDY">Riikonen 1994</LINK>; <LINK REF="STD-Vellenga-1996" TYPE="STUDY">Vellenga 1996</LINK>) for the outcome of duration of grade IV neutropenia (ANC &lt; 500/mm<SUP>3</SUP>) with stronger benefit with G-CSF (test of interaction P = 0.02) (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>). However, both CSF types (G-CSF and GM-CSF) plus antibiotics were statistically significantly superior to antibiotics alone for this outcome but a stronger effect was observed with G-CSF use.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Hospital discharge criteria</HEADING>
<P>We also tested a possible impact of criteria for discharge from hospital on various outcomes. The criteria of discharge after 24 hours of resolution of fever was employed by one study (<LINK REF="STD-Ravaud-1998" TYPE="STUDY">Ravaud 1998</LINK>). Three studies used the criteria of discharge after 48 hours of resolution of fever (<LINK REF="STD-Biesma-1990" TYPE="STUDY">Biesma 1990</LINK>; <LINK REF="STD-Garcia_x002d_Carbonero-2001" TYPE="STUDY">Garcia-Carbonero 2001</LINK>; <LINK REF="STD-Mayordomo-1995" TYPE="STUDY">Mayordomo 1995</LINK>). Three studies used the criteria of discharge after 72 hours of resolution of fever (<LINK REF="STD-Mitchell-1997" TYPE="STUDY">Mitchell 1997</LINK>; <LINK REF="STD-Riikonen-1994" TYPE="STUDY">Riikonen 1994</LINK>; <LINK REF="STD-Vellenga-1996" TYPE="STUDY">Vellenga 1996</LINK>). One study used the criteria of discharge after 96 hours of resolution of fever (<LINK REF="STD-Maher-1994" TYPE="STUDY">Maher 1994</LINK>). The study by Rodriguez et al used criteria of discharge after at least 48 to 72 hours of resolution of fever (<LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>). Four studies did not report the hospital discharge criteria (<LINK REF="STD-Anaissie-1996" TYPE="STUDY">Anaissie 1996</LINK>; <LINK REF="STD-Arnberg-1998" TYPE="STUDY">Arnberg 1998</LINK>; <LINK REF="STD-Aviles-1996" TYPE="STUDY">Aviles 1996</LINK>; <LINK REF="STD-Lopez_x002d_Hernandez-2000" TYPE="STUDY">Lopez-Hernandez 2000</LINK>). Different criteria required for hospital discharge (time since defervescence) had no effect on any endpoint (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>; <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>; <LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>). We noticed a statistically significant subgroup differences between these trials based on hospital discharge criteria ((discharge after 24 hrs of resolution of fever: RR 0.54 (95% CI 0.35 to 0.84); 1 RCT; 68 participants); discharge after 48 hrs of resolution of fever: RR 0.14 (95% CI 0.04 to 0.48); 2 RCTs; 324 participants); discharge after 72 hrs of resolution of fever: RR 0.80 (95% CI 0.66 to 0.97); 1 RCT; 186 participants); discharge after 96 hrs of resolution of fever: RR 0.52 (95% CI 0.37 to 0.74); 1 RCT; 216 participants)] for the outcome of time to neutrophil recovery with the strongest benefit with discharge after 48 hours of resolution of fever (test of interaction P = 0.006) (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>). However, all these trials trials with varying hospital discharge criterions (discharge after 24, 48, 72, 96hours post fever resolution) favored use of antibiotics and CSF compared with antibiotics alone.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Type of malignancy</HEADING>
<P>The trials enrolling participants with mixed cancers (<LINK REF="STD-Anaissie-1996" TYPE="STUDY">Anaissie 1996</LINK>; <LINK REF="STD-Garcia_x002d_Carbonero-2001" TYPE="STUDY">Garcia-Carbonero 2001</LINK>; <LINK REF="STD-Maher-1994" TYPE="STUDY">Maher 1994</LINK>; <LINK REF="STD-Mayordomo-1995" TYPE="STUDY">Mayordomo 1995</LINK>; <LINK REF="STD-Mitchell-1997" TYPE="STUDY">Mitchell 1997</LINK>; <LINK REF="STD-Riikonen-1994" TYPE="STUDY">Riikonen 1994</LINK>) favored the use of CSF plus antibiotics (RR 0.64 (95% CI 0.45 to 0.89); 6 RCTs; 884 participants) compared with trial (<LINK REF="STD-Yoshida-1999" TYPE="STUDY">Yoshida 1999</LINK>) enrolling participants with only hematological malignancies (RR 1.17 (95% CI 0.81 to 1.70); 1 RCT; 203 participants) (test of interaction P = 0.02) for the outcome of number of participants hospitalized for more than 10 days (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>). We noticed a statistically significant subgroup differences between trials based on type of malignancy [(mix tumors: SMD -1.50 (95% CI -2.50 to -0.50); 7 RCTs; 948 participants); (hematological malignancies: SMD -4.55 (95% CI -5.24 to -3.86); 1 RCT; 119 participants); (solid tumors: SMD -0.53 (95% CI -1.01 to -0.04); 1 RCT; 68 participants) for the outcome of duration of grade IV neutropenia (ANC &lt; 500/mm<SUP>3</SUP>) with stronger benefit for people with hematological malignancies (test of interaction P &lt; 0.00001) (<LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>). However, all of these trials enrolling participants with various different kinds of cancers (mix versus hematological malignancies versus solid tumors) favored use of antibiotics and CSF compared with antibiotics alone. Our results did not change based on the type of malignancy for any of the other outcomes with significant heterogeneity (<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>; <LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analyses</HEADING>
<P>Our results did not change based on the methodological quality of studies for any outcomes. We have shown the analysis for the outcome of participants hospitalized for more than 10 days for allocation concealment (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>) and blinding (<LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>) for illustration purposes.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-07-27 10:43:36 +0100" MODIFIED_BY="Clare Jess">
<SUMMARY_OF_RESULTS MODIFIED="2016-07-27 10:43:36 +0100" MODIFIED_BY="Clare Jess">
<P>This systematic review summarized the totality of the evidence for the use of CSFs plus antibiotics in the treatment of chemotherapy-induced febrile neutropenia among people with cancer. Overall and infection-related mortality were not influenced by the addition of CSF to antibiotics. Participants treated with a CSF and antibiotics were less likely to be hospitalized for more than 10 days and had more participants with a faster neutrophil recovery than those treated with antibiotics alone. Similarly, people receiving CSF and antibiotics had shorter duration of neutropenia, more rapid recovery from fever and shorter duration of antibiotics use compared with people receiving antibiotics alone. The addition of CSF to antibiotics was well tolerated by participants: we found no significant difference in the incidence of DVT in individuals treated with CSF and antibiotics compared with those treated with antibiotics alone. However, we noticed a higher incidence of bone or joint pain, or flu-like symptoms among participants receiving CSF and antibiotics compared with those receiving antibiotics alone.</P>
<P>In our meta-analysis, a CSF plus antibiotics was found to reduce the number of participants hospitalized for more than 10 days, a finding sustained in subgroup and sensitivity analyses. In particular, when meta-analysis was restricted to trials with an adequate allocation concealment and to double-blind trials, the two most powerful ways of avoiding bias, the result was unchanged (<LINK REF="REF-Mhaskar-2012" TYPE="REFERENCE">Mhaskar 2012</LINK>). The use of different criteria for hospital discharge also had no effect on this outcome. This benefit of CSF in shortening the duration of hospitalization has the potential to further influence current clinical practice. Shortening hospitalization translates into a reduction in costs, but this has to be weighed against the cost of CSF; hence, an cost effectiveness analysis should be performed in the light of this finding. A shorter duration in hospital may also translate into a better quality of life for the individual (<LINK REF="REF-Smeenk-1998" TYPE="REFERENCE">Smeenk 1998</LINK>); however, we did not perform a formal analysis of quality of life.</P>
<P>A link between use of CSFs and an increase in the number of participants achieving neutrophil recovery was expected, but this is the first time that such an increase has been linked to clinical benefit, as defined by a shorter duration of hospitalization. Our findings show the benefit of using CSF in reducing the duration of fever and time to withdrawal from antibiotics. This has the potential to influence the decision about the use of CSFs, since the antibiotics used can be associated with substantial costs. Median time to antibiotic withdrawal was statistically significantly shorter in the intervention group than in the control group in all trials, representing a clinical benefit. Treatment-related harms, such as bone and joint pain, flu-like syndromes, were common and in some reports intense, but were not life-threatening.</P>
<P>In summary, this systematic review highlights the beneficial effect of a CSF added to antibiotics in terms of reducing the duration of hospitalization and expediting neutrophil recovery, compared with antibiotics alone, in participants diagnosed with chemotherapy-induced febrile neutropenia. We think it would be highly desirable that individual patient data meta-analyses is carried out in order to further explore the impact of CSF on overall and infection-related mortality among this group of individuals.</P>
<P>To augment the main clinical effectiveness systematic review we sought to identify economic evaluations, to support a Brief Economic Commentary, that have compared the use of a CSF plus antibiotics versus antibiotics alone for the treatment of individuals with established chemotherapy-induced febrile neutropenia. Systematic supplemental searches were undertaken to identify evaluations relevant to this question. Results were screened using the review inclusion criteria, less study design, however, no full economic evaluations were identified. Several of the included RCTs identified economic benefits regarding a reduction in overall length of stay attributable to the use of CSF plus antibiotics, however they fell short of undertaking a full economic evaluation.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2014-10-22 12:08:18 +0100" MODIFIED_BY="Clare Jess">
<P>Our analysis included 14 trials (15 comparisons) with a total of 1553 participants, 797 of whom were randomized to receive CSF plus antibiotics and 756 to antibiotics alone. For this update we conducted a comprehensive search of the literature without any language restrictions and we believe that there is low risk of potential publication bias and we found no evidence of this via the funnel plots. The conclusions we reach in this analysis have direct application to clinical practice for people diagnosed with chemotherapy-induced febrile neutropenia. Our findings clearly demonstrate the superiority of supplementing antibiotics with a CSF compared with the use of antibiotics alone, with regard to reducing the duration of hospitalization and expediting neutrophil recovery.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2014-10-30 14:44:18 +0000" MODIFIED_BY="[Empty name]">
<P>We assessed the quality of the included trials according to previously described quality domains (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). The majority of included trials were not free of selection bias. Most included studies reported analyses according to the ITT principle, but some were not blinded and had high risks of performance and detection bias. Majority of the included trials were free of other biases. We considered the overall quality of evidence for a majority of the outcomes to be moderate to low across various outcomes according to the The Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). The main reasons to downgrade the quality of evidence were inconsistency across the included studies and imprecision of results.</P>
<P>We noted via a sub-group analysis that participants diagnosed with hematological malignancies appeared to statistically non-significantly benefit more from the addition of CSF to antibiotics than those with solid and mix tumors for the outcome of overall mortality (<LINK REF="CMP-005.05" TYPE="ANALYSIS">Analysis 5.5</LINK>). However, this possible beneficial effect of CSF on mortality in people diagnosed with hematological malignancies was highly influenced by the results of one trial (<LINK REF="STD-Aviles-1996" TYPE="STUDY">Aviles 1996</LINK>). In this study, three times more participants died in the control group than in the intervention group (<LINK REF="STD-Aviles-1996" TYPE="STUDY">Aviles 1996</LINK>). This difference between groups is much higher than that seen in other, similar studies, and concerns regarding the comparability of the two groups investigated in this trial have been raised (<LINK REF="REF-Rubenstein-2000" TYPE="REFERENCE">Rubenstein 2000</LINK>). Also in this trial by Aviles et al all deaths were considered to be due to infection (<LINK REF="STD-Aviles-1996" TYPE="STUDY">Aviles 1996</LINK>). Hence, we recommend caution in drawing a definitive conclusion about a possible beneficial effect of CSF on the outcome of overall mortality in individuals with hematological tumors. We noticed substantial heterogeneity for the outcome of number of participants hospitalized for more than 10 days. We explored the possible causes of heterogeneity to determine whether it was appropriate to pool the trials for this outcome. All trials but one trial (<LINK REF="STD-Yoshida-1999" TYPE="STUDY">Yoshida 1999</LINK>) had a point estimate that favored the intervention group. This trial enrolled only people with hematological malignancies. We explored the impact of type of malignancy on number of participants hospitalized for more than 10 days (<LINK TAG="SUBGROUP_ANALYSIS" TYPE="SECTION">Subgroup analysis and investigation of heterogeneity</LINK>: type of malignancy). We also noticed that only two reached statistical significance (<LINK REF="STD-Maher-1994" TYPE="STUDY">Maher 1994</LINK>; <LINK REF="STD-Mayordomo-1995" TYPE="STUDY">Mayordomo 1995</LINK>). By inspecting the forest plot, we could detect that trial by Mayordomo et al (<LINK REF="STD-Mayordomo-1995" TYPE="STUDY">Mayordomo 1995</LINK>) and Maher et al (<LINK REF="STD-Maher-1994" TYPE="STUDY">Maher 1994</LINK>) indicated a much stronger effect than that detected in all other trials. We therefore repeated our analysis, excluding these trials (<LINK REF="STD-Maher-1994" TYPE="STUDY">Maher 1994</LINK>; <LINK REF="STD-Mayordomo-1995" TYPE="STUDY">Mayordomo 1995</LINK>). The exclusion resulted in a substantial reduction in the statistical heterogeneity (I<SUP>2 </SUP>= 48%; P = 0.10) and the significance of the effect of CSF plus antibiotics on this outcome disappeared (RR 0.85, 95% CI = 0.61 to 1.17; P = 0.32). All but two studies (<LINK REF="STD-Maher-1994" TYPE="STUDY">Maher 1994</LINK>; <LINK REF="STD-Mayordomo-1995" TYPE="STUDY">Mayordomo 1995</LINK>) favored the use of CSF plus antibiotics over the use of antibiotics alone, and the heterogeneity detected was mainly due to a superior effect of CSF plus antibiotics detected in these trials. Hence, our interpretation of these results is that CSF plus antibiotics significantly reduce the number of participants hospitalized for more than 10 days compared to the use of antibiotics alone, but that the magnitude of this effect cannot be precisely estimated using the currently available data. We also noticed considerable heterogeneity for the outcome of time to withdrawal from antibiotics. We noted that in all of the trials for this outcome the mean/median duration of ATB use was similar (mean of 5 days) among patients receiving CSF(<LINK REF="STD-Garcia_x002d_Carbonero-2001" TYPE="STUDY">Garcia-Carbonero 2001</LINK>; <LINK REF="STD-Mitchell-1997" TYPE="STUDY">Mitchell 1997</LINK>; <LINK REF="STD-Ravaud-1998" TYPE="STUDY">Ravaud 1998</LINK>). However, the high precision observed around the effect size in the trial by Garcio-Carbonero et al (<LINK REF="STD-Garcia_x002d_Carbonero-2001" TYPE="STUDY">Garcia-Carbonero 2001</LINK>) compared with other two trial estimates was potentially leading to the substantial heterogeneity. The heterogeneity disappeared completely once we removed this trial from the analysis (P value = 0.72, I<SUP>2 </SUP>= 0%) and the overall effect still showed benefit with the use of CSF plus ATB compared with ATB alone.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2014-07-28 17:04:32 +0100" MODIFIED_BY="[Empty name]">
<P>We did not find any methodological issues in the preparation of the review that could put it at risk for bias.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-10-22 12:13:21 +0100" MODIFIED_BY="Clare Jess">
<P>In 2002, Berghmans et al published a systematic review that addressed the question of the addition of CSF to antibiotics in the treatment of individuals with febrile neutropenia (<LINK REF="REF-Berghmans-2002" TYPE="REFERENCE">Berghmans 2002</LINK>). This systematic review identified 11 trials and performed a meta-analysis of mortality that included nine trials. The RR for mortality was 0.71 (95% CI 0.44 to 1.15). This result is similar to our findings. However, Berghmans et al failed to extract and include mortality data from two studies (<LINK REF="STD-Biesma-1990" TYPE="STUDY">Biesma 1990</LINK>; <LINK REF="STD-Ravaud-1998" TYPE="STUDY">Ravaud 1998</LINK>). In addition, Berghmans et al used a very restricted search strategy (<LINK REF="REF-Berghmans-2002" TYPE="REFERENCE">Berghmans 2002</LINK>): it included only articles in English, published up to 1998, and did not search relevant abstracts and conference proceedings. These restrictions related to the search methods may have led to the failure to include three studies satisfying the study inclusion criteria (<LINK REF="STD-Garcia_x002d_Carbonero-2001" TYPE="STUDY">Garcia-Carbonero 2001</LINK>; <LINK REF="STD-Lopez_x002d_Hernandez-2000" TYPE="STUDY">Lopez-Hernandez 2000</LINK>; <LINK REF="STD-Montalar-1998" TYPE="STUDY">Montalar 1998</LINK>). Although the pooled results for mortality in Berghmans et al do not differ from ours, our analysis is broader (in that we included additional endpoints) and up-to-date (we included the trial by <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>) compared with the systematic review by Berghmans et al (<LINK REF="REF-Berghmans-2002" TYPE="REFERENCE">Berghmans 2002</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-07-27 10:43:36 +0100" MODIFIED_BY="Clare Jess">
<IMPLICATIONS_PRACTICE MODIFIED="2014-10-22 12:04:31 +0100" MODIFIED_BY="Clare Jess">
<P>The use of CSF plus antibiotics in people with chemotherapy-induced febrile neutropenia was not found to improve overall survival compared with antibiotics alone but did reduce the time participants spent in hospital and the duration neutropenia, time to recovering from fever and time to withdrawal from antibiotics. The people receiving CSF plus antibiotics also had a faster neutrophil recovery compared with people receiving antibiotics alone. The incidence of adverse events with CSF in addition to antibiotics appear to be similar compared with antibiotics alone. The impact of CSF plus antibiotics on infection-related mortality was not clear.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-07-27 10:43:36 +0100" MODIFIED_BY="Clare Jess">
<P>Following these results, it is unlikely that future trials will feature a no-treatment control group. To assess the effect of CSF plus antibiotics on mortality therefore, an individual patient data analysis is highly desirable. The current scarcity of relevant economic evaluations highlights an evidence gap and the need for further research fully explore the cost-effectiveness of these treatment alternatives.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-07-27 10:43:36 +0100" MODIFIED_BY="Clare Jess">
<P>We would like to thank Dr Chris Williams for his enthusiastic support at the very beginning of this study; Jane Dennis and Machiko Miyakoshi for translating a Japanese article; and Yemi Agboola for the cooperative effort in locating the studies. We would like to thank Mrs Coralia Vázquez-Otero (from the USF Center for EBM) for translating an article that was published in Spanish.</P>
<P>We would also like to thank the Cochrane Gynaecological, Neuro-oncology and Orphan Cancers Editorial Team for their contribution to the editorial process for the original review and this update.</P>
<P>We would also like to thank Dawn Craig and Luke Vale (Institute of Health &amp; Society, Newcastle University) and Ian Shemilt (Economic and Evidence Synthesis Methodology, EPPI-Centre, University College London) for their help in preparing the Brief Economic Commentary.</P>
<P>This project was supported by the National Institute for Health Research, via Cochrane Infrastructure to the Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-10-22 12:18:59 +0100" MODIFIED_BY="Clare Jess">
<P>OACC - None known<BR/>BD - None known<BR/>TEAB - None known<BR/>GL - PI on research grant to the Fred Hutchinson Cancer Research Center, Seattle, WA, USA<BR/>RM - None known<BR/>LMP - None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-10-21 20:29:27 +0100" MODIFIED_BY="[Empty name]">
<P>For this update: RM performed the search for articles, selected articles, extracted and analyzed data, wrote the first and final draft of the manuscript. OACC, TAEB and LMP performed the search for articles, selected articles, extracted and analyzed data and approved the final version. GL designed the study and approved the final version. OACC and RM performed the search for articles, selected articles, extracted data, and approved the final version. BD designed the study, wrote the protocol, performed the search for articles, selected articles, extracted and analyzed data, wrote the manuscript and approved the final version. </P>
<P>All authors contributed to the analysis and interpretation of data and results.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-05-01 23:16:50 +0100" MODIFIED_BY="[Empty name]">
<P>None</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-07-27 10:45:50 +0100" MODIFIED_BY="Clare Jess">
<STUDIES MODIFIED="2014-10-20 14:27:51 +0100" MODIFIED_BY="Clare Jess">
<INCLUDED_STUDIES MODIFIED="2014-07-14 18:42:46 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Anaissie-1996" MODIFIED="2014-06-19 09:28:12 +0100" MODIFIED_BY="[Empty name]" NAME="Anaissie 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-06-19 09:28:12 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;eng&lt;/p&gt;" NOTES_MODIFIED="2014-06-19 09:28:12 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Anaissie EJ, Vartivarian S, Bodey GP, Legrand C, Kantarjian H, Abi-Said D, et al</AU>
<TI>Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived in cancer patients with fever and neutropenia</TI>
<SO>The American Journal of Medicine</SO>
<YR>1996</YR>
<VL>100</VL>
<NO>1</NO>
<PG>17-23</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163388"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163387"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arnberg-1998" MODIFIED="2014-06-19 09:28:41 +0100" MODIFIED_BY="[Empty name]" NAME="Arnberg 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-06-19 09:28:41 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;eng&lt;/p&gt;" NOTES_MODIFIED="2014-06-19 09:28:41 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arnberg H, Letocha H, Nou F, Westlin JF, Nilsson S</AU>
<TI>GM-CSF in chemotherapy-induced febrile neutropenia - a double-blind randomized study</TI>
<SO>Anticancer Research</SO>
<YR>1998</YR>
<VL>18</VL>
<NO>2B</NO>
<PG>1255-60</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163390"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163389"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aviles-1996" NAME="Aviles 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;eng&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aviles A, Guzman R, Garcia EL, Talavera A, Diaz-Maqueo JC</AU>
<TI>Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia</TI>
<SO>Anticancer Drugs</SO>
<YR>1996</YR>
<VL>7</VL>
<NO>4</NO>
<PG>392-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163392"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163391"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Biesma-1990" MODIFIED="2014-07-14 18:40:41 +0100" MODIFIED_BY="[Empty name]" NAME="Biesma 1990" YEAR="1990">
<REFERENCE MODIFIED="2014-07-14 18:40:41 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;eng&lt;/p&gt;" NOTES_MODIFIED="2014-07-14 18:40:41 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Biesma B, de Vries EG, Willemse PH, Sluiter WJ, Postmus PE, Limburg PC, et al</AU>
<TI>Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever</TI>
<SO>European Journal of Cancer</SO>
<YR>1990</YR>
<VL>26</VL>
<NO>9</NO>
<PG>932-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163394"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163393"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garcia_x002d_Carbonero-2001" MODIFIED="2014-07-14 18:40:54 +0100" MODIFIED_BY="[Empty name]" NAME="Garcia-Carbonero 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-07-14 18:40:54 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Eng&lt;/p&gt;" NOTES_MODIFIED="2014-07-14 18:40:54 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garcia-Carbonero R, Mayordomo JI, Tornamira MV, Lopez-Brea M, Rueda A, Guillem V, et al</AU>
<TI>Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2001</YR>
<VL>93</VL>
<NO>1</NO>
<PG>31-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163396"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163395"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lopez_x002d_Hernandez-2000" MODIFIED="2014-07-14 18:41:07 +0100" MODIFIED_BY="[Empty name]" NAME="Lopez-Hernandez 2000" YEAR="2000">
<REFERENCE MODIFIED="2014-07-14 18:41:07 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;spa&lt;/p&gt;" NOTES_MODIFIED="2014-07-14 18:41:07 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lopez-Hernandez MA, Jimenez-Alvarado R, Borbolla-Escoboza R, de Diego Flores-Chapa J, Alvarado-Ibarra M, Gonzalez-Avante M, et al</AU>
<TI>Granulocyte colony-stimulating factor in the treatment of febrile neutropenia</TI>
<SO>Gaceta Médica de México</SO>
<YR>2000</YR>
<VL>136</VL>
<NO>2</NO>
<PG>99-105</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163398"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163397"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maher-1994" MODIFIED="2014-07-14 18:41:19 +0100" MODIFIED_BY="[Empty name]" NAME="Maher 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-07-14 18:41:19 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;eng&lt;/p&gt;" NOTES_MODIFIED="2014-07-14 18:41:19 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maher DW, Lieschke GJ, Green M, Bishop J, Stuart-Harris R, Wolf M, et al</AU>
<TI>Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1994</YR>
<VL>121</VL>
<NO>7</NO>
<PG>492-501</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163400"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163399"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mayordomo-1995" MODIFIED="2014-07-14 18:41:33 +0100" MODIFIED_BY="[Empty name]" NAME="Mayordomo 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-07-14 18:41:33 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;eng&lt;/p&gt;" NOTES_MODIFIED="2014-07-14 18:41:33 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mayordomo JI, Rivera F, Diaz-Puente MT, Lianes P, Colomer R, Lopez-Brea M, et al</AU>
<TI>Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1995</YR>
<VL>87</VL>
<NO>11</NO>
<PG>803-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163402"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163401"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mitchell-1997" MODIFIED="2014-07-14 18:41:44 +0100" MODIFIED_BY="[Empty name]" NAME="Mitchell 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-07-14 18:41:44 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;eng&lt;/p&gt;" NOTES_MODIFIED="2014-07-14 18:41:44 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mitchell PL, Morland B, Stevens MC, Dick G, Easlea D, Meyer LC, et al</AU>
<TI>Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1997</YR>
<VL>15</VL>
<NO>3</NO>
<PG>1163-70</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163404"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163403"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ravaud-1998" MODIFIED="2014-07-14 18:42:01 +0100" MODIFIED_BY="[Empty name]" NAME="Ravaud 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-07-14 18:42:01 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;eng&lt;/p&gt;" NOTES_MODIFIED="2014-07-14 18:42:01 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ravaud A, Chevreau C, Cany L, Houyau P, Dohollou N, Roche H, et al</AU>
<TI>Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1998</YR>
<VL>16</VL>
<NO>9</NO>
<PG>2930-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163406"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163405"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Riikonen-1994" NAME="Riikonen 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;eng&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riikonen P, Saarinen UM, Makipernaa A, Hovi L, Komulainen A, Pihkala J, Jalanko H</AU>
<TI>Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1994</YR>
<VL>13</VL>
<NO>3</NO>
<PG>197-202</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163408"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163407"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rodriguez-2005" MODIFIED="2014-07-14 18:42:18 +0100" MODIFIED_BY="[Empty name]" NAME="Rodriguez 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-07-14 18:42:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodriguez ZN, Tordecilla CJ, Campbell BM, Joannon SP, Rizzardini LC, Soto AV, et al</AU>
<TI>Usefulness of G-CSF in pediatric high risk cancer patients with fever and neutropenia</TI>
<TO>Utilidad del factor estimulador de colonias de granulocitos (G-CSF) en episodios de neutropenia febril de alto riesgo en ninos con cancer.</TO>
<SO>Revista Chilena de Infectologia</SO>
<YR>2005</YR>
<VL>22</VL>
<NO>3</NO>
<PG>223-7</PG>
<IDENTIFIERS MODIFIED="2012-10-31 17:40:17 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163410"/><IDENTIFIER TYPE="PUBMED" VALUE="16077888"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163409"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vellenga-1996" MODIFIED="2014-07-14 18:42:31 +0100" MODIFIED_BY="[Empty name]" NAME="Vellenga 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-07-14 18:42:31 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;eng&lt;/p&gt;" NOTES_MODIFIED="2014-07-14 18:42:31 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vellenga E, Uyl-de Groot CA, de Wit R, Keizer HJ, Lowenberg B, ten Haaft MA, et al</AU>
<TI>Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1996</YR>
<VL>14</VL>
<NO>2</NO>
<PG>619-27</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163412"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163411"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yoshida-1999" MODIFIED="2014-07-14 18:42:46 +0100" MODIFIED_BY="[Empty name]" NAME="Yoshida 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-07-14 18:42:46 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;eng&lt;/p&gt;" NOTES_MODIFIED="2014-07-14 18:42:46 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yoshida M, Karasawa M, Naruse T, Fukuda M, Hirashima K, Oh H, et al</AU>
<TI>Effect of granulocyte-colony stimulating factor on empiric therapy with flomoxef sodium and tobramycin in febrile neutropenic patients with hematological malignancies. Kan-etsu Hematological Disease and Infection Study Group</TI>
<SO>International Journal of Hematology</SO>
<YR>1999</YR>
<VL>69</VL>
<NO>2</NO>
<PG>81-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163414"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163413"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-10-20 14:27:51 +0100" MODIFIED_BY="Clare Jess">
<STUDY DATA_SOURCE="PUB" ID="STD-Balcerska-1995" MODIFIED="2014-07-17 16:24:37 +0100" MODIFIED_BY="[Empty name]" NAME="Balcerska 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-07-17 16:24:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Balcerska A, Ploszynska A, Polczynska K, Maciejka-Kapuscinska L, Wlazlowski M, Drozynska E, et al</AU>
<TI>The effect of cytokines G-CSF and GM-CSF in therapy of childhood malignancies</TI>
<TO>Ocena Skutecznosci Czynnikow Wzrostu G-CSF I GM-CSF W Leczeniu Wspomagajacym Choroby Nowotworowej U Dzieci</TO>
<SO>Annales Academiae Medicae Gedanensis</SO>
<YR>1995</YR>
<VL>25</VL>
<PG>117-24</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163416"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163415"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beveridge-1998" MODIFIED="2014-07-17 16:27:33 +0100" MODIFIED_BY="[Empty name]" NAME="Beveridge 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-07-14 18:43:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beveridge RA, Miller JA, Kales AN, Binder RA, Robert NJ, Harvey JH, et al</AU>
<TI>A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression</TI>
<SO>Cancer Investigation</SO>
<YR>1998</YR>
<VL>16</VL>
<NO>6</NO>
<PG>366-73</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163418"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163417"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bodey-1994" MODIFIED="2014-07-14 18:43:26 +0100" MODIFIED_BY="[Empty name]" NAME="Bodey 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-07-14 18:43:26 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;eng&lt;/p&gt;" NOTES_MODIFIED="2014-07-14 18:43:26 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bodey GP, Anaissie E, Gutterman J, Vadhan-Raj S</AU>
<TI>Role of granulocyte-macrophage colony-stimulating factor as adjuvant treatment in neutropenic patients with bacterial and fungal infection</TI>
<SO>European Journal of Clinical Microbiology &amp; Infectious Diseases</SO>
<YR>1994</YR>
<VL>13 Suppl 2</VL>
<PG>S18-22</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163420"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163419"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feng-1998" MODIFIED="2014-07-14 18:43:44 +0100" MODIFIED_BY="[Empty name]" NAME="Feng 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-07-14 18:43:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feng F, Zhou L</AU>
<TI>Randomized controlled study of leucomax (recombinant human granulocyte-macrophage colony stimulating factor, rhGM-CSF) in the treatment of cancer chemotherapy-induced leucopenia</TI>
<SO>Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]</SO>
<YR>1998</YR>
<VL>20</VL>
<NO>6</NO>
<PG>451-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163422"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163421"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fengyi-1998" MODIFIED="2014-07-14 18:44:03 +0100" MODIFIED_BY="[Empty name]" NAME="Fengyi 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-07-14 18:44:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fengyi F, Liqiang Z</AU>
<TI>Randomized controlled study of leucomax (recombinant human granulocyte- macrophage colony stimulating factor, rhGM-CSF) in the treatment of cancer chemotherapy-induced leucopenia</TI>
<SO>Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]</SO>
<YR>1998</YR>
<VL>20</VL>
<NO>6</NO>
<PG>451-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163424"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163423"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garcia_x002d_Carb-1999a" MODIFIED="2014-10-20 14:27:51 +0100" MODIFIED_BY="Clare Jess" NAME="Garcia-Carb 1999a" YEAR="1999">
<REFERENCE MODIFIED="2014-07-14 18:44:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garcia-Carbonero R, Mayordomo JI, Tornamira MV, Lopez-Brea M, Rueda A, Guillem V, et al</AU>
<TI>Filgrastim in the treatment of high-risk febrile neutropenia: results of a multicenter randomized phase III trial</TI>
<SO>Proceedings of the Annual Meeting of the American Society of Clinical Oncology</SO>
<YR>1999</YR>
<VL>18</VL>
<PG>Abstract #2253</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163426"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163425"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garcia_x002d_Carb-1999b" MODIFIED="2014-10-20 14:27:48 +0100" MODIFIED_BY="Clare Jess" NAME="Garcia-Carb 1999b" YEAR="1999">
<REFERENCE MODIFIED="2014-10-17 15:11:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garcia-Carbonero R, Mayordomo JI, Tornamira MV, Lopez-Brea M, Rueda A, Guillem V, et al</AU>
<TI>Randomized comparison of broad spectrum antibiotics with or without filgrastim in the treatment of patients with high-risk fever and grade IV neutropenia</TI>
<SO>European Journal of Cancer</SO>
<YR>1999</YR>
<VL>35</VL>
<NO>Supplement 4</NO>
<PG>360</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163428"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163427"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gebbia-1994" NAME="Gebbia 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;eng&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gebbia V, Valenza R, Testa A, Cannata G, Borsellino N, Gebbia N</AU>
<TI>A prospective randomized trial of thymopentin versus granulocyte--colony stimulating factor with or without thymopentin in the prevention of febrile episodes in cancer patients undergoing highly cytotoxic chemotherapy</TI>
<SO>Anticancer Research</SO>
<YR>1994</YR>
<VL>14</VL>
<NO>2B</NO>
<PG>731-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163430"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163429"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gunay-1998" NAME="Gunay 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gunay U, Tanritanir A, Meral A, Sevinir BB, Hacimollaoglu MK</AU>
<TI>The effects of granulocyte colony-stimulating factor (G-CSF) and intravenous immunoglobulin (IVIG) on the treatment of neutropenic fever in children.</TI>
<SO>Cocuk Sagligi Ve Hastaliklari Dergisi</SO>
<YR>1998</YR>
<VL>41</VL>
<NO>4</NO>
<PG>433-44</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163432"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163431"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herrmann-1990" MODIFIED="2014-07-14 18:44:46 +0100" MODIFIED_BY="[Empty name]" NAME="Herrmann 1990" YEAR="1990">
<REFERENCE MODIFIED="2014-07-14 18:44:46 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;eng&lt;/p&gt;" NOTES_MODIFIED="2014-07-14 18:44:46 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herrmann F, Schulz G, Wieser M, Kolbe K, Nicolay U, Noack M, et al</AU>
<TI>Effect of granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy</TI>
<SO>The American Journal of Medicine</SO>
<YR>1990</YR>
<VL>88</VL>
<NO>6</NO>
<PG>619-24</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163434"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163433"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaku-1993" MODIFIED="2014-07-14 18:44:56 +0100" MODIFIED_BY="[Empty name]" NAME="Kaku 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-07-14 18:44:56 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Clinical Trial&lt;/p&gt;" NOTES_MODIFIED="2014-07-14 18:44:56 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaku K, Takahashi M, Moriyama Y, Nakahata T, Masaoka T, Yoshida Y, et al</AU>
<TI>Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) after chemotherapy in patients with non-Hodgkin's lymphoma; a placebo-controlled double blind phase III trial</TI>
<SO>Leukemia and Lymphoma</SO>
<YR>1993</YR>
<VL>11</VL>
<NO>3-4</NO>
<PG>229-38</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163436"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163435"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kawa-1999" MODIFIED="2014-07-14 18:45:07 +0100" MODIFIED_BY="[Empty name]" NAME="Kawa 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-07-14 18:45:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kawa K, Keiko Y, Dong PY, Sako M, Tanaka H, Hara J, et al</AU>
<TI>A multi-institutional study of optimal use of recombinant granulocyte colony stimulating factor (lenograstim) in pediatric malignancies - III</TI>
<SO>Biotherapy</SO>
<YR>1999</YR>
<VL>13</VL>
<NO>4</NO>
<PG>361-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163438"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163437"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kotake-1999" MODIFIED="2014-07-14 18:45:18 +0100" MODIFIED_BY="[Empty name]" NAME="Kotake 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-07-14 18:45:18 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Clinical Trial&lt;/p&gt;" NOTES_MODIFIED="2014-07-14 18:45:18 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kotake T, Usami M, Miki T, Togashi M, Akaza H, Kubota Y, et al</AU>
<TI>Effect of recombinant human granulocyte colony stimulating factor (lenograstim) on chemotherapy induced neutropenia in patients with urothelial cancer</TI>
<SO>International Journal of Urology</SO>
<YR>1999</YR>
<VL>6</VL>
<NO>2</NO>
<PG>61-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163440"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163439"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mayordomo-1992" MODIFIED="2014-10-17 15:23:05 +0100" MODIFIED_BY="[Empty name]" NAME="Mayordomo 1992" YEAR="1992">
<REFERENCE MODIFIED="2014-10-17 15:23:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mayordomo JI, Rivera F, Diaz-Puente MT, Lianes MP, Lopez-Brea M, López E</AU>
<TI>Progress report of a randomized trial on the value of adding G-CSF or GM-CSF to standard antibiotic therapy in the treatment of febrile neutropenia</TI>
<SO>Annals of Oncology</SO>
<YR>1992</YR>
<VL>3</VL>
<NO>Supplement 5: Growth factors / Oncogenes / Tumour suppressor</NO>
<PG>2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163442"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163441"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mayordomo-1993" MODIFIED="2014-10-17 15:24:07 +0100" MODIFIED_BY="[Empty name]" NAME="Mayordomo 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-10-17 15:24:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Mayordomo JI, Rivera F, Diaz Puente MT, Lianes MP, Lopez-Brea M, Lopez E, et al</AU>
<TI>Decreasing morbidity and cost of treating febrile neutropenia by adding G-CSF and GM-CSF to standard antibiotic therapy: results of a randomized trial</TI>
<SO>Proceedings of the Annual Meeting of the American Society of Clinical Oncology</SO>
<YR>1993</YR>
<VL>12</VL>
<PG>Abstract # 1510</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163444"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163443"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Michon-1998" MODIFIED="2014-07-14 18:46:15 +0100" MODIFIED_BY="[Empty name]" NAME="Michon 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-07-14 18:46:15 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;eng&lt;/p&gt;" NOTES_MODIFIED="2014-07-14 18:46:15 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Michon JM, Hartmann O, Bouffet E, Meresse V, Coze C, Rubie H, et al</AU>
<TI>An open-label, multicentre, randomised phase 2 study of recombinant human granulocyte colony-stimulating factor (filgrastim) as an adjunct to combination chemotherapy in paediatric patients with metastatic neuroblastoma</TI>
<SO>European Journal of Cancer</SO>
<YR>1998</YR>
<VL>34</VL>
<NO>7</NO>
<PG>1063-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163446"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163445"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Montalar-1998" MODIFIED="2014-10-17 15:27:46 +0100" MODIFIED_BY="[Empty name]" NAME="Montalar 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-10-17 15:27:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Montalar J, Santaballa A, Oltra A, Segura A, Aparicio A, Pastor M</AU>
<TI>Ofloxacin with or without stimulating colony-factors in the treatment of neutropenic fever</TI>
<SO>Annals of Oncology</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>Supplement 4 palliative and supportive care</NO>
<PG>151 abstract #724</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163448"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163447"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moriyama-1993" MODIFIED="2014-07-14 18:46:44 +0100" MODIFIED_BY="[Empty name]" NAME="Moriyama 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-07-14 18:46:44 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;eng&lt;/p&gt;" NOTES_MODIFIED="2014-07-14 18:46:44 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moriyama Y, Takahashi M, Kaku K, Yoshida Y, Masaoka T, Nakanishi S, et al</AU>
<TI>Effect of granulocyte-macrophage colony-stimulating factor on chemotherapy-induced granulocytopenia in patients with malignancies</TI>
<SO>Acta Haematologica</SO>
<YR>1993</YR>
<VL>89</VL>
<NO>2</NO>
<PG>70-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163450"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163449"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Motoyoshi-1986" MODIFIED="2014-07-14 18:46:56 +0100" MODIFIED_BY="[Empty name]" NAME="Motoyoshi 1986" YEAR="1986">
<REFERENCE MODIFIED="2014-07-14 18:46:56 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;eng&lt;/p&gt;" NOTES_MODIFIED="2014-07-14 18:46:56 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Motoyoshi K, Takaku F, Maekawa T, Miura Y, Kimura K, Furusawa S, et al</AU>
<TI>Protective effect of partially purified human urinary colony-stimulating factor on granulocytopenia after antitumor chemotherapy</TI>
<SO>Experimental Hematology</SO>
<YR>1986</YR>
<VL>14</VL>
<NO>11</NO>
<PG>1069-75</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163452"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163451"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nakajima-1995" MODIFIED="2014-07-14 18:47:08 +0100" MODIFIED_BY="[Empty name]" NAME="Nakajima 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-07-14 18:47:08 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;jpn&lt;/p&gt;" NOTES_MODIFIED="2014-07-14 18:47:08 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nakajima H, Ikeda Y, Hirashima K, Toyama K, Okuma M, Saito H, et al</AU>
<TI>A randomized controlled study of rG.CSF in patients with neutropenia after induction therapy for acute myelogenous leukemia. (rG.CSF Clinical Study Group)</TI>
<SO>Rinsho Ketsueki [The Japanese Journal of Clinical Hematology]</SO>
<YR>1995</YR>
<VL>36</VL>
<NO>6</NO>
<PG>597-605</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163454"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163453"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ohno-1997" MODIFIED="2014-07-14 18:47:22 +0100" MODIFIED_BY="[Empty name]" NAME="Ohno 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-07-14 18:47:22 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;eng&lt;/p&gt;" NOTES_MODIFIED="2014-07-14 18:47:22 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ohno R, Miyawaki S, Hatake K, Kuriyama K, Saito K, Kanamaru A, et al</AU>
<TI>Human urinary macrophage colony-stimulating factor reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia: a double-blind controlled study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1997</YR>
<VL>15</VL>
<NO>8</NO>
<PG>2954-65</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163456"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163455"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oshita-2000" MODIFIED="2014-07-14 18:47:35 +0100" MODIFIED_BY="[Empty name]" NAME="Oshita 2000" YEAR="2000">
<REFERENCE MODIFIED="2014-07-14 18:47:35 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Clinical Trial&lt;/p&gt;" NOTES_MODIFIED="2014-07-14 18:47:35 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oshita F, Yamada K, Nomura I, Tanaka G, Ikehara M, Noda K</AU>
<TI>Prophylactic administration of granulocyte colony-stimulating factor when monocytopenia appears lessens neutropenia caused by chemotherapy for lung cancer</TI>
<SO>American Journal of Clinical Oncology</SO>
<YR>2000</YR>
<VL>23</VL>
<NO>3</NO>
<PG>278-82</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163458"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163457"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ravaud-1995" MODIFIED="2014-07-14 18:47:48 +0100" MODIFIED_BY="[Empty name]" NAME="Ravaud 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-07-14 18:47:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ravaud A, Chevreau C, Bonichon F, Mihura J, Bui BN, Tabah I</AU>
<TI>A phase III trial of recombinant granulocyte-macrophage colony stimulating factor (GM-CSF) as corrective treatment in patients (pts) with neutropenic fever following antineoplastic chemotherapy (CT): results of an intermediate analysis</TI>
<SO>Proceedings of the Annual Meeting of the American Society of Clinical Oncology</SO>
<YR>1995</YR>
<PG>Abstract A716</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163460"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163459"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schroder-1999" MODIFIED="2014-07-14 18:48:03 +0100" MODIFIED_BY="[Empty name]" NAME="Schroder 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-07-14 18:48:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schroder CP, de Vries EG, Mulder NH, Willemse PH, Sleijfer DT, Hospers GA, et al</AU>
<TI>Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B</TI>
<SO>The Journal of Antimicrobial Chemotherapy</SO>
<YR>1999</YR>
<VL>43</VL>
<NO>5</NO>
<PG>741-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163462"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163461"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soda-1996" MODIFIED="2014-07-14 18:48:15 +0100" MODIFIED_BY="[Empty name]" NAME="Soda 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-07-14 18:48:15 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;eng&lt;/p&gt;" NOTES_MODIFIED="2014-07-14 18:48:15 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soda H, Oka M, Fukuda M, Kinoshita A, Sakamoto A, Araki J, et al</AU>
<TI>Optimal schedule for administering granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in non-small-cell lung cancer</TI>
<SO>Cancer Chemotherapy and Pharmacology</SO>
<YR>1996</YR>
<VL>38</VL>
<NO>1</NO>
<PG>9-12</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163464"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163463"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Timmer_x002d_Bonte-2005" MODIFIED="2014-07-14 18:48:28 +0100" MODIFIED_BY="[Empty name]" NAME="Timmer-Bonte 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-07-14 18:48:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Timmer-Bonte JN, de Boo TM, Smit HJ, Biesma B, Wilschut FA, Cheragwandi SA, et al</AU>
<TI>Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch randomized phase III study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>31</NO>
<PG>7974-84</PG>
<IDENTIFIERS MODIFIED="2012-11-28 21:17:41 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163466"/><IDENTIFIER TYPE="PUBMED" VALUE="16258098"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163465"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Torrecillas-1998" MODIFIED="2014-07-14 18:48:43 +0100" MODIFIED_BY="[Empty name]" NAME="Torrecillas 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-07-14 18:48:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Torrecillas L, Cervantes G, Zamora R, Acosta A, Cepeda F, Cortés P, et al</AU>
<TI>GM-CSF discontinuation safe level for patients with chemotherapy induced febrile or afebrile neutropenia</TI>
<SO>Proceedings of the Annual Meeting of the American Society of Clinical Oncology</SO>
<YR>1998</YR>
<PG>Abstract #304</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163468"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163467"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Uyl_x002d_de-Groot-1997" NAME="Uyl-de Groot 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;eng&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Uyl-de Groot CA, Vellenga E, de Vries EG, Lowenberg B, Stoter GJ, Rutten FF</AU>
<TI>Treatment costs and quality of life with granulocyte-macrophage colony-stimulating factor in patients with antineoplastic therapy-related febrile neutropenia. Results of a randomised placebo-controlled trial</TI>
<SO>Pharmacoeconomics</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>3</NO>
<PG>351-60</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163470"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163469"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Pelt-1997" NAME="van Pelt 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;eng&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Pelt LJ, de Craen AJ, Langeveld NE, Weening RS</AU>
<TI>Granulocyte-macrophage colony-stimulating factor (GM-CSF) ameliorates chemotherapy-induced neutropenia in children with solid tumors</TI>
<SO>Pediatric Hematology and Oncology</SO>
<YR>1997</YR>
<VL>14</VL>
<NO>6</NO>
<PG>539-45</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163472"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163471"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vellenga-1996b" MODIFIED="2014-07-14 18:48:56 +0100" MODIFIED_BY="[Empty name]" NAME="Vellenga 1996b" YEAR="1996">
<REFERENCE MODIFIED="2014-07-14 18:48:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vellenga E, Uyl-De Groot C, Stoter G, Lowenberg B, De Vries E</AU>
<TI>Faster recovery of leukocytes due to haemopoietic growth factor in patients with chemotherapy-related granulocytopenia and fever, but no shortened hospital stay</TI>
<SO>Nederlands Tijdschrift voor Geneeskunde</SO>
<YR>1996</YR>
<VL>140</VL>
<NO>32</NO>
<PG>1650-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163474"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163473"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yalcin-1996" MODIFIED="2014-07-14 18:49:09 +0100" MODIFIED_BY="[Empty name]" NAME="Yalcin 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-07-14 18:49:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yalcin S, Guler N, Kansu E, Ertenli I, Gullu I, Barista I, et al</AU>
<TI>Granulocyte-colony stimulating factor (G-CSF) administration for chemotherapy-induced neutropenia</TI>
<SO>Hematology</SO>
<YR>1996</YR>
<VL>1</VL>
<NO>2</NO>
<PG>155-61</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163476"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163475"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamazaki-1989" NAME="Yamazaki 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yamazaki K, Kumamoto Y, Tsukamoto T, Hirose T</AU>
<TI>Prophylaxis of fever during leukocytopenia by anticancer chemotherapy</TI>
<SO>Chemotherapy</SO>
<YR>1989</YR>
<VL>37</VL>
<NO>6</NO>
<PG>838-47</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3163478"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3163477"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-05-04 14:46:19 +0100" MODIFIED_BY="Clare Jess">
<ADDITIONAL_REFERENCES MODIFIED="2016-05-04 14:46:19 +0100" MODIFIED_BY="Clare Jess">
<REFERENCE ID="REF-Berghmans-2002" MODIFIED="2014-07-14 18:49:26 +0100" MODIFIED_BY="[Empty name]" NAME="Berghmans 2002" TYPE="JOURNAL_ARTICLE">
<AU>Berghmans T, Paesmans M, Lafitte JJ, Mascaux C, Meert AP, Jacquy C, et al</AU>
<TI>Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis</TI>
<SO>Supportive Care in Cancer</SO>
<YR>2002</YR>
<VL>10</VL>
<NO>3</NO>
<PG>181-8</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="11904782"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Castro-1999" MODIFIED="2014-07-14 18:49:36 +0100" MODIFIED_BY="[Empty name]" NAME="Castro 1999" TYPE="JOURNAL_ARTICLE">
<AU>Castro AA, Clark OA, Atallah AN</AU>
<TI>Optimal search strategy for clinical trials in the Latin American and Caribbean Health Science Literature database (LILACS database): update</TI>
<SO>Sao Paulo Medical Journal</SO>
<YR>1999</YR>
<VL>117</VL>
<NO>3</NO>
<PG>138-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Naurois-2010" MODIFIED="2014-07-14 18:49:45 +0100" MODIFIED_BY="[Empty name]" NAME="de Naurois 2010" TYPE="JOURNAL_ARTICLE">
<AU>de Naurois J, Novitzky-Basso I, Gill MJ, Marti FM, Cullen MH, Roila F, et al</AU>
<TI>Management of febrile neutropenia: ESMO Clinical Practice Guidelines</TI>
<SO>Annals of Oncology</SO>
<YR>2010</YR>
<VL>21 Suppl 5</VL>
<PG>v252-v6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1994" NAME="Dickersin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Scherer R, Lefebvre C</AU>
<TI>Identifying relevant studies for systematic reviews</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<NO>6964</NO>
<PG>1286-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2012-11-28 17:02:43 +0000" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Smith GD, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-2001" MODIFIED="2014-07-14 18:49:56 +0100" MODIFIED_BY="[Empty name]" NAME="Egger 2001" TYPE="BOOK">
<AU>Egger M, Smith GD, Altman D</AU>
<SO>Systematic Reviews in Health Care</SO>
<YR>2001</YR>
<EN>2nd</EN>
<PB>BMJ Books</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Freyer-1998" MODIFIED="2012-11-28 17:02:51 +0000" MODIFIED_BY="[Empty name]" NAME="Freyer 1998" TYPE="JOURNAL_ARTICLE">
<AU>Freyer G, Ligneau B, Trillet-Lenoir V</AU>
<TI>Colony-stimulating factors in the prevention of solid tumors induced by chemotherapy in patients with febrile neutropenia</TI>
<SO>International Journal of Antimicrobial Agents</SO>
<YR>1998</YR>
<VL>10</VL>
<NO>1</NO>
<PG>3-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Giamerellou-2001" MODIFIED="2014-06-19 16:15:44 +0100" MODIFIED_BY="[Empty name]" NAME="Giamerellou 2001" TYPE="JOURNAL_ARTICLE">
<AU>Giamarellou H, Antoniadou A</AU>
<TI>Infectious complications of febrile leukopenia</TI>
<SO>Infectious Disease Clinics of North America</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>2</NO>
<PG>457-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro" MODIFIED="2014-05-02 21:04:07 +0100" MODIFIED_BY="[Empty name]" NAME="GRADEpro" TYPE="COMPUTER_PROGRAM">
<TI>GRADEpro</TI>
<YR>2008</YR>
<EN>3.2 for Windows</EN>
<PB>Jan Brozek, Andrew Oxman, Holger Schünemann</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Griffin-2001" MODIFIED="2014-07-14 18:50:06 +0100" MODIFIED_BY="[Empty name]" NAME="Griffin 2001" TYPE="BOOK_SECTION">
<AU>Griffin JD</AU>
<TI>Hematopoietic growth factors</TI>
<SO>Cancer: Principles and Practice of Oncology</SO>
<YR>2001</YR>
<EN>6th</EN>
<ED>DeVitaJr VT, Hellman S, Rosenberg SA</ED>
<PB>Lippincott Williams &amp; Wilkins</PB>
<CY>Philadelphia, PA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011" MODIFIED="2014-05-02 21:04:07 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al</AU>
<TI>GRADE guidelines: 7. Rating the quality of evidence - inconsistency</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1294-302</PG>
<IDENTIFIERS MODIFIED="2014-05-02 21:04:05 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21803546"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011a" MODIFIED="2014-05-02 21:04:07 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011a" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al</AU>
<TI>GRADE guidelines: 8. Rating the quality of evidence - indirectness</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1303-10</PG>
<IDENTIFIERS MODIFIED="2014-05-02 21:04:05 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21802903"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011b" MODIFIED="2014-05-02 21:04:07 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011b" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt G, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al</AU>
<TI>GRADE guidelines: 6. Rating the quality of evidence - imprecision</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1283-93</PG>
<IDENTIFIERS MODIFIED="2014-05-02 21:04:05 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21839614"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011c" MODIFIED="2014-05-02 21:04:07 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011c" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al</AU>
<TI>GRADE guidelines: 5. Rating the quality of evidence - publication bias</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1277-82</PG>
<IDENTIFIERS MODIFIED="2014-05-02 21:04:05 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21802904"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011d" MODIFIED="2014-05-02 21:04:07 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011d" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al</AU>
<TI>GRADE guidelines: 4. Rating the quality of evidence - risk of bias</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>407-15</PG>
<IDENTIFIERS MODIFIED="2014-05-02 21:04:05 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21247734"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011e" MODIFIED="2014-05-02 21:04:07 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011e" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt G, Oxman AD, Akl E, Kunz R, Vist G, Brozek J, et al</AU>
<TI>GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>383-94</PG>
<IDENTIFIERS MODIFIED="2014-05-02 21:04:05 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21195583"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011a" MODIFIED="2014-10-22 11:48:32 +0100" MODIFIED_BY="Clare Jess" NAME="Higgins 2011a" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011.</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011b" MODIFIED="2014-10-22 11:48:27 +0100" MODIFIED_BY="Clare Jess" NAME="Higgins 2011b" TYPE="OTHER">
<AU>Higgins JPT, Deeks JJ</AU>
<TI>Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011c" MODIFIED="2014-10-22 11:48:21 +0100" MODIFIED_BY="Clare Jess" NAME="Higgins 2011c" TYPE="OTHER">
<AU>Higgins JPT, Altman DG, Sterne JAC</AU>
<TI>Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011d" MODIFIED="2014-10-22 11:48:08 +0100" MODIFIED_BY="Clare Jess" NAME="Higgins 2011d" TYPE="OTHER">
<AU>Higgins JPT, Altman DG, Sterne JAC</AU>
<TI>Chapter 16.5.4: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hozo-2005" MODIFIED="2014-07-14 18:50:37 +0100" MODIFIED_BY="[Empty name]" NAME="Hozo 2005" TYPE="JOURNAL_ARTICLE">
<AU>Hozo SP, Djulbegovic B, Hozo I</AU>
<TI>Estimating the mean and variance from the median, range, and the size of a sample</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2005</YR>
<VL>5</VL>
<PG>13</PG>
<IDENTIFIERS MODIFIED="2014-04-30 22:04:21 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="15840177"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hozo-2005a" MODIFIED="2014-06-25 10:06:29 +0100" MODIFIED_BY="Clare Jess" NAME="Hozo 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Hozo I, Djulbegovic B, Clark O, Lyman GH,</AU>
<TI>Use of re-randomized data in meta-analysis</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>5</NO>
<PG>17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-IHS-1990" MODIFIED="2014-07-14 18:50:45 +0100" MODIFIED_BY="[Empty name]" NAME="IHS 1990" TYPE="JOURNAL_ARTICLE">
<AU>Immunocompromised Host Society</AU>
<TI>The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel</TI>
<SO>The Journal of Infectious Diseases</SO>
<YR>1990</YR>
<VL>161</VL>
<NO>3</NO>
<PG>397-401</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lyman-2002" MODIFIED="2014-07-14 18:50:54 +0100" MODIFIED_BY="[Empty name]" NAME="Lyman 2002" TYPE="JOURNAL_ARTICLE">
<AU>Lyman GH, Kuderer NM, Djulbegovic B</AU>
<TI>Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis</TI>
<SO>The American Journal of Medicine</SO>
<YR>2002</YR>
<VL>112</VL>
<NO>5</NO>
<PG>406-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mhaskar-2012" MODIFIED="2014-10-20 14:29:50 +0100" MODIFIED_BY="Clare Jess" NAME="Mhaskar 2012" TYPE="JOURNAL_ARTICLE">
<AU>Mhaskar Rahul, Djulbegovic Benjamin, Magazin Anja, Soares Heloisa P, Kumar Ambuj</AU>
<TI>Published methodological quality of randomized controlled trials does not reflect the actual quality assessed in protocols</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2012</YR>
<VL>65</VL>
<NO>6</NO>
<PG>602-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2009" MODIFIED="2014-05-02 21:04:07 +0100" MODIFIED_BY="[Empty name]" NAME="Moher 2009" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Liberati A, Tetzlaff J, Altman DG</AU>
<TI>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2009</YR>
<VL>62</VL>
<NO>10</NO>
<PG>1006-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Paesmans-1998" MODIFIED="2012-11-28 17:03:53 +0000" MODIFIED_BY="[Empty name]" NAME="Paesmans 1998" TYPE="JOURNAL_ARTICLE">
<AU>Paesmans M</AU>
<TI>Statistical considerations in clinical trials testing empiric antibiotic regimens in patients with febrile neutropenia</TI>
<SO>Supportive Care in Cancer</SO>
<YR>1998</YR>
<VL>6</VL>
<NO>5</NO>
<PG>438-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Petros-2001" MODIFIED="2014-07-14 18:51:05 +0100" MODIFIED_BY="[Empty name]" NAME="Petros 2001" TYPE="BOOK_SECTION">
<AU>Petros WP</AU>
<TI>Colony-stimulating factors</TI>
<SO>Cancer Chemotherapy and Biotherapy - Principles and Practice</SO>
<YR>2001</YR>
<EN>5th</EN>
<ED>Chabner BA, Longo DL</ED>
<PB>Lippincott Williams &amp; Wilkins</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pizzo-1999" MODIFIED="2014-07-14 18:51:13 +0100" MODIFIED_BY="[Empty name]" NAME="Pizzo 1999" TYPE="JOURNAL_ARTICLE">
<AU>Pizzo PA</AU>
<TI>Fever in immunocompromised patients</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>341</VL>
<NO>12</NO>
<PG>893-900</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Review-Manager-5.3" MODIFIED="2014-10-17 18:25:50 +0100" MODIFIED_BY="[Empty name]" NAME="Review Manager 5.3" TYPE="OTHER">
<TI>Review Manager (RevMan) [Computer program]. Version 5.3</TI>
<SO>Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration</SO>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS MODIFIED="2014-06-19 10:37:32 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Rubenstein-2000" MODIFIED="2012-11-28 17:04:06 +0000" MODIFIED_BY="[Empty name]" NAME="Rubenstein 2000" TYPE="JOURNAL_ARTICLE">
<AU>Rubenstein EB</AU>
<TI>Colony stimulating factors in patients with fever and neutropenia</TI>
<SO>International Journal of Antimicrobial Agents</SO>
<YR>2000</YR>
<VL>16</VL>
<NO>2</NO>
<PG>117-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schelenz-2012" MODIFIED="2016-05-04 14:46:19 +0100" MODIFIED_BY="Clare Jess" NAME="Schelenz 2012" TYPE="JOURNAL_ARTICLE">
<AU>Schelenz S, Giles D, Abdallah S</AU>
<TI>Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre</TI>
<SO>Annals of Oncology</SO>
<YR>2012</YR>
<VL>23</VL>
<NO>7</NO>
<PG>1889-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Segal-2001" MODIFIED="2014-07-14 18:51:20 +0100" MODIFIED_BY="[Empty name]" NAME="Segal 2001" TYPE="BOOK_SECTION">
<AU>Segal BH, Walsh TJ, Holland SM</AU>
<TI>Infections in the cancer patient</TI>
<SO>Cancer: Principles and Practice of Oncology</SO>
<YR>2001</YR>
<EN>6th</EN>
<ED>DeVitaJr VT, Hellman S, Rosenberg SA</ED>
<PB>Lippincott Williams &amp; Wilkins</PB>
<CY>Philadelphia, PA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smeenk-1998" MODIFIED="2014-07-25 20:06:19 +0100" MODIFIED_BY="[Empty name]" NAME="Smeenk 1998" TYPE="JOURNAL_ARTICLE">
<AU>Smeenk FW, van Haastregt JC, de Witte LP, Crebolder HF</AU>
<TI>Effectiveness of home care programmes for patients with incurable cancer on their quality of life and time spent in hospital: systematic review</TI>
<SO>BMJ</SO>
<YR>1998</YR>
<VL>316</VL>
<NO>7149</NO>
<PG>1939-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tierney-2007" MODIFIED="2012-10-31 16:20:40 +0000" MODIFIED_BY="[Empty name]" NAME="Tierney 2007" TYPE="JOURNAL_ARTICLE">
<AU>Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR</AU>
<TI>Practical methods for incorporating summary time-to-event data into meta-analysis</TI>
<SO>Trials</SO>
<YR>2007</YR>
<VL>8</VL>
<PG>16</PG>
<IDENTIFIERS MODIFIED="2012-10-31 16:20:38 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="17555582"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wang-2015" MODIFIED="2016-05-04 14:46:10 +0100" MODIFIED_BY="Clare Jess" NAME="Wang 2015" TYPE="JOURNAL_ARTICLE">
<AU>Wang XJ, Lopez SE, Chan A. Economic burden of chemotherapy-induced febrile neutropenia in patients with lymphoma: A systematic review</AU>
<TI>Economic burden of chemotherapy-induced febrile neutropenia in patients with lymphoma: A systematic review</TI>
<SO>Critical Reviews in Oncology / Hematology</SO>
<YR>2015</YR>
<VL>94</VL>
<NO>2</NO>
<PG>201-12</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-07-14 18:51:30 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Clark-2000" MODIFIED="2014-07-14 18:51:30 +0100" MODIFIED_BY="[Empty name]" NAME="Clark 2000" TYPE="OTHER">
<AU>Clark OA, Lyman G, Castro AA, Clark LG, Djulbegovic B</AU>
<TI>Colony stimulating factors for chemotherapy induced febrile neutropenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2014-05-05 14:57:09 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD003039"/><IDENTIFIER TYPE="OTHER" VALUE="CD003039"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-10-22 12:05:02 +0100" MODIFIED_BY="Clare Jess">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-10-22 12:05:02 +0100" MODIFIED_BY="Clare Jess" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-10-22 12:04:42 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Anaissie-1996">
<CHAR_METHODS MODIFIED="2014-06-23 15:24:33 +0100" MODIFIED_BY="Clare Jess">
<P>Not placebo-controlled, not blinded, industry-sponsored, single-center trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-17 15:04:10 +0100" MODIFIED_BY="[Empty name]">
<P>Adults; mixed tumors; ANC &lt; 1 x 10<SUP>9</SUP>/L</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-20 14:13:57 +0100" MODIFIED_BY="Clare Jess">
<P>GM-CSF (Sandoz) 3 mcg/kg IV</P>
<P>ATB: Ticarcilin plus Netilmicin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-10-22 12:04:42 +0100" MODIFIED_BY="Clare Jess">
<P>Overall mortality<BR/>Infection-related mortality<BR/>People with hospitalization for greater than 10 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-18 17:10:02 +0100" MODIFIED_BY="[Empty name]">
<P>Hospital discharge criteria: Not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-18 17:09:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Arnberg-1998">
<CHAR_METHODS MODIFIED="2014-07-14 22:27:41 +0100" MODIFIED_BY="[Empty name]">
<P>Placebo-controlled, not blinded, industry and public-sponsored, single-center trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-17 15:04:34 +0100" MODIFIED_BY="[Empty name]">
<P>Adults; mixed tumors; ANC &lt; 1 x 10<SUP>9</SUP>/L</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-17 15:55:30 +0100" MODIFIED_BY="[Empty name]">
<P>GM-CSF (not specified) 5.5 mcg/kg SC</P>
<P>ATB: Many different antibiotics</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Bone and joint pain or flu-like symptoms<BR/>Deep vein thrombosis</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-18 17:09:56 +0100" MODIFIED_BY="[Empty name]">
<P>Hospital discharge criteria: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-10-20 14:14:00 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Aviles-1996">
<CHAR_METHODS MODIFIED="2014-06-23 15:24:34 +0100" MODIFIED_BY="Clare Jess">
<P>Not placebo-controlled, not blinded, unclear sponsorship, single-center trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-17 15:04:51 +0100" MODIFIED_BY="[Empty name]">
<P>Adults; hematologic tumors; ANC &lt; 0.1 x 10<SUP>9</SUP>/L</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-20 14:14:00 +0100" MODIFIED_BY="Clare Jess">
<P>G-CSF (not specified) 5 mcg/kg SC</P>
<P>ATB: Amikacin plus Ceftazidime</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-23 15:24:34 +0100" MODIFIED_BY="Clare Jess">
<P>Overall mortality<BR/>Infection-related mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-10 17:35:23 +0100" MODIFIED_BY="[Empty name]">
<P>Hospital discharge criteria: not reported</P>
<P>Duration of grade IV neutropenia reported as days to absolute granulocyte recovery to &gt; 0.5 x 10<SUP>9</SUP>/L</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-10-20 14:14:01 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Biesma-1990">
<CHAR_METHODS MODIFIED="2014-06-23 15:24:34 +0100" MODIFIED_BY="Clare Jess">
<P>Placebo-controlled, industry-sponsored, single-center trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-17 15:05:06 +0100" MODIFIED_BY="[Empty name]">
<P>Adults; mixed tumors; ANC &lt; 1 x 10<SUP>9</SUP>/L</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-20 14:14:01 +0100" MODIFIED_BY="Clare Jess">
<P>GM-CSF (not specified) 2.8 mcg/kg IV</P>
<P>ATB: Tobramicin plus Cefuroxime</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-23 15:24:34 +0100" MODIFIED_BY="Clare Jess">
<P>Overall mortality<BR/>Infection-related mortality<BR/>Deep vein thrombosis</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-10 17:35:43 +0100" MODIFIED_BY="[Empty name]">
<P>Hospital discharge criteria: afebrile for at least 48 hours</P>
<P>Duration of grade IV neutropenia reported as days to absolute granulocyte recovery to &gt; 0.5 x 10<SUP>9</SUP>/L</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-10-22 12:04:51 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Garcia_x002d_Carbonero-2001">
<CHAR_METHODS MODIFIED="2014-06-23 15:24:34 +0100" MODIFIED_BY="Clare Jess">
<P>Not placebo-controlled, industry- and public-sponsored, multicenter trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-17 15:05:22 +0100" MODIFIED_BY="[Empty name]">
<P>Adults; mixed tumors; ANC &lt; 0.5 x 10<SUP>9</SUP>/L</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-20 14:14:01 +0100" MODIFIED_BY="Clare Jess">
<P>G-CSF (not specified) 5 mcg/kg SC</P>
<P>ATB: Amikacin plus Ceftazidime</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-10-22 12:04:51 +0100" MODIFIED_BY="Clare Jess">
<P>Overall mortality<BR/>Infection-related mortality<BR/>People with hospitalization for greater than 10 days<BR/>Time to neutrophil recovery<BR/>Deep vein thrombosis</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-10 17:36:54 +0100" MODIFIED_BY="[Empty name]">
<P>Hospital discharge criteria: afebrile for at least 48 hours; ANC at least 1000/mm<SUP>3</SUP>
</P>
<P>Duration of grade IV neutropenia reported as days to ANC &gt; 500mm<SUP>3</SUP>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-10-20 14:14:02 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Lopez_x002d_Hernandez-2000">
<CHAR_METHODS MODIFIED="2014-06-23 15:24:34 +0100" MODIFIED_BY="Clare Jess">
<P>Not placebo-controlled, unclear funding, single-center trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-17 15:05:38 +0100" MODIFIED_BY="[Empty name]">
<P>Adults and children; hematological tumors; ANC &lt; 0.5 x 10<SUP>9</SUP>/L</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-20 14:14:02 +0100" MODIFIED_BY="Clare Jess">
<P>G-CSF (filgrastim) 5 mcg/kg SC</P>
<P>ATB: Amikacin plus Ceftriaxone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-23 15:24:35 +0100" MODIFIED_BY="Clare Jess">
<P>Overall mortality<BR/>Infection-related mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-18 17:09:26 +0100" MODIFIED_BY="[Empty name]">
<P>Hospital discharge criteria: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-10-22 12:04:55 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Maher-1994">
<CHAR_METHODS MODIFIED="2014-06-23 15:24:35 +0100" MODIFIED_BY="Clare Jess">
<P>Placebo-controlled, industry-funded, multicenter trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-17 15:06:02 +0100" MODIFIED_BY="[Empty name]">
<P>Adults; mixed tumors; ANC &lt; 1 x 10<SUP>9</SUP>/L</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-20 14:14:04 +0100" MODIFIED_BY="Clare Jess">
<P>G-CSF (filgrastim) 12 mcg/kg SC</P>
<P>ATB: Piperacilin plus Tobramicin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-10-22 12:04:55 +0100" MODIFIED_BY="Clare Jess">
<P>Overall mortality<BR/>People with hospitalization for greater than 10 days<BR/>Bone and joint pain or flu-like symptoms<BR/>Time to neutrophil recovery</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-10 17:37:37 +0100" MODIFIED_BY="[Empty name]">
<P>Hospital discharge criteria: afebrile for at least 96 hours; ANC at least 500/mm<SUP>3</SUP>
</P>
<P>Duration of grade IV neutropenia reported as median number of days of neutropenia ANC &lt; 0.5 x 10<SUP>9</SUP>/L</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-10-22 12:04:59 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Mayordomo-1995">
<CHAR_METHODS MODIFIED="2014-06-23 15:24:36 +0100" MODIFIED_BY="Clare Jess">
<P>Placebo-controlled, industry-funded, single-center trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-17 15:06:41 +0100" MODIFIED_BY="[Empty name]">
<P>Adults; mixed tumors; ANC &lt; 0.5 x 10<SUP>9</SUP>/L</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-17 15:58:53 +0100" MODIFIED_BY="[Empty name]">
<P>G-CSF (filgrastim) 5 mcg/kg IV<BR/>OR<BR/>GM-CSF (molgramostim) 5 mcg/kg IV</P>
<P>ATB: Amikacin + Ceftazidime</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-10-22 12:04:59 +0100" MODIFIED_BY="Clare Jess">
<P>Overall mortality<BR/>Infection-related mortality<BR/>People with hospitalization for greater than 10 days<BR/>Bone and joint pain or flu-like symptoms<BR/>Time to neutrophil recovery</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-10 17:37:54 +0100" MODIFIED_BY="[Empty name]">
<P>Hospital discharge criteria: afebrile for at least 48 hours; ANC at least 1000/mm<SUP>3</SUP>
</P>
<P>Duration of grade IV neutropenia reported as median number of days of neutropenia ANC &lt; 0.5 x 10<SUP>9</SUP>/L</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-10-22 12:05:02 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Mitchell-1997">
<CHAR_METHODS MODIFIED="2014-06-23 15:24:36 +0100" MODIFIED_BY="Clare Jess">
<P>Placebo-controlled, industry-funded, multicenter trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-17 15:06:57 +0100" MODIFIED_BY="[Empty name]">
<P>Children; mixed tumors; ANC &lt; 0.5 x 10<SUP>9</SUP>/L</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-20 14:14:13 +0100" MODIFIED_BY="Clare Jess">
<P>G-CSF (filgrastim) 5 mcg/kg IV</P>
<P>ATB: Gentamicin plus Piperacilin plus Flucloxacilin OR Gentamicin plus Imipenen-Cilastatin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-10-22 12:05:02 +0100" MODIFIED_BY="Clare Jess">
<P>Overall mortality<BR/>People with hospitalization for greater than 10 days<BR/>Time to neutrophil recovery</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-10 17:38:24 +0100" MODIFIED_BY="[Empty name]">
<P>Hospital discharge criteria: afebrile for at least 72 hours; ANC at least 200/mm<SUP>3</SUP>
</P>
<P>Duration of grade IV neutropenia reported as days to absolute granulocyte recovery to &gt; 0.5 x 10<SUP>9</SUP>/L</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-10-20 14:14:14 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Ravaud-1998">
<CHAR_METHODS MODIFIED="2014-06-23 15:24:37 +0100" MODIFIED_BY="Clare Jess">
<P>Not placebo-controlled, industry-funded, multicenter trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-17 15:07:12 +0100" MODIFIED_BY="[Empty name]">
<P>Adults; solid tumors; ANC &lt; 1 x 10<SUP>9</SUP>/L</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-20 14:14:14 +0100" MODIFIED_BY="Clare Jess">
<P>GM-CSF (molgramostim) 5 mcg/kg SC</P>
<P>ATB: Amikacin plus Ceftriaxone OR Piperacilin plus Ofloxacin for people receiving Cisplatin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-23 15:24:37 +0100" MODIFIED_BY="Clare Jess">
<P>Overall mortality<BR/>Infection-related mortality<BR/>Bone and joint pain or flu-like symptoms<BR/>Time to neutrophil recovery</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-10 17:39:16 +0100" MODIFIED_BY="[Empty name]">
<P>Hospital discharge criteria: afebrile for at least 24 hours; ANC at least 1000/mm<SUP>3</SUP>
</P>
<P>Duration of grade IV neutropenia reported as median number of days of neutropenia ANC &lt; 0.5 x 10<SUP>9</SUP>/L</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-10-10 17:38:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Riikonen-1994">
<CHAR_METHODS MODIFIED="2014-06-23 15:24:37 +0100" MODIFIED_BY="Clare Jess">
<P>Placebo-controlled, public-funded, multi-center trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-17 15:07:27 +0100" MODIFIED_BY="[Empty name]">
<P>Children, mixed tumors; ANC &lt; 0.2 x 10<SUP>9</SUP>/L</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-17 16:00:59 +0100" MODIFIED_BY="[Empty name]">
<P>GM-CSF (Sandoz) 5 mcg/kg IV</P>
<P>ATB: Imipenen-Cilastatin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-23 15:24:37 +0100" MODIFIED_BY="Clare Jess">
<P>Overall mortality<BR/>Infection-related mortality<BR/>Duration of hospitalization<BR/>Bone and joint pain or flu-like symptoms</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-10 17:38:42 +0100" MODIFIED_BY="[Empty name]">
<P>Hospital discharge criteria: afebrile for at least 72 hours; ANC at least 500/mm<SUP>3</SUP>
</P>
<P>Duration of grade IV neutropenia reported as days to absolute granulocyte recovery to &gt; 0.5 x 10<SUP>9</SUP>/L</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-18 17:08:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rodriguez-2005">
<CHAR_METHODS MODIFIED="2014-06-23 15:24:37 +0100" MODIFIED_BY="Clare Jess">
<P>Not-placebo controlled, unclear funding, single-center trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-17 15:03:21 +0100" MODIFIED_BY="[Empty name]">
<P>Children, mixed tumors, ANC &#8804; 0.5 x 10<SUP>9</SUP>/L</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-17 16:01:49 +0100" MODIFIED_BY="[Empty name]">
<P>G-CSF (Neupogen (Filgrastim), Roche) 5 mcg/kg/day IV</P>
<P>ATB: Cloxacillin / Cefotaxim / Amikacin. Vancomycin for people with previous infection due to Gram-positive cocci resistant to Oxacilllin.</P>
<P>Metronidazol for people with diarrhea</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-23 15:24:38 +0100" MODIFIED_BY="Clare Jess">
<P>Overall mortality<BR/>Infection-related mortality</P>
<P>Duration of hospitalization</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-18 17:08:52 +0100" MODIFIED_BY="[Empty name]">
<P>Hospital discharge criteria: afebrile for at least 48 to 72 hours</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-10-10 17:39:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vellenga-1996">
<CHAR_METHODS MODIFIED="2014-07-18 17:07:52 +0100" MODIFIED_BY="[Empty name]">
<P>Placebo-controlled, public- and industry-funded, multicenter trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-17 15:07:45 +0100" MODIFIED_BY="[Empty name]">
<P>Adults; mixed tumors; ANC &lt; 0.5 x 10<SUP>9</SUP>/L</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-17 16:02:30 +0100" MODIFIED_BY="[Empty name]">
<P>GM-CSF (Sandoz) 5 mcg/kg SC</P>
<P>ATB: Imipenem, cefuroxime in combination with an aminoglycoside, Augmentin in combination with an aminoglycoside, and Ceftazidime</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-23 15:24:38 +0100" MODIFIED_BY="Clare Jess">
<P>Overall mortality<BR/>Infection-related mortality<BR/>Duration of hospitalization<BR/>Deep vein thrombosis<BR/>Bone and joint pain or flu-like symptoms</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-10 17:39:33 +0100" MODIFIED_BY="[Empty name]">
<P>Hospital discharge criteria: afebrile for at least 72 hours; ANC at least 1000/mm<SUP>3</SUP>
</P>
<P>Duration of grade IV neutropenia reported as median number of days of neutropenia ANC &lt; 0.5 x 10<SUP>9</SUP>/L</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-10-20 14:14:14 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Yoshida-1999">
<CHAR_METHODS MODIFIED="2014-06-23 15:24:39 +0100" MODIFIED_BY="Clare Jess">
<P>Not placebo-controlled, unclear funding, multicenter trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-17 15:08:04 +0100" MODIFIED_BY="[Empty name]">
<P>Adults; hematological tumors; ANC &lt; 1 x 10<SUP>9</SUP>/L</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-20 14:14:14 +0100" MODIFIED_BY="Clare Jess">
<P>G-CSF (filgrastim or lenograstim) variable doses, IV</P>
<P>ATB: Flomoxef Sodium plus Tobramicin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-14 18:52:19 +0100" MODIFIED_BY="[Empty name]">
<P>Duration of hospitalization</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-18 17:08:36 +0100" MODIFIED_BY="[Empty name]">
<P>Hospital discharge criteria: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ATB = Antibiotics; ITT = intention to treat analysis; ANC = absolute neutrophil count; G = granulocyte; M = macrophage; CSF = colony-stimulating factor; IV = intravenous; SC = subcutaneous</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Balcerska-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Beveridge-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess">
<P>Studied non-febrile people and did not have a no-therapy group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Bodey-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess">
<P>Duplicate publication of <LINK REF="STD-Anaissie-1996" TYPE="STUDY">Anaissie 1996</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Feng-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess">
<P>Cross-over study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Fengyi-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess">
<P>Cross-over study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Garcia_x002d_Carb-1999a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess">
<P>Duplicate publication of <LINK REF="STD-Garcia_x002d_Carbonero-2001" TYPE="STUDY">Garcia-Carbonero 2001</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Garcia_x002d_Carb-1999b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess">
<P>Duplicate publication of <LINK REF="STD-Garcia_x002d_Carbonero-2001" TYPE="STUDY">Garcia-Carbonero 2001</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-09 20:24:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gebbia-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-09 20:24:12 +0100" MODIFIED_BY="[Empty name]">
<P>Included non-neutropenic participants. The treatment began immediately after chemotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gunay-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Herrmann-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Kaku-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess">
<P>People who had developed febrile neutropenia were randomized to receive CSF only after the next cycle of chemotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Kawa-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess">
<P>Randomized participants were to receive CSF before or after neutropenia developed</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kotake-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Mayordomo-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess">
<P>Duplicate publication of <LINK REF="STD-Garcia_x002d_Carbonero-2001" TYPE="STUDY">Garcia-Carbonero 2001</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Mayordomo-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess">
<P>Duplicate publication of <LINK REF="STD-Garcia_x002d_Carbonero-2001" TYPE="STUDY">Garcia-Carbonero 2001</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-09 20:24:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Michon-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-09 20:24:31 +0100" MODIFIED_BY="[Empty name]">
<P>Did not included people with febrile neutropenia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Montalar-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Data not extractable</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Moriyama-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Motoyoshi-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess">
<P>Cross-over trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-09 20:24:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nakajima-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-09 20:24:34 +0100" MODIFIED_BY="[Empty name]">
<P>Also included people who had documented infection but were not neutropenic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-09 20:24:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ohno-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-09 20:24:37 +0100" MODIFIED_BY="[Empty name]">
<P>Included non-neutropenic people. The treatment began immediately after chemotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Oshita-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess">
<P>Participants were randomized to receive CSF after the development of monocytopenia or leukopenia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Ravaud-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess">
<P>Duplicate of <LINK REF="STD-Ravaud-1998" TYPE="STUDY">Ravaud 1998</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schroder-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-09 20:24:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Soda-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-09 20:24:44 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized participants to receive CSF before or after the neutropenia developed</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Timmer_x002d_Bonte-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess">
<P>A randomized trial addressing the prophylactic role of G-CSF</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Torrecillas-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess">
<P>Participants were randomized to duration of CSF use</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Uyl_x002d_de-Groot-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess">
<P>Duplicate publication of <LINK REF="STD-Vellenga-1996" TYPE="STUDY">Vellenga 1996</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-09 20:24:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-Pelt-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-09 20:24:50 +0100" MODIFIED_BY="[Empty name]">
<P>Not neutropenic participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Vellenga-1996b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess">
<P>Duplicate publication of <LINK REF="STD-Vellenga-1996" TYPE="STUDY">Vellenga 1996</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yalcin-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-09 20:24:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yamazaki-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-09 20:24:55 +0100" MODIFIED_BY="[Empty name]">
<P>Not neutropenic participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-07-18 17:07:11 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-07-17 14:49:42 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:34 +0100" MODIFIED_BY="Clare Jess" RESULT="YES" STUDY_ID="STD-Anaissie-1996">
<DESCRIPTION>
<P>Computer-generated sequence of numbers was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:34 +0100" MODIFIED_BY="Clare Jess" RESULT="UNKNOWN" STUDY_ID="STD-Arnberg-1998">
<DESCRIPTION>
<P>We were not able to assess the adequacy of method of sequence generation based on the information provided in the article</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:34 +0100" MODIFIED_BY="Clare Jess" RESULT="UNKNOWN" STUDY_ID="STD-Aviles-1996">
<DESCRIPTION>
<P>We were not able to assess the adequacy of method of sequence generation based on the information provided in the article</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:34 +0100" MODIFIED_BY="Clare Jess" RESULT="NO" STUDY_ID="STD-Biesma-1990">
<DESCRIPTION>
<P>Description of method of sequence generation not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-28 14:24:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Garcia_x002d_Carbonero-2001">
<DESCRIPTION>
<P>Sequence was computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-17 14:49:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lopez_x002d_Hernandez-2000">
<DESCRIPTION>
<P>Random sequence was computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:35 +0100" MODIFIED_BY="Clare Jess" RESULT="NO" STUDY_ID="STD-Maher-1994">
<DESCRIPTION>
<P>Description of method of sequence generation not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:36 +0100" MODIFIED_BY="Clare Jess" RESULT="NO" STUDY_ID="STD-Mayordomo-1995">
<DESCRIPTION>
<P>Description of method of sequence generation not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:37 +0100" MODIFIED_BY="Clare Jess" RESULT="NO" STUDY_ID="STD-Mitchell-1997">
<DESCRIPTION>
<P>Description of method of sequence generation not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:37 +0100" MODIFIED_BY="Clare Jess" RESULT="NO" STUDY_ID="STD-Ravaud-1998">
<DESCRIPTION>
<P>Description of method of sequence generation is not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:37 +0100" MODIFIED_BY="Clare Jess" RESULT="UNKNOWN" STUDY_ID="STD-Riikonen-1994">
<DESCRIPTION>
<P>We were not able to assess the adequacy of method of sequence generation based on the information provided in the article</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:38 +0100" MODIFIED_BY="Clare Jess" RESULT="UNKNOWN" STUDY_ID="STD-Rodriguez-2005">
<DESCRIPTION>
<P>We were not able to assess the adequacy of method of sequence generation based on the information provided in the article</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:38 +0100" MODIFIED_BY="Clare Jess" RESULT="NO" STUDY_ID="STD-Vellenga-1996">
<DESCRIPTION>
<P>Description of method of sequence generation is not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess" RESULT="NO" STUDY_ID="STD-Yoshida-1999">
<DESCRIPTION>
<P>Description of method of sequence generation is not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:34 +0100" MODIFIED_BY="Clare Jess" RESULT="UNKNOWN" STUDY_ID="STD-Anaissie-1996">
<DESCRIPTION>
<P>We were not able to assess the adequacy of allocation concealment based on the information provided in the article</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:34 +0100" MODIFIED_BY="Clare Jess" RESULT="UNKNOWN" STUDY_ID="STD-Arnberg-1998">
<DESCRIPTION>
<P>We were not able to assess the adequacy of allocation concealment based on the information provided in the article</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-28 16:20:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aviles-1996">
<DESCRIPTION>
<P>Sealed envelopes were used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:34 +0100" MODIFIED_BY="Clare Jess" RESULT="NO" STUDY_ID="STD-Biesma-1990">
<DESCRIPTION>
<P>Description of methods to conceal allocation not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:34 +0100" MODIFIED_BY="Clare Jess" RESULT="YES" STUDY_ID="STD-Garcia_x002d_Carbonero-2001">
<DESCRIPTION>
<P>Participants were randomly assigned by the consecutive drawing of sequentially numbered, opaque, sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:35 +0100" MODIFIED_BY="Clare Jess" RESULT="UNKNOWN" STUDY_ID="STD-Lopez_x002d_Hernandez-2000">
<DESCRIPTION>
<P>We were not able to assess the adequacy of allocation concealment based on the information provided in the article</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:35 +0100" MODIFIED_BY="Clare Jess" RESULT="YES" STUDY_ID="STD-Maher-1994">
<DESCRIPTION>
<P>The randomization code was maintained by the Biostatistical Department of Amgen, Inc., and was not broken until all collected data had been verified by Amgen and its designee, Biomedicus, and had been audited by a separate department at Amgen</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-28 14:40:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mayordomo-1995">
<DESCRIPTION>
<P>Sealed envelopes were used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:37 +0100" MODIFIED_BY="Clare Jess" RESULT="YES" STUDY_ID="STD-Mitchell-1997">
<DESCRIPTION>
<P>The study drug and placebo were delivered to the ward in identically labeled syringes, and the staff and investigators were unaware of treatment allocation until the study had been completed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:37 +0100" MODIFIED_BY="Clare Jess" RESULT="UNKNOWN" STUDY_ID="STD-Ravaud-1998">
<DESCRIPTION>
<P>We were not able to assess the adequacy of allocation concealment based on the information provided in the article</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:37 +0100" MODIFIED_BY="Clare Jess" RESULT="UNKNOWN" STUDY_ID="STD-Riikonen-1994">
<DESCRIPTION>
<P>We were not able to assess the adequacy of allocation concealment based on the information provided in the article</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:38 +0100" MODIFIED_BY="Clare Jess" RESULT="UNKNOWN" STUDY_ID="STD-Rodriguez-2005">
<DESCRIPTION>
<P>We were not able to assess the adequacy of allocation concealment based on the information provided in the article</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:39 +0100" MODIFIED_BY="Clare Jess" RESULT="UNKNOWN" STUDY_ID="STD-Vellenga-1996">
<DESCRIPTION>
<P>Description of method of allocation concealment is not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess" RESULT="NO" STUDY_ID="STD-Yoshida-1999">
<DESCRIPTION>
<P>Description of method of allocation concealment is not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-06-23 15:24:39 +0100" MODIFIED_BY="Clare Jess" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-11-01 17:55:35 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Anaissie-1996">
<DESCRIPTION>
<P>There was no blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-06-23 15:24:34 +0100" MODIFIED_BY="Clare Jess" RESULT="YES" STUDY_ID="STD-Arnberg-1998">
<DESCRIPTION>
<P>Double blinding was employed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-11-28 14:26:28 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Aviles-1996">
<DESCRIPTION>
<P>There was no blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-06-23 15:24:34 +0100" MODIFIED_BY="Clare Jess" RESULT="YES" STUDY_ID="STD-Biesma-1990">
<DESCRIPTION>
<P>Double blinding was employed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-11-28 14:26:37 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Garcia_x002d_Carbonero-2001">
<DESCRIPTION>
<P>There was no blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-11-28 14:30:23 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lopez_x002d_Hernandez-2000">
<DESCRIPTION>
<P>There was no blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-06-23 15:24:35 +0100" MODIFIED_BY="Clare Jess" RESULT="YES" STUDY_ID="STD-Maher-1994">
<DESCRIPTION>
<P>Double blinding was employed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-11-28 14:41:15 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mayordomo-1995">
<DESCRIPTION>
<P>There was no blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-06-23 15:24:37 +0100" MODIFIED_BY="Clare Jess" RESULT="YES" STUDY_ID="STD-Mitchell-1997">
<DESCRIPTION>
<P>Double blinding was employed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-11-28 14:54:03 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ravaud-1998">
<DESCRIPTION>
<P>There was no blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-06-23 15:24:37 +0100" MODIFIED_BY="Clare Jess" RESULT="YES" STUDY_ID="STD-Riikonen-1994">
<DESCRIPTION>
<P>Double blinding was employed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-11-28 15:23:31 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rodriguez-2005">
<DESCRIPTION>
<P>There was no blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-06-23 15:24:39 +0100" MODIFIED_BY="Clare Jess" RESULT="YES" STUDY_ID="STD-Vellenga-1996">
<DESCRIPTION>
<P>Double blinding was employed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-11-28 15:16:49 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yoshida-1999">
<DESCRIPTION>
<P>There was no blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2014-06-23 15:24:39 +0100" MODIFIED_BY="Clare Jess" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-11-01 17:55:36 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Anaissie-1996">
<DESCRIPTION>
<P>There was no blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-06-23 15:24:34 +0100" MODIFIED_BY="Clare Jess" RESULT="UNKNOWN" STUDY_ID="STD-Arnberg-1998">
<DESCRIPTION>
<P>We were not able to assess who were blinded based on the information provided in the article</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-11-01 18:01:15 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Aviles-1996">
<DESCRIPTION>
<P>There was no blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-06-23 15:24:34 +0100" MODIFIED_BY="Clare Jess" RESULT="UNKNOWN" STUDY_ID="STD-Biesma-1990">
<DESCRIPTION>
<P>We were not able to assess who were blinded based on the information provided in the article</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-11-28 14:26:44 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Garcia_x002d_Carbonero-2001">
<DESCRIPTION>
<P>There was no blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-11-28 14:30:23 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lopez_x002d_Hernandez-2000">
<DESCRIPTION>
<P>There was no blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-06-23 15:24:35 +0100" MODIFIED_BY="Clare Jess" RESULT="UNKNOWN" STUDY_ID="STD-Maher-1994">
<DESCRIPTION>
<P>We were not able to assess who were blinded based on the information provided in the article</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-11-28 14:41:15 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mayordomo-1995">
<DESCRIPTION>
<P>There was no blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-06-23 15:24:37 +0100" MODIFIED_BY="Clare Jess" RESULT="YES" STUDY_ID="STD-Mitchell-1997">
<DESCRIPTION>
<P>Staff and investigators were unaware of treatment allocation until the study had been completed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-11-28 14:54:03 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ravaud-1998">
<DESCRIPTION>
<P>There was no blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-06-23 15:24:37 +0100" MODIFIED_BY="Clare Jess" RESULT="UNKNOWN" STUDY_ID="STD-Riikonen-1994">
<DESCRIPTION>
<P>We were not able to assess who were blinded based on the information provided in the article</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-11-28 15:23:31 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rodriguez-2005">
<DESCRIPTION>
<P>There was no blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-06-23 15:24:39 +0100" MODIFIED_BY="Clare Jess" RESULT="UNKNOWN" STUDY_ID="STD-Vellenga-1996">
<DESCRIPTION>
<P>We were not able to assess who were blinded based on the information provided in the article</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-11-28 15:16:49 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yoshida-1999">
<DESCRIPTION>
<P>There was no blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2014-06-23 15:24:39 +0100" MODIFIED_BY="Clare Jess" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-11-01 17:55:37 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Anaissie-1996">
<DESCRIPTION>
<P>There was no blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-06-23 15:24:34 +0100" MODIFIED_BY="Clare Jess" RESULT="UNKNOWN" STUDY_ID="STD-Arnberg-1998">
<DESCRIPTION>
<P>We were not able to assess the outcomes for which blinding was employed based on the information provided in the article</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-11-28 14:15:09 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Aviles-1996">
<DESCRIPTION>
<P>There was no blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-06-23 15:24:34 +0100" MODIFIED_BY="Clare Jess" RESULT="UNKNOWN" STUDY_ID="STD-Biesma-1990">
<DESCRIPTION>
<P>We were not able to assess the outcomes for which blinding was employed based on the information provided in the article</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-11-28 14:26:45 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Garcia_x002d_Carbonero-2001">
<DESCRIPTION>
<P>There was no blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-11-28 14:30:24 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lopez_x002d_Hernandez-2000">
<DESCRIPTION>
<P>There was no blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-06-23 15:24:35 +0100" MODIFIED_BY="Clare Jess" RESULT="UNKNOWN" STUDY_ID="STD-Maher-1994">
<DESCRIPTION>
<P>We were not able to assess the outcomes for which blinding was employed based on the information provided in the article</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-11-28 14:41:15 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mayordomo-1995">
<DESCRIPTION>
<P>There was no blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-06-23 15:24:37 +0100" MODIFIED_BY="Clare Jess" RESULT="UNKNOWN" STUDY_ID="STD-Mitchell-1997">
<DESCRIPTION>
<P>We were not able to assess the outcomes for which blinding was employed based on the information provided in the article</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-11-28 14:54:03 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ravaud-1998">
<DESCRIPTION>
<P>There was no blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-06-23 15:24:37 +0100" MODIFIED_BY="Clare Jess" RESULT="UNKNOWN" STUDY_ID="STD-Riikonen-1994">
<DESCRIPTION>
<P>We were not able to assess the outcomes for which blinding was employed based on the information provided in the article</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-11-28 15:23:31 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rodriguez-2005">
<DESCRIPTION>
<P>There was no blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-06-23 15:24:39 +0100" MODIFIED_BY="Clare Jess" RESULT="UNKNOWN" STUDY_ID="STD-Vellenga-1996">
<DESCRIPTION>
<P>We were not able to assess the outcomes for which blinding was employed based on the information provided in the article</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-11-28 15:16:49 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yoshida-1999">
<DESCRIPTION>
<P>There was no blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-07-18 17:07:11 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-23 15:24:34 +0100" MODIFIED_BY="Clare Jess" RESULT="YES" STUDY_ID="STD-Anaissie-1996">
<DESCRIPTION>
<P>ITT analysis used, Withdrawals are described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-23 15:24:34 +0100" MODIFIED_BY="Clare Jess" RESULT="YES" STUDY_ID="STD-Arnberg-1998">
<DESCRIPTION>
<P>ITT analysis used, withdrawals are described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-23 15:24:34 +0100" MODIFIED_BY="Clare Jess" RESULT="NO" STUDY_ID="STD-Aviles-1996">
<DESCRIPTION>
<P>ITT analysis was not used, withdrawals are described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-23 15:24:34 +0100" MODIFIED_BY="Clare Jess" RESULT="NO" STUDY_ID="STD-Biesma-1990">
<DESCRIPTION>
<P>ITT analysis was not used, withdrawals are described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-23 15:24:34 +0100" MODIFIED_BY="Clare Jess" RESULT="YES" STUDY_ID="STD-Garcia_x002d_Carbonero-2001">
<DESCRIPTION>
<P>ITT analysis used, withdrawals are described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-07-18 17:07:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lopez_x002d_Hernandez-2000">
<DESCRIPTION>
<P>ITT analysis not used, Withdrawals are described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-23 15:24:35 +0100" MODIFIED_BY="Clare Jess" RESULT="YES" STUDY_ID="STD-Maher-1994">
<DESCRIPTION>
<P>ITT analysis used, withdrawals are described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-23 15:24:36 +0100" MODIFIED_BY="Clare Jess" RESULT="YES" STUDY_ID="STD-Mayordomo-1995">
<DESCRIPTION>
<P>ITT analysis used, withdrawals are described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-23 15:24:37 +0100" MODIFIED_BY="Clare Jess" RESULT="YES" STUDY_ID="STD-Mitchell-1997">
<DESCRIPTION>
<P>ITT analysis used, withdrawals are described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-23 15:24:37 +0100" MODIFIED_BY="Clare Jess" RESULT="YES" STUDY_ID="STD-Ravaud-1998">
<DESCRIPTION>
<P>ITT analysis used, withdrawals are described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-23 15:24:37 +0100" MODIFIED_BY="Clare Jess" RESULT="NO" STUDY_ID="STD-Riikonen-1994">
<DESCRIPTION>
<P>ITT analysis not used, withdrawals are described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-23 15:24:38 +0100" MODIFIED_BY="Clare Jess" RESULT="YES" STUDY_ID="STD-Rodriguez-2005">
<DESCRIPTION>
<P>ITT analysis used, withdrawals are not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-23 15:24:39 +0100" MODIFIED_BY="Clare Jess" RESULT="YES" STUDY_ID="STD-Vellenga-1996">
<DESCRIPTION>
<P>ITT analysis used, withdrawals are described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess" RESULT="YES" STUDY_ID="STD-Yoshida-1999">
<DESCRIPTION>
<P>ITT analysis used, withdrawals are described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:34 +0100" MODIFIED_BY="Clare Jess" RESULT="NO" STUDY_ID="STD-Anaissie-1996">
<DESCRIPTION>
<P>Prespecified values of sample size, alpha and beta errors were not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:34 +0100" MODIFIED_BY="Clare Jess" RESULT="UNKNOWN" STUDY_ID="STD-Arnberg-1998">
<DESCRIPTION>
<P>Prespecified values of sample size, alpha and beta errors were not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:34 +0100" MODIFIED_BY="Clare Jess" RESULT="NO" STUDY_ID="STD-Aviles-1996">
<DESCRIPTION>
<P>Prespecified values of sample size, alpha and beta errors were not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:34 +0100" MODIFIED_BY="Clare Jess" RESULT="NO" STUDY_ID="STD-Biesma-1990">
<DESCRIPTION>
<P>Prespecified values of sample size, alpha and beta errors were not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:34 +0100" MODIFIED_BY="Clare Jess" RESULT="YES" STUDY_ID="STD-Garcia_x002d_Carbonero-2001">
<DESCRIPTION>
<P>Prespecified values of sample size, alpha and beta errors were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:35 +0100" MODIFIED_BY="Clare Jess" RESULT="NO" STUDY_ID="STD-Lopez_x002d_Hernandez-2000">
<DESCRIPTION>
<P>Prespecified values of sample size, alpha and beta errors were not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:35 +0100" MODIFIED_BY="Clare Jess" RESULT="YES" STUDY_ID="STD-Maher-1994">
<DESCRIPTION>
<P>Prespecified values of sample size, alpha and beta errors were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:36 +0100" MODIFIED_BY="Clare Jess" RESULT="YES" STUDY_ID="STD-Mayordomo-1995">
<DESCRIPTION>
<P>Prespecified values of sample size, alpha and beta errors were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:37 +0100" MODIFIED_BY="Clare Jess" RESULT="YES" STUDY_ID="STD-Mitchell-1997">
<DESCRIPTION>
<P>Prespecified values of sample size, alpha and beta errors were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:37 +0100" MODIFIED_BY="Clare Jess" RESULT="YES" STUDY_ID="STD-Ravaud-1998">
<DESCRIPTION>
<P>Prespecified values of sample size, alpha and beta errors were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:37 +0100" MODIFIED_BY="Clare Jess" RESULT="YES" STUDY_ID="STD-Riikonen-1994">
<DESCRIPTION>
<P>Prespecified values of sample size, alpha and beta errors were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:38 +0100" MODIFIED_BY="Clare Jess" RESULT="YES" STUDY_ID="STD-Rodriguez-2005">
<DESCRIPTION>
<P>Prespecified values of sample size, alpha and beta errors were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:39 +0100" MODIFIED_BY="Clare Jess" RESULT="YES" STUDY_ID="STD-Vellenga-1996">
<DESCRIPTION>
<P>Prespecified values of sample size, alpha and beta errors were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-23 15:24:40 +0100" MODIFIED_BY="Clare Jess" RESULT="NO" STUDY_ID="STD-Yoshida-1999">
<DESCRIPTION>
<P>Prespecified values of sample size, alpha and beta errors were not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2014-10-30 14:42:11 +0000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2014-10-30 14:42:11 +0000" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2014-07-14 18:40:20 +0100" MODIFIED_BY="[Empty name]">Benefits and harms of CSF plus antibiotics versus antibiotics alone</TITLE>
<TABLE COLS="6" ROWS="26">
<TR>
<TD COLSPAN="6">
<P>
<B>CSF plus ATB compared to ATB alone for chemotherapy induced febrile neutropenia</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Population:</B> people with chemotherapy-induced febrile neutropenia<BR/>
<B>Settings: </B>in-patient/hospital<BR/>
<B>Intervention:</B> CSF plus ATB<BR/>
<B>Comparison: </B>ATB alone</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>ATB alone</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>CSF + ATB</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Overall mortality</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>HR 0.74 </B>
<BR/>(0.47 to 1.16)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1335<BR/>(13)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>70 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>52 per 1000</B>
<BR/>(33 to 80)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>29 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>22 per 1000</B>
<BR/>(14 to 34)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Infection-related mortality</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.75 </B>
<BR/>(0.47 to 1.20)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>897<BR/>(10)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>56 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>43 per 1000</B>
<BR/>(27 to 67)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>22 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>17 per 1000</B>
<BR/>(10 to 26)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>People hospitalized for &gt; 10 days</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.65 </B>
<BR/>(0.44 to 0.95)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1087<BR/>(7)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>3,4</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>349 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>227 per 1000</B>
<BR/>(153 to 331)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>338 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>220 per 1000</B>
<BR/>(149 to 321)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Duration of grade IV neutropenia </B>(lower values signify better outcomes)</P>
</TD>
<TD COLSPAN="2">
<P>The mean duration of grade IV neutropenia in the intervention groups was<BR/>
<B>1.70 standard deviations lower</B>
<BR/>(2.65 to 0.76 lower)</P>
</TD>
<TD>
<P>
<B>SMD -1.70</B>
</P>
<P>(-2.65 to -0.76)</P>
</TD>
<TD>
<P>1135<BR/>(9)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>3,5</SUP>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Time to recovery from fever</B>
</P>
<P>(lower values signify better outcomes)</P>
</TD>
<TD COLSPAN="2">
<P>The mean time to recovery from fever in the intervention groups was<BR/>
<B>0.49 standard deviations lower</B>
<BR/>(0.9 to 0.09 lower)</P>
</TD>
<TD>
<P>
<B>SMD -0.49</B>
</P>
<P>(-0.9 to -0.09)</P>
</TD>
<TD>
<P>966<BR/>(9)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>3,6</SUP>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Time to withdrawal from ATB </B>
</P>
<P>(lower values signify better outcomes)</P>
</TD>
<TD COLSPAN="2">
<P>The mean time to withdrawal from ATB in the intervention groups was<BR/>
<B>1.5 standard deviations lower</B>
<BR/>(2.83 to 0.18 lower)</P>
</TD>
<TD>
<P>
<B>SMD -1.5</B>
</P>
<P>(-2.83 to -0.18)</P>
</TD>
<TD>
<P>457<BR/>(3)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>3,7</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Deep vein thrombosis</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.68 </B>
<BR/>(0.72 to 3.93)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>389<BR/>(4)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,3</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>26 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>43 per 1000</B>
<BR/>(18 to 101)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>5 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>8 per 1000</B>
<BR/>(4 to 20)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>ATB:</B> antibiotics; <B>CI:</B> confidence interval; <B>HR:</B> hazard ratio; <B>RR:</B> risk ratio; <B>SMD</B>: standardized mean difference</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Seven of the included articles described an adequate method of randomization (<LINK REF="STD-Anaissie-1996" TYPE="STUDY">Anaissie 1996</LINK>; <LINK REF="STD-Aviles-1996" TYPE="STUDY">Aviles 1996</LINK>; <LINK REF="STD-Garcia_x002d_Carbonero-2001" TYPE="STUDY">Garcia-Carbonero 2001</LINK>; <LINK REF="STD-Lopez_x002d_Hernandez-2000" TYPE="STUDY">Lopez-Hernandez 2000</LINK>; <LINK REF="STD-Riikonen-1994" TYPE="STUDY">Riikonen 1994</LINK>; <LINK REF="STD-Vellenga-1996" TYPE="STUDY">Vellenga 1996</LINK>; <LINK REF="STD-Yoshida-1999" TYPE="STUDY">Yoshida 1999</LINK>) and five reported adequate concealment of the sequence of allocation (<LINK REF="STD-Aviles-1996" TYPE="STUDY">Aviles 1996</LINK>; <LINK REF="STD-Garcia_x002d_Carbonero-2001" TYPE="STUDY">Garcia-Carbonero 2001</LINK>; <LINK REF="STD-Maher-1994" TYPE="STUDY">Maher 1994</LINK>; <LINK REF="STD-Mayordomo-1995" TYPE="STUDY">Mayordomo 1995</LINK>; <LINK REF="STD-Mitchell-1997" TYPE="STUDY">Mitchell 1997</LINK>). Seven trials were placebo controlled (<LINK REF="STD-Arnberg-1998" TYPE="STUDY">Arnberg 1998</LINK>; <LINK REF="STD-Biesma-1990" TYPE="STUDY">Biesma 1990</LINK>; <LINK REF="STD-Maher-1994" TYPE="STUDY">Maher 1994</LINK>; <LINK REF="STD-Mayordomo-1995" TYPE="STUDY">Mayordomo 1995</LINK>; <LINK REF="STD-Mitchell-1997" TYPE="STUDY">Mitchell 1997</LINK>; <LINK REF="STD-Riikonen-1994" TYPE="STUDY">Riikonen 1994</LINK>; <LINK REF="STD-Vellenga-1996" TYPE="STUDY">Vellenga 1996</LINK>). A sample size was preplanned in seven (<LINK REF="STD-Garcia_x002d_Carbonero-2001" TYPE="STUDY">Garcia-Carbonero 2001</LINK>; <LINK REF="STD-Maher-1994" TYPE="STUDY">Maher 1994</LINK>; <LINK REF="STD-Mayordomo-1995" TYPE="STUDY">Mayordomo 1995</LINK>; <LINK REF="STD-Mitchell-1997" TYPE="STUDY">Mitchell 1997</LINK>; <LINK REF="STD-Ravaud-1998" TYPE="STUDY">Ravaud 1998</LINK>; <LINK REF="STD-Vellenga-1996" TYPE="STUDY">Vellenga 1996</LINK>; <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>), but the planned number was not reached in one trial (<LINK REF="STD-Ravaud-1998" TYPE="STUDY">Ravaud 1998</LINK>). Hence we downgraded the quality of evidence by 1 for the risk of bias (also see footnote # 2 below).<BR/>
<SUP>2</SUP> Of all the included trials only that by Aviles et al (<LINK REF="STD-Aviles-1996" TYPE="STUDY">Aviles 1996</LINK>) appeared to show a benefit of CSF plus antibiotics compared with antibiotics alone for the outcome of overall mortality. It is important to note that 33% (15 of 45) of the events for this outcome in the control group were reported in this trial. These 15 deaths represent 33% (15 of 45) of the total of deaths in the control group among all trials. Similarly, there were 15 infection-related deaths among the 471 participants randomized to the intervention group and 25 among 426 randomized to the control group. However, it is important to note that 60% (15 of 25) of the events in the control group were reported in one study (<LINK REF="STD-Aviles-1996" TYPE="STUDY">Aviles 1996</LINK>).<BR/>
<SUP>3</SUP> A majority of the individual randomized controlled trials and the pooled estimates have wide CIs. We downgraded the quality of evidence by 1 for the observed imprecision.</P>
<P>
<SUP>4</SUP> Substantial heterogeneity was detected (P = 0.0009, I<SUP>2 </SUP>= 70%). As planned, we explored the possible causes of heterogeneity to determine if it was appropriate to pool the trials. All trials but one trial (<LINK REF="STD-Yoshida-1999" TYPE="STUDY">Yoshida 1999</LINK>) had a point estimate that favored the intervention group. This trial enrolled only people with hematological malignancies. We explored the impact of type of malignancy on number of participants hospitalized for more than 10 days (<LINK TAG="SUBGROUP_ANALYSIS" TYPE="SECTION">Subgroup analysis and investigation of heterogeneity</LINK>: type of malignancy). The trials enrolling people with mixed cancers favored the use of CSF plus antibiotics (RR 0.64, 95% CI 0.45 to 0.89) compared with trial enrolling people with only hematological malignancies (RR 1.17, 95% CI 0.81 to 1.70) (test of interaction P = 0.02) for the outcome of number of participants hospitalized for more than 10 days (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>). We also noticed that only two trials reached statistical significance (<LINK REF="STD-Maher-1994" TYPE="STUDY">Maher 1994</LINK>; <LINK REF="STD-Mayordomo-1995" TYPE="STUDY">Mayordomo 1995</LINK>). By inspecting the forest plot, we could detect that trial by Mayordomo et al (<LINK REF="STD-Mayordomo-1995" TYPE="STUDY">Mayordomo 1995</LINK>) and Maher et al (<LINK REF="STD-Maher-1994" TYPE="STUDY">Maher 1994</LINK>) indicated a much stronger effect than that detected in all other trials. We therefore repeated our analysis, excluding these trials (<LINK REF="STD-Maher-1994" TYPE="STUDY">Maher 1994</LINK>; <LINK REF="STD-Mayordomo-1995" TYPE="STUDY">Mayordomo 1995</LINK>). The exclusion resulted in a substantial reduction in the statistical heterogeneity (I<SUP>2 </SUP>= 48%; P = 0.10) and the significance of the effect of CSF plus antibiotics on this outcome disappeared (RR 0.85, 95% CI = 0.61 to 1.17; P = 0.32). Hence we downgraded the quality of evidence by 1 for the observed inconsistency.</P>
<P>
<SUP>5</SUP> Considerable heterogeneity was detected (P value &lt; 0.00001, I<SUP>2 </SUP>= 98%). In a subgroup analysis according to CSF type, G-CSF showed a statistically significantly stronger beneficial effect than GM-CSF for the outcome of duration of grade IV neutropenia (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>). Nonetheless, we downgraded the quality of evidence by 1 for the observed inconsistency.</P>
<P>
<SUP>6</SUP> Considerable heterogeneity was detected (P value &lt; 0.00001, I<SUP>2 </SUP>= 89%). We downgraded the quality of evidence by 1 for the observed inconsistency.</P>
<P>
<SUP>7</SUP> Considerable heterogeneity was detected (P value &lt; 0.00001, I<SUP>2 </SUP>= 97%). We downgraded the quality of evidence by 1 for the observed inconsistency. We noted that in all of these trials the mean/median duration of ATB use was similar (mean of 5 days) among patients receiving CSF. However, the high precision observed around the effect size in the trial by Garcio-Carbonero et al (<LINK REF="STD-Garcia_x002d_Carbonero-2001" TYPE="STUDY">Garcia-Carbonero 2001</LINK>) compared with other two trial estimates was potentially leading to the substantial heterogeneity. The heterogeneity disappeared completely once we removed this trial from the analysis (P value = 0.72, I<SUP>2 </SUP>= 0%) and the overall effect still showed benefit with the use of CSF plus ATB compared with ATB alone.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2014-07-17 16:04:59 +0100" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-10-30 14:40:57 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2014-10-30 14:40:57 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Benefits and harms - CSF + antibiotics vs antibiotics alone</NAME>
<IV_OUTCOME CHI2="9.955338139059915" CI_END="1.1608448029154315" CI_START="0.4692074886294322" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_SIZE="0.738022407969079" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.06477416138992682" LOG_CI_START="-0.32863506508914714" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.13193045184961016" MODIFIED="2014-10-17 17:56:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5344091140711396" P_Q="1.0" P_Z="0.18865967102027018" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="688" TOTAL_2="647" WEIGHT="100.0" Z="1.3145544978878931">
<NAME>Overall mortality</NAME>
<GROUP_LABEL_1>CSF plus ATB</GROUP_LABEL_1>
<GROUP_LABEL_2>ATB alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors CSF plus ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ATB alone</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="5.188111442339334" CI_START="0.192748365395385" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.7150092963004789" LOG_CI_START="-0.715009296300479" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-17 16:29:39 +0100" MODIFIED_BY="[Empty name]" ORDER="291" SE="0.84" STUDY_ID="STD-Anaissie-1996" TOTAL_1="50" TOTAL_2="50" WEIGHT="7.568428527215798"/>
<IV_DATA CI_END="403.3997351921896" CI_START="0.1588288662842363" EFFECT_SIZE="8.004468914296353" ESTIMABLE="YES" ESTIMATE="2.08" LOG_CI_END="2.6057356087884753" LOG_CI_START="-0.799070564070948" LOG_EFFECT_SIZE="0.9033325223587638" MODIFIED="2014-10-17 16:29:56 +0100" MODIFIED_BY="[Empty name]" ORDER="293" SE="2.0" STUDY_ID="STD-Arnberg-1998" TOTAL_1="14" TOTAL_2="15" WEIGHT="1.3350707922008667"/>
<IV_DATA CI_END="0.7948374524378763" CI_START="0.11643962828686279" EFFECT_SIZE="0.3042212640667041" ESTIMABLE="YES" ESTIMATE="-1.19" LOG_CI_END="-0.09972167728959028" LOG_CI_START="-0.933899189640149" LOG_EFFECT_SIZE="-0.5168104334648697" MODIFIED="2014-10-17 16:30:08 +0100" MODIFIED_BY="[Empty name]" ORDER="287" SE="0.49" STUDY_ID="STD-Aviles-1996" TOTAL_1="61" TOTAL_2="58" WEIGHT="22.241912406511734"/>
<IV_DATA CI_END="436.99771623720187" CI_START="0.17205725681918843" EFFECT_SIZE="8.671137658463456" ESTIMABLE="YES" ESTIMATE="2.16" LOG_CI_END="2.6404791673407355" LOG_CI_START="-0.7643270055186878" LOG_EFFECT_SIZE="0.938076080911024" MODIFIED="2014-10-17 16:30:16 +0100" MODIFIED_BY="[Empty name]" ORDER="289" SE="2.0" STUDY_ID="STD-Biesma-1990" TOTAL_1="12" TOTAL_2="14" WEIGHT="1.3350707922008667"/>
<IV_DATA CI_END="3.400684007112884" CI_START="0.2660751237525739" EFFECT_SIZE="0.951229424500714" ESTIMABLE="YES" ESTIMATE="-0.05" LOG_CI_END="0.5315662789944938" LOG_CI_START="-0.574995727184819" LOG_EFFECT_SIZE="-0.021714724095162587" MODIFIED="2014-10-17 16:30:30 +0100" MODIFIED_BY="[Empty name]" ORDER="292" SE="0.65" STUDY_ID="STD-Garcia_x002d_Carbonero-2001" TOTAL_1="104" TOTAL_2="99" WEIGHT="12.639723476457908"/>
<IV_DATA CI_END="4.537413525202088" CI_START="0.04275123728826379" EFFECT_SIZE="0.4404316545059993" ESTIMABLE="YES" ESTIMATE="-0.82" LOG_CI_END="0.6568083612650121" LOG_CI_START="-1.369051311586345" LOG_EFFECT_SIZE="-0.35612147516066645" MODIFIED="2014-10-17 16:30:48 +0100" MODIFIED_BY="[Empty name]" ORDER="294" SE="1.19" STUDY_ID="STD-Lopez_x002d_Hernandez-2000" TOTAL_1="21" TOTAL_2="19" WEIGHT="3.771120096605795"/>
<IV_DATA CI_END="1.7050343099339382" CI_START="0.3417809536023755" EFFECT_SIZE="0.7633794943368531" ESTIMABLE="YES" ESTIMATE="-0.27" LOG_CI_END="0.23173312260421292" LOG_CI_START="-0.4662521428319689" LOG_EFFECT_SIZE="-0.11725951011387802" MODIFIED="2014-10-17 16:31:00 +0100" MODIFIED_BY="[Empty name]" ORDER="288" SE="0.41" STUDY_ID="STD-Maher-1994" TOTAL_1="109" TOTAL_2="107" WEIGHT="31.76848999883086"/>
<IV_DATA CI_END="11.779606186931472" CI_START="0.4376351323148584" EFFECT_SIZE="2.2704998375324057" ESTIMABLE="YES" ESTIMATE="0.82" LOG_CI_END="1.0711307714611453" LOG_CI_START="-0.35888782113981255" LOG_EFFECT_SIZE="0.3561214751606665" MODIFIED="2014-10-17 16:31:14 +0100" MODIFIED_BY="[Empty name]" ORDER="297" SE="0.84" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="22" WEIGHT="7.568428527215798"/>
<IV_DATA CI_END="7.382875997309072" CI_START="0.13544857049806638" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.8682255740791531" LOG_CI_START="-0.8682255740791531" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-17 16:31:22 +0100" MODIFIED_BY="[Empty name]" ORDER="290" SE="1.02" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="21" WEIGHT="5.132913464824555"/>
<IV_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-17 16:25:30 +0100" MODIFIED_BY="[Empty name]" ORDER="295" SE="0.0" STUDY_ID="STD-Mitchell-1997" TOTAL_1="94" TOTAL_2="92" WEIGHT="0.0"/>
<IV_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.8338141226232082" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" MODIFIED="2014-10-17 16:31:38 +0100" MODIFIED_BY="[Empty name]" ORDER="298" SE="2.0" STUDY_ID="STD-Ravaud-1998" TOTAL_1="34" TOTAL_2="34" WEIGHT="1.3350707922008667"/>
<IV_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-17 16:25:30 +0100" MODIFIED_BY="[Empty name]" ORDER="285" SE="0.0" STUDY_ID="STD-Riikonen-1994" TOTAL_1="28" TOTAL_2="30" WEIGHT="0.0"/>
<IV_DATA CI_END="174.15191083097233" CI_START="0.06856809299921493" EFFECT_SIZE="3.4556134647626755" ESTIMABLE="YES" ESTIMATE="1.24" LOG_CI_END="2.240928243989744" LOG_CI_START="-1.1638779288696797" LOG_EFFECT_SIZE="0.5385251575600323" MODIFIED="2014-10-17 16:31:48 +0100" MODIFIED_BY="[Empty name]" ORDER="296" SE="2.0" STUDY_ID="STD-Rodriguez-2005" TOTAL_1="18" TOTAL_2="17" WEIGHT="1.3350707922008667"/>
<IV_DATA CI_END="5.225540419472196" CI_START="0.055378811512145895" EFFECT_SIZE="0.5379444375946745" ESTIMABLE="YES" ESTIMATE="-0.62" LOG_CI_END="0.7181312113492166" LOG_CI_START="-1.2566563689092491" LOG_EFFECT_SIZE="-0.26926257878001614" MODIFIED="2014-10-17 16:32:01 +0100" MODIFIED_BY="[Empty name]" ORDER="286" SE="1.16" STUDY_ID="STD-Vellenga-1996" TOTAL_1="65" TOTAL_2="69" WEIGHT="3.968700333534087"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="9.089722349810614" CI_END="1.2049360190661371" CI_START="0.46567540636653987" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_SIZE="0.7490721395995876" ESTIMABLE="YES" I2="11.988510846355156" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.08096398690737643" LOG_CI_START="-0.33191669777983135" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.1254763554362275" MODIFIED="2014-10-17 16:35:50 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3347838323298884" P_Q="1.0" P_Z="0.23354201877553593" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.07027679104552281" TOTALS="YES" TOTAL_1="471" TOTAL_2="426" WEIGHT="100.0" Z="1.1912842944089999">
<NAME>Infection related mortality</NAME>
<GROUP_LABEL_1>CSF plus ATB</GROUP_LABEL_1>
<GROUP_LABEL_2>ATB alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors CSF plus ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ATB alone</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="2.5598892210813107" CI_START="0.05079466322511451" EFFECT_SIZE="0.3605949401730783" ESTIMABLE="YES" ESTIMATE="-1.02" LOG_CI_END="0.40822117167353905" LOG_CI_START="-1.2941819147561728" LOG_EFFECT_SIZE="-0.44298037154131686" MODIFIED="2014-10-17 15:51:13 +0100" MODIFIED_BY="[Empty name]" ORDER="265" SE="1.0" STUDY_ID="STD-Anaissie-1996" TOTAL_1="50" TOTAL_2="50" WEIGHT="5.495765946167664"/>
<IV_DATA CI_END="0.7648953843758224" CI_START="0.13107523691572276" EFFECT_SIZE="0.3166367693790533" ESTIMABLE="YES" ESTIMATE="-1.15" LOG_CI_END="-0.11639795974205437" LOG_CI_START="-0.8824793486354248" LOG_EFFECT_SIZE="-0.4994386541887395" MODIFIED="2014-10-17 16:03:58 +0100" MODIFIED_BY="[Empty name]" ORDER="261" SE="0.45" STUDY_ID="STD-Aviles-1996" TOTAL_1="61" TOTAL_2="61" WEIGHT="21.563384181830788"/>
<IV_DATA CI_END="1.50982356089158" CI_START="0.6893592080241279" EFFECT_SIZE="1.0202013400267558" ESTIMABLE="YES" ESTIMATE="0.02" LOG_CI_END="0.17892619828103623" LOG_CI_START="-0.16155441900490616" LOG_EFFECT_SIZE="0.008685889638065021" MODIFIED="2014-10-17 16:04:02 +0100" MODIFIED_BY="[Empty name]" ORDER="268" SE="0.2" STUDY_ID="STD-Biesma-1990" TOTAL_1="12" TOTAL_2="14" WEIGHT="53.338428561758505"/>
<IV_DATA CI_END="8.12030687738327" CI_START="0.24798972968363955" EFFECT_SIZE="1.4190675485932571" ESTIMABLE="YES" ESTIMATE="0.35" LOG_CI_END="0.9095724421273599" LOG_CI_START="-0.6055663047950837" LOG_EFFECT_SIZE="0.1520030686661381" MODIFIED="2014-10-17 16:04:09 +0100" MODIFIED_BY="[Empty name]" ORDER="267" SE="0.89" STUDY_ID="STD-Garcia_x002d_Carbonero-2001" TOTAL_1="104" TOTAL_2="99" WEIGHT="6.820673749893499"/>
<IV_DATA CI_END="4.323038805737429" CI_START="0.047645905452321745" EFFECT_SIZE="0.45384479528235583" ESTIMABLE="YES" ESTIMATE="-0.79" LOG_CI_END="0.6357891339935153" LOG_CI_START="-1.3219744154006532" LOG_EFFECT_SIZE="-0.34309264070356893" MODIFIED="2014-10-17 16:03:39 +0100" MODIFIED_BY="[Empty name]" ORDER="260" SE="1.15" STUDY_ID="STD-Lopez_x002d_Hernandez-2000" TOTAL_1="21" TOTAL_2="19" WEIGHT="4.223211342275546"/>
<IV_DATA CI_END="230.42558509599056" CI_START="0.0907244880223872" EFFECT_SIZE="4.57222519514216" ESTIMABLE="YES" ESTIMATE="1.52" LOG_CI_END="2.362530698922655" LOG_CI_START="-1.0422754739367692" LOG_EFFECT_SIZE="0.6601276124929428" MODIFIED="2014-10-17 16:07:40 +0100" MODIFIED_BY="[Empty name]" ORDER="262" SE="2.0" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="21" WEIGHT="1.4451082919328184"/>
<IV_DATA CI_END="10.216035383083533" CI_START="0.11259493098094936" EFFECT_SIZE="1.0725081812542165" ESTIMABLE="YES" ESTIMATE="0.07" LOG_CI_END="1.009282388430312" LOG_CI_START="-0.9484811609638567" LOG_EFFECT_SIZE="0.030400613733227652" MODIFIED="2014-10-17 16:06:34 +0100" MODIFIED_BY="[Empty name]" ORDER="263" SE="1.15" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="22" WEIGHT="4.223211342275546"/>
<IV_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.8338141226232082" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" MODIFIED="2014-10-17 16:08:27 +0100" MODIFIED_BY="[Empty name]" ORDER="264" SE="2.0" STUDY_ID="STD-Ravaud-1998" TOTAL_1="34" TOTAL_2="34" WEIGHT="1.4451082919328184"/>
<IV_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-17 15:47:18 +0100" MODIFIED_BY="[Empty name]" ORDER="270" SE="0.0" STUDY_ID="STD-Riikonen-1994" TOTAL_1="28" TOTAL_2="30" WEIGHT="0.0"/>
<IV_DATA CI_END="174.15191083097233" CI_START="0.06856809299921493" EFFECT_SIZE="3.4556134647626755" ESTIMABLE="YES" ESTIMATE="1.24" LOG_CI_END="2.240928243989744" LOG_CI_START="-1.1638779288696797" LOG_EFFECT_SIZE="0.5385251575600323" MODIFIED="2014-10-17 16:10:28 +0100" MODIFIED_BY="[Empty name]" ORDER="269" SE="2.0" STUDY_ID="STD-Rodriguez-2005" TOTAL_1="18" TOTAL_2="7" WEIGHT="1.4451082919328184"/>
<IV_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-17 15:47:18 +0100" MODIFIED_BY="[Empty name]" ORDER="266" SE="0.0" STUDY_ID="STD-Vellenga-1996" TOTAL_1="65" TOTAL_2="69" WEIGHT="0.0"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="22.501324884052927" CI_END="0.9526698015390064" CI_START="0.44480128013234976" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6509598660961993" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="182" I2="68.89072071946741" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.021057601165146364" LOG_CI_START="-0.35183397153028045" LOG_EFFECT_SIZE="-0.18644578634771336" METHOD="MH" MODIFIED="2014-10-17 17:37:40 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.00208092009634131" P_Q="1.0" P_Z="0.02713911316396967" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.17640597149618617" TOTALS="YES" TOTAL_1="565" TOTAL_2="522" WEIGHT="99.99999999999999" Z="2.209511071830095">
<NAME>Patients with hospitalization for greater than10 days</NAME>
<GROUP_LABEL_1>CSF plus ATB</GROUP_LABEL_1>
<GROUP_LABEL_2>ATB alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors CSF plus ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ATB alone</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.091771683962423" CI_START="0.43900198903207566" EFFECT_SIZE="0.6923076923076923" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="26" LOG_CI_END="0.038131826315114824" LOG_CI_START="-0.3575335120501386" LOG_EFFECT_SIZE="-0.1597008428675119" MODIFIED="2014-07-28 15:36:50 +0100" MODIFIED_BY="[Empty name]" ORDER="257" O_E="0.0" SE="0.23241577833076224" STUDY_ID="STD-Anaissie-1996" TOTAL_1="50" TOTAL_2="50" VAR="0.05401709401709401" WEIGHT="16.383934708665915"/>
<DICH_DATA CI_END="1.63988773696822" CI_START="0.6016672931718803" EFFECT_SIZE="0.9933110367892977" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" LOG_CI_END="0.21481411824036745" LOG_CI_START="-0.22064359625480207" LOG_EFFECT_SIZE="-0.0029147390072172936" MODIFIED="2014-10-10 20:28:24 +0100" MODIFIED_BY="[Empty name]" ORDER="261" O_E="0.0" SE="0.25579001704491355" STUDY_ID="STD-Garcia_x002d_Carbonero-2001" TOTAL_1="104" TOTAL_2="99" VAR="0.06542853281983717" WEIGHT="15.610826384835669"/>
<DICH_DATA CI_END="0.8130748301230439" CI_START="0.3944753449233908" EFFECT_SIZE="0.5663373323923783" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="52" LOG_CI_END="-0.08986948292499009" LOG_CI_START="-0.40398013541611133" LOG_EFFECT_SIZE="-0.2469248091705507" MODIFIED="2014-10-17 17:36:52 +0100" MODIFIED_BY="[Empty name]" ORDER="260" O_E="0.0" SE="0.18451015214609112" STUDY_ID="STD-Maher-1994" TOTAL_1="109" TOTAL_2="107" VAR="0.034043996244973694" WEIGHT="17.938878780839413"/>
<DICH_DATA CI_END="0.5839566004470578" CI_START="0.010132875899996046" EFFECT_SIZE="0.07692307692307693" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="-0.23361942837859279" LOG_CI_START="-1.9942672762350806" LOG_EFFECT_SIZE="-1.1139433523068367" MODIFIED="2014-10-17 17:36:52 +0100" MODIFIED_BY="[Empty name]" ORDER="259" O_E="0.0" SE="1.0342132611783073" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="21" VAR="1.0695970695970696" WEIGHT="3.0298774049763164"/>
<DICH_DATA CI_END="0.606460826035732" CI_START="0.03279392596006056" EFFECT_SIZE="0.14102564102564102" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="-0.21719724687651348" LOG_CI_START="-1.4842065881879973" LOG_EFFECT_SIZE="-0.8507019175322553" MODIFIED="2014-10-17 17:36:53 +0100" MODIFIED_BY="[Empty name]" ORDER="258" O_E="0.0" SE="0.7442475588837554" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="22" VAR="0.5539044289044289" WEIGHT="5.16935875303064"/>
<DICH_DATA CI_END="1.679725007800233" CI_START="0.5086682046226763" EFFECT_SIZE="0.9243498817966903" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" LOG_CI_END="0.22523818805306842" LOG_CI_START="-0.29356540801141945" LOG_EFFECT_SIZE="-0.03416360997917553" MODIFIED="2014-10-10 19:51:58 +0100" MODIFIED_BY="[Empty name]" ORDER="265" O_E="0.0" SE="0.3047478004474988" STUDY_ID="STD-Mitchell-1997" TOTAL_1="94" TOTAL_2="92" VAR="0.09287122187758853" WEIGHT="14.01988936916745"/>
<DICH_DATA CI_END="0.8535681487055642" CI_START="0.1494327319987213" EFFECT_SIZE="0.35714285714285715" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="15" LOG_CI_END="-0.06876179918281475" LOG_CI_START="-0.8255542635016236" LOG_EFFECT_SIZE="-0.4471580313422192" MODIFIED="2014-10-10 19:52:05 +0100" MODIFIED_BY="[Empty name]" ORDER="264" O_E="0.0" SE="0.4445436397239844" STUDY_ID="STD-Riikonen-1994" TOTAL_1="28" TOTAL_2="30" VAR="0.19761904761904764" WEIGHT="10.093539917919543"/>
<DICH_DATA CI_END="1.6994623450112405" CI_START="0.8058091452909492" EFFECT_SIZE="1.1702317290552584" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="33" LOG_CI_END="0.23031154636244203" LOG_CI_START="-0.09376780802376854" LOG_EFFECT_SIZE="0.06827186916933672" MODIFIED="2014-10-17 17:37:40 +0100" MODIFIED_BY="[Empty name]" ORDER="262" O_E="0.0" SE="0.19036581698513677" STUDY_ID="STD-Yoshida-1999" TOTAL_1="102" TOTAL_2="101" VAR="0.03623914427641859" WEIGHT="17.75369468056505"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="16.49466403493344" CI_END="0.8109325012265797" CI_START="0.33556954675676975" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5216552998742915" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="172" I2="69.6871667745964" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.09101529321769991" LOG_CI_START="-0.47421745867645376" LOG_EFFECT_SIZE="-0.28261637594707684" METHOD="MH" MODIFIED="2014-07-25 19:55:18 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.005564938113574058" P_Q="1.0" P_Z="0.003840232981253106" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.1422701265753342" TOTALS="YES" TOTAL_1="419" TOTAL_2="375" WEIGHT="99.99999999999999" Z="2.890995762690302">
<NAME>Time to neutrophil recovery</NAME>
<GROUP_LABEL_1>CSF + ATB</GROUP_LABEL_1>
<GROUP_LABEL_2>ATB alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors CSF plus ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ATB alone</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0933934015424545" CI_START="0.051797318736123366" EFFECT_SIZE="0.23798076923076922" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.03877644866442071" LOG_CI_START="-1.2856927207228064" LOG_EFFECT_SIZE="-0.6234581360291929" MODIFIED="2014-07-25 19:54:33 +0100" MODIFIED_BY="[Empty name]" ORDER="268" O_E="0.0" SE="0.7779997463261832" STUDY_ID="STD-Garcia_x002d_Carbonero-2001" TOTAL_1="104" TOTAL_2="99" VAR="0.6052836052836054" WEIGHT="6.777799217537966"/>
<DICH_DATA CI_END="0.7408162874866677" CI_START="0.3715963486500309" EFFECT_SIZE="0.5246757355267321" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="58" LOG_CI_END="-0.13028947788143516" LOG_CI_START="-0.429928562086722" LOG_EFFECT_SIZE="-0.28010901998407856" MODIFIED="2014-07-25 19:54:33 +0100" MODIFIED_BY="[Empty name]" ORDER="269" O_E="0.0" SE="0.17600948129957372" STUDY_ID="STD-Maher-1994" TOTAL_1="109" TOTAL_2="107" VAR="0.030979337507344988" WEIGHT="29.2455109497084"/>
<DICH_DATA CI_END="1.134013013337193" CI_START="0.003599420884461303" EFFECT_SIZE="0.06388888888888888" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.054618038320650084" LOG_CI_START="-2.443767367820039" LOG_EFFECT_SIZE="-1.1945746647496944" MODIFIED="2014-07-25 19:54:33 +0100" MODIFIED_BY="[Empty name]" ORDER="267" O_E="0.0" SE="1.467563954774257" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="22" VAR="2.153743961352657" WEIGHT="2.2067674259932564"/>
<DICH_DATA CI_END="0.8626033503367427" CI_START="0.002898203443128352" EFFECT_SIZE="0.05" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="-0.06418885939440955" LOG_CI_START="-2.537871131933553" LOG_EFFECT_SIZE="-1.3010299956639813" MODIFIED="2014-07-25 19:54:33 +0100" MODIFIED_BY="[Empty name]" ORDER="271" O_E="0.0" SE="1.4530532118142254" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="21" VAR="2.1113636363636363" WEIGHT="2.248266414083856"/>
<DICH_DATA CI_END="0.9708937884569786" CI_START="0.658396501621064" EFFECT_SIZE="0.7995205274198381" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="71" LOG_CI_END="-0.012828277414351085" LOG_CI_START="-0.1815124854062118" LOG_EFFECT_SIZE="-0.0971703814102814" MODIFIED="2014-07-25 19:54:33 +0100" MODIFIED_BY="[Empty name]" ORDER="270" O_E="0.0" SE="0.09908593877471525" STUDY_ID="STD-Mitchell-1997" TOTAL_1="94" TOTAL_2="92" VAR="0.00981802326286662" WEIGHT="33.31468693814341"/>
<DICH_DATA CI_END="0.8385104838080086" CI_START="0.3457808029848721" EFFECT_SIZE="0.5384615384615384" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="26" LOG_CI_END="-0.07649150308591675" LOG_CI_START="-0.46119912149924314" LOG_EFFECT_SIZE="-0.26884531229257996" MODIFIED="2014-07-25 19:54:33 +0100" MODIFIED_BY="[Empty name]" ORDER="266" O_E="0.0" SE="0.2259791593894118" STUDY_ID="STD-Ravaud-1998" TOTAL_1="34" TOTAL_2="34" VAR="0.051066580478345176" WEIGHT="26.2069690545331"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="373.17540475142533" CI_END="-0.7568572778884832" CI_START="-2.6483944819768244" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="SMD" EFFECT_SIZE="-1.7026258799326537" ESTIMABLE="YES" I2="97.588265495151" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2014-10-17 18:31:04 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.1102230246251565E-15" P_Q="1.0" P_Z="4.180206437126671E-4" Q="0.0" RANDOM="YES" SCALE="15.4" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="2.255026237981974" TOTALS="YES" TOTAL_1="588" TOTAL_2="547" UNITS="" WEIGHT="99.99999999999999" Z="3.5284375021554872">
<NAME>Duration of grade IV neutropenia</NAME>
<GROUP_LABEL_1>CSF plus ATB</GROUP_LABEL_1>
<GROUP_LABEL_2>ATB alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors CSF plus ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ATB alone</GRAPH_LABEL_2>
<CONT_DATA CI_END="-3.8630621429187046" CI_START="-5.2417012038127035" EFFECT_SIZE="-4.552381673365704" ESTIMABLE="YES" MEAN_1="7.5" MEAN_2="14.8" MODIFIED="2014-05-01 22:27:53 +0100" MODIFIED_BY="[Empty name]" ORDER="378" SD_1="2.0" SD_2="1.0" SE="0.35170010055504286" STUDY_ID="STD-Aviles-1996" TOTAL_1="61" TOTAL_2="58" WEIGHT="9.788821840496999"/>
<CONT_DATA CI_END="0.6135351786365997" CI_START="-0.8189056257095417" EFFECT_SIZE="-0.10268522353647108" ESTIMABLE="YES" MEAN_1="6.3" MEAN_2="6.7" MODIFIED="2014-10-07 15:38:31 +0100" MODIFIED_BY="[Empty name]" ORDER="379" SD_1="3.2" SD_2="4.3" SE="0.3654252873126883" STUDY_ID="STD-Biesma-1990" TOTAL_1="15" TOTAL_2="15" WEIGHT="9.748484497506663"/>
<CONT_DATA CI_END="-3.7799163925878263" CI_START="-4.785322438261804" EFFECT_SIZE="-4.282619415424815" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="3.0" MODIFIED="2014-05-01 22:27:52 +0100" MODIFIED_BY="[Empty name]" ORDER="380" SD_1="0.01" SD_2="0.333" SE="0.2564858470881332" STUDY_ID="STD-Garcia_x002d_Carbonero-2001" TOTAL_1="104" TOTAL_2="99" WEIGHT="10.03306868152967"/>
<CONT_DATA CI_END="-0.17062327540468808" CI_START="-0.7106335211190538" EFFECT_SIZE="-0.4406283982618709" ESTIMABLE="YES" MEAN_1="3.3" MEAN_2="4.3" MODIFIED="2014-05-01 19:41:09 +0100" MODIFIED_BY="[Empty name]" ORDER="382" SD_1="2.0" SD_2="2.5" SE="0.13776024712032914" STUDY_ID="STD-Maher-1994" TOTAL_1="109" TOTAL_2="107" WEIGHT="10.239584969265687"/>
<CONT_DATA CI_END="-0.9184367897784403" CI_START="-2.1014068041701104" EFFECT_SIZE="-1.5099217969742753" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="5.75" MODIFIED="2014-05-01 22:27:47 +0100" MODIFIED_BY="[Empty name]" ORDER="383" SD_1="1.25" SD_2="3.75" SE="0.3017836102404907" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="22" WEIGHT="9.92492330238288">
<FOOTNOTE>GM-CSF</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="-0.9261965054835081" CI_START="-2.1284423199057416" EFFECT_SIZE="-1.5273194126946248" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="5.75" MODIFIED="2014-05-01 18:49:07 +0100" MODIFIED_BY="[Empty name]" ORDER="391" SD_1="1.25" SD_2="3.75" SE="0.30670099652478183" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="21" WEIGHT="9.91228143869218">
<FOOTNOTE>G-CSF</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="-2.492393359241935" CI_START="-3.3212864295189966" EFFECT_SIZE="-2.906839894380466" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="5.0" MODIFIED="2014-05-01 22:27:51 +0100" MODIFIED_BY="[Empty name]" ORDER="384" SD_1="0.5" SD_2="0.833" SE="0.21145619940347488" STUDY_ID="STD-Mitchell-1997" TOTAL_1="94" TOTAL_2="92" WEIGHT="10.1249962287054"/>
<CONT_DATA CI_END="-0.04207115863029898" CI_START="-1.0100926580195093" EFFECT_SIZE="-0.5260819083249041" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="4.2" MODIFIED="2014-05-01 19:38:21 +0100" MODIFIED_BY="[Empty name]" ORDER="385" SD_1="1.75" SD_2="2.0" SE="0.24694879779037784" STUDY_ID="STD-Ravaud-1998" TOTAL_1="34" TOTAL_2="34" WEIGHT="10.053868066422476"/>
<CONT_DATA CI_END="-0.3831713165037638" CI_START="-1.4708786961640392" EFFECT_SIZE="-0.9270250063339015" ESTIMABLE="YES" MEAN_1="4.5" MEAN_2="8.58" MODIFIED="2014-10-10 17:21:08 +0100" MODIFIED_BY="[Empty name]" ORDER="386" SD_1="3.5" SD_2="5.0" SE="0.27748147114946303" STUDY_ID="STD-Riikonen-1994" TOTAL_1="28" TOTAL_2="30" WEIGHT="9.984835648951378"/>
<CONT_DATA CI_END="0.03487441074032699" CI_START="-0.6467558878969464" EFFECT_SIZE="-0.3059407385783097" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="4.0" MODIFIED="2014-05-01 22:29:53 +0100" MODIFIED_BY="[Empty name]" ORDER="388" SD_1="3.25" SD_2="3.25" SE="0.17388847550615374" STUDY_ID="STD-Vellenga-1996" TOTAL_1="65" TOTAL_2="69" WEIGHT="10.189135326046653"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="78.7171868207032" CI_END="-0.08579057776667565" CI_START="-0.8973135166356313" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.4915520472011535" ESTIMABLE="YES" I2="88.56666458304767" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2014-10-17 18:13:56 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="2.9054536554440347E-13" P_Q="1.0" P_Z="0.0175793419243182" Q="0.0" RANDOM="YES" SCALE="3.86" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.36387363413108514" TOTALS="YES" TOTAL_1="502" TOTAL_2="464" UNITS="" WEIGHT="100.00000000000001" Z="2.374361248208085">
<NAME>Time to recovering from fever</NAME>
<GROUP_LABEL_1>CSF plus ATB</GROUP_LABEL_1>
<GROUP_LABEL_2>ATB alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors CSF plus ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ATB alone</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.4785229543463472" CI_START="-2.351260966229865" EFFECT_SIZE="-1.914891960288106" ESTIMABLE="YES" MEAN_1="6.1" MEAN_2="11.4" MODIFIED="2014-05-01 14:48:17 +0100" MODIFIED_BY="[Empty name]" ORDER="131" SD_1="2.75" SD_2="2.75" SE="0.22264133901631958" STUDY_ID="STD-Aviles-1996" TOTAL_1="61" TOTAL_2="58" WEIGHT="10.366448489875694"/>
<CONT_DATA CI_END="0.9573715089499887" CI_START="-0.6458332784416482" EFFECT_SIZE="0.15576911525417028" ESTIMABLE="YES" MEAN_1="2.9" MEAN_2="2.4" MODIFIED="2014-04-30 21:21:53 +0100" MODIFIED_BY="[Empty name]" ORDER="132" SD_1="3.6" SD_2="2.5" SE="0.4089883283666209" STUDY_ID="STD-Biesma-1990" TOTAL_1="12" TOTAL_2="12" WEIGHT="8.069233050138163"/>
<CONT_DATA CI_END="-0.04563846942141192" CI_START="-1.326546961042164" EFFECT_SIZE="-0.6860927152317879" ESTIMABLE="YES" MEAN_1="5.5" MEAN_2="7.6" MODIFIED="2014-10-17 18:13:56 +0100" MODIFIED_BY="[Empty name]" ORDER="517" SD_1="3.0" SD_2="3.0" SE="0.326768374756984" STUDY_ID="STD-Lopez_x002d_Hernandez-2000" TOTAL_1="21" TOTAL_2="19" WEIGHT="9.106390135687807"/>
<CONT_DATA CI_END="0.26672874944371977" CI_START="-0.26672874944371977" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="3.0" MODIFIED="2014-04-30 21:26:13 +0100" MODIFIED_BY="[Empty name]" ORDER="134" SD_1="3.0" SD_2="4.667" SE="0.1360885973148701" STUDY_ID="STD-Maher-1994" TOTAL_1="109" TOTAL_2="107" WEIGHT="11.208168534227529"/>
<CONT_DATA CI_END="-0.4744141771913817" CI_START="-1.5858673409668602" EFFECT_SIZE="-1.030140759079121" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="4.0" MODIFIED="2014-10-10 19:13:37 +0100" MODIFIED_BY="[Empty name]" ORDER="352" SD_1="1.5" SD_2="2.5" SE="0.2835391804498652" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="22" WEIGHT="9.647178088935952">
<FOOTNOTE>GM-CSF</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="-0.541557311039923" CI_START="-1.6794088928093511" EFFECT_SIZE="-1.110483101924637" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="4.0" MODIFIED="2014-10-10 19:13:36 +0100" MODIFIED_BY="[Empty name]" ORDER="135" SD_1="2.75" SD_2="2.5" SE="0.2902735945008827" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="21" WEIGHT="9.563989456551168">
<FOOTNOTE>G-CSF</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="0.04634806532418545" CI_START="-0.5306797207087747" EFFECT_SIZE="-0.2421658276922946" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="3.0" MODIFIED="2014-04-30 21:58:12 +0100" MODIFIED_BY="[Empty name]" ORDER="136" SD_1="3.0" SD_2="5.0" SE="0.14720367072672805" STUDY_ID="STD-Mitchell-1997" TOTAL_1="94" TOTAL_2="92" WEIGHT="11.116628854499954"/>
<CONT_DATA CI_END="0.4753610900391237" CI_START="-0.4753610900391237" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="2.0" MODIFIED="2014-04-30 21:54:57 +0100" MODIFIED_BY="[Empty name]" ORDER="137" SD_1="2.0" SD_2="2.75" SE="0.24253562503633297" STUDY_ID="STD-Ravaud-1998" TOTAL_1="34" TOTAL_2="34" WEIGHT="10.139489589844816"/>
<CONT_DATA CI_END="0.4080141339145007" CI_START="-0.6228174197788947" EFFECT_SIZE="-0.10740164293219699" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="2.3" MODIFIED="2014-04-30 21:57:23 +0100" MODIFIED_BY="[Empty name]" ORDER="138" SD_1="1.25" SD_2="2.25" SE="0.2629720652584596" STUDY_ID="STD-Riikonen-1994" TOTAL_1="28" TOTAL_2="30" WEIGHT="9.897591081888457"/>
<CONT_DATA CI_END="0.3387811723135764" CI_START="-0.3387811723135764" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="3.0" MODIFIED="2014-04-30 21:59:46 +0100" MODIFIED_BY="[Empty name]" ORDER="140" SD_1="3.25" SD_2="3.25" SE="0.17285071306709668" STUDY_ID="STD-Vellenga-1996" TOTAL_1="65" TOTAL_2="69" WEIGHT="10.884882718350479"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="69.92355953989522" CI_END="-0.17641390257494383" CI_START="-2.831457948579276" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-1.5039359255771099" ESTIMABLE="YES" I2="97.13973371327172" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2014-10-30 14:40:57 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="5.551115123125783E-16" P_Q="1.0" P_Z="0.02639007659177784" Q="0.0" RANDOM="YES" SCALE="5.62" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="1.3340487867611612" TOTALS="YES" TOTAL_1="232" TOTAL_2="225" UNITS="" WEIGHT="99.99999999999997" Z="2.220422861626784">
<NAME>Time to withdrawal from antibiotics</NAME>
<GROUP_LABEL_1>CSF plus ATB</GROUP_LABEL_1>
<GROUP_LABEL_2>ATB alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors CSF plus ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ATB alone</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.4601945378835355" CI_START="-3.2457579703388557" EFFECT_SIZE="-2.8529762541111956" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="6.0" MODIFIED="2014-10-30 14:40:57 +0000" MODIFIED_BY="[Empty name]" ORDER="128" SD_1="0.01" SD_2="0.5" SE="0.200402517253313" STUDY_ID="STD-Garcia_x002d_Carbonero-2001" TOTAL_1="104" TOTAL_2="99" WEIGHT="33.38367906037894"/>
<CONT_DATA CI_END="-0.5795539071722889" CI_START="-1.1822417345671852" EFFECT_SIZE="-0.8808978208697371" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="6.0" MODIFIED="2014-04-30 19:49:32 +0100" MODIFIED_BY="[Empty name]" ORDER="126" SD_1="1.0" SD_2="1.25" SE="0.1537497199307796" STUDY_ID="STD-Mitchell-1997" TOTAL_1="94" TOTAL_2="92" WEIGHT="33.78993710305489"/>
<CONT_DATA CI_END="-0.27945786413677176" CI_START="-1.2671801748601952" EFFECT_SIZE="-0.7733190194984835" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="7.8" MODIFIED="2014-04-30 20:25:27 +0100" MODIFIED_BY="[Empty name]" ORDER="127" SD_1="2.75" SD_2="4.25" SE="0.2519746073179025" STUDY_ID="STD-Ravaud-1998" TOTAL_1="34" TOTAL_2="34" WEIGHT="32.82638383656616"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.7750852518281033" CI_END="3.930664770912806" CI_START="0.7182739797726948" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6802661182550427" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.594466006335772" LOG_CI_START="-0.1437098660542678" LOG_EFFECT_SIZE="0.2253780701407521" METHOD="MH" MODIFIED="2014-10-17 16:36:10 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.6203717414092307" P_Q="1.0" P_Z="0.23137560560768167" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="194" TOTAL_2="195" WEIGHT="100.00000000000001" Z="1.196822916876947">
<NAME>Deep vein thrombosis</NAME>
<GROUP_LABEL_1>CSF+ATB</GROUP_LABEL_1>
<GROUP_LABEL_2>ATB alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors CSF+ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ATB alone</GRAPH_LABEL_2>
<DICH_DATA CI_END="72.6230071114122" CI_START="0.14100214804229522" EFFECT_SIZE="3.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8610742278439367" LOG_CI_START="-0.8507742712041247" LOG_EFFECT_SIZE="0.505149978319906" ORDER="35" O_E="0.0" SE="1.592953232207399" STUDY_ID="STD-Arnberg-1998" TOTAL_1="14" TOTAL_2="15" VAR="2.5374999999999996" WEIGHT="7.409499022447907"/>
<DICH_DATA CI_END="4.295191072276675" CI_START="0.6234148621923613" EFFECT_SIZE="1.6363636363636365" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6329824882579832" LOG_CI_START="-0.20522284836782104" LOG_EFFECT_SIZE="0.21387981994508107" ORDER="36" O_E="0.0" SE="0.4923659639173309" STUDY_ID="STD-Biesma-1990" TOTAL_1="11" TOTAL_2="12" VAR="0.24242424242424238" WEIGHT="77.55661554902896"/>
<DICH_DATA CI_END="7.701901885635553" CI_START="0.013085216438548437" EFFECT_SIZE="0.31746031746031744" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8865979818537753" LOG_CI_START="-1.8832190894329763" LOG_EFFECT_SIZE="-0.49831055378960054" ORDER="37" O_E="0.0" SE="1.627004258489466" STUDY_ID="STD-Garcia_x002d_Carbonero-2001" TOTAL_1="104" TOTAL_2="99" VAR="2.6471428571428572" WEIGHT="7.1026026112375025"/>
<DICH_DATA CI_END="108.41460728697989" CI_START="0.2593942928780504" EFFECT_SIZE="5.303030303030303" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.035087800991484" LOG_CI_START="-0.58603958337467" LOG_EFFECT_SIZE="0.7245241088084069" MODIFIED="2014-10-10 19:59:49 +0100" MODIFIED_BY="[Empty name]" ORDER="38" O_E="0.0" SE="1.539663200366486" STUDY_ID="STD-Vellenga-1996" TOTAL_1="65" TOTAL_2="69" VAR="2.3705627705627705" WEIGHT="7.9312828172856475"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.17761188316183" CI_END="2.4161448085517154" CI_START="1.0398792808687536" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5850864096293078" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.38312295961395443" LOG_CI_START="0.016982925168401167" LOG_EFFECT_SIZE="0.20005294239117774" METHOD="MH" MODIFIED="2014-10-10 20:54:05 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.5241381496183956" P_Q="1.0" P_Z="0.032210811099752046" Q="0.0" RANDOM="YES" SCALE="62.58" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="328" TOTAL_2="294" WEIGHT="100.0" Z="2.141784700936774">
<NAME>Bone and joint pain or flu-like symptoms</NAME>
<GROUP_LABEL_1>CSF + ATB</GROUP_LABEL_1>
<GROUP_LABEL_2>ATB alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors CSF + ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ATB alone</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="39" O_E="0.0" SE="0.0" STUDY_ID="STD-Arnberg-1998" TOTAL_1="14" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.2355832264380107" CI_START="0.9167213000587313" EFFECT_SIZE="1.4315749235474007" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="24" LOG_CI_END="0.34939084244827695" LOG_CI_START="-0.03776267768176563" LOG_EFFECT_SIZE="0.15581408238325564" MODIFIED="2014-10-10 18:11:37 +0100" MODIFIED_BY="[Empty name]" ORDER="40" O_E="0.0" SE="0.22741589416521962" STUDY_ID="STD-Maher-1994" TOTAL_1="109" TOTAL_2="107" VAR="0.05171798891896637" WEIGHT="89.43922171092349"/>
<DICH_DATA CI_END="38.81548618317306" CI_START="0.07013953109210917" EFFECT_SIZE="1.65" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5890050302868088" LOG_CI_START="-1.154037141858996" LOG_EFFECT_SIZE="0.21748394421390627" MODIFIED="2014-05-01 14:52:15 +0100" MODIFIED_BY="[Empty name]" ORDER="41" O_E="0.0" SE="1.6112765501961857" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="21" VAR="2.596212121212121" WEIGHT="1.7816790236719589">
<FOOTNOTE>G-CSF</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="91.85505408031263" CI_START="0.2915530916413657" EFFECT_SIZE="5.175" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.9631030571992998" LOG_CI_START="-0.5352823489413892" LOG_EFFECT_SIZE="0.7139103541289553" MODIFIED="2014-05-01 14:52:30 +0100" MODIFIED_BY="[Empty name]" ORDER="353" O_E="0.0" SE="1.467563954774257" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="22" VAR="2.153743961352657" WEIGHT="2.1477096444005364">
<FOOTNOTE>GM-CSF</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="160.96009561105961" CI_START="0.5032303173808164" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2067182213488903" LOG_CI_START="-0.29823320247024027" LOG_EFFECT_SIZE="0.9542425094393249" ORDER="42" O_E="0.0" SE="1.4714208660608852" STUDY_ID="STD-Ravaud-1998" TOTAL_1="34" TOTAL_2="34" VAR="2.1650793650793654" WEIGHT="2.136465180895092"/>
<DICH_DATA CI_END="170.9632134765728" CI_START="0.5413893875703542" EFFECT_SIZE="9.620689655172415" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.23290267236394" LOG_CI_START="-0.26649026161465716" LOG_EFFECT_SIZE="0.9832062053746415" ORDER="43" O_E="0.0" SE="1.4681557816135875" STUDY_ID="STD-Riikonen-1994" TOTAL_1="28" TOTAL_2="30" VAR="2.155481399085404" WEIGHT="2.1459784711337435"/>
<DICH_DATA CI_END="15.64894352488065" CI_START="0.06390207737730504" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.194485023236973" LOG_CI_START="-1.194485023236973" LOG_EFFECT_SIZE="0.0" ORDER="44" O_E="0.0" SE="1.4032928308912467" STUDY_ID="STD-Vellenga-1996" TOTAL_1="65" TOTAL_2="65" VAR="1.9692307692307693" WEIGHT="2.3489459689751846"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2014-10-17 18:13:38 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Subgroup analysis - Study population (children vs. adults)</NAME>
<DICH_OUTCOME CHI2="22.501324884052927" CI_END="0.9526698015390065" CI_START="0.44480128013234976" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6509598660961993" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="182" I2="68.89072071946741" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.021057601165146315" LOG_CI_START="-0.35183397153028045" LOG_EFFECT_SIZE="-0.18644578634771336" METHOD="MH" MODIFIED="2014-10-10 20:29:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.00208092009634131" P_Q="0.896715970807007" P_Z="0.02713911316396967" Q="0.016850893653095035" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.17640597149618623" TOTALS="YES" TOTAL_1="565" TOTAL_2="522" WEIGHT="100.0" Z="2.209511071830095">
<NAME>Patients with hospitalization for greater than10 days</NAME>
<GROUP_LABEL_1>CSF plus ATB</GROUP_LABEL_1>
<GROUP_LABEL_2>ATB alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors CSF plus ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ATB alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="19.21323188614446" CI_END="1.0304763008235291" CI_START="0.4101438558594876" DF="5" EFFECT_SIZE="0.6501103932345518" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="149" I2="73.97626786774104" ID="CMP-002.01.01" LOG_CI_END="0.013038008206527158" LOG_CI_START="-0.3870637899920962" LOG_EFFECT_SIZE="-0.1870128908927845" MODIFIED="2014-10-10 20:29:21 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0017540256249960473" P_Z="0.06691770305538615" STUDIES="5" TAU2="0.2032598692788554" TOTAL_1="443" TOTAL_2="400" WEIGHT="75.88657071291301" Z="1.8322263606154297">
<NAME>Adults</NAME>
<DICH_DATA CI_END="1.091771683962423" CI_START="0.43900198903207566" EFFECT_SIZE="0.6923076923076923" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="26" LOG_CI_END="0.038131826315114824" LOG_CI_START="-0.3575335120501386" LOG_EFFECT_SIZE="-0.1597008428675119" MODIFIED="2014-07-25 19:55:43 +0100" MODIFIED_BY="[Empty name]" ORDER="279" O_E="0.0" SE="0.23241577833076224" STUDY_ID="STD-Anaissie-1996" TOTAL_1="50" TOTAL_2="50" VAR="0.05401709401709401" WEIGHT="16.38393470866592"/>
<DICH_DATA CI_END="1.63988773696822" CI_START="0.6016672931718803" EFFECT_SIZE="0.9933110367892977" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" LOG_CI_END="0.21481411824036745" LOG_CI_START="-0.22064359625480207" LOG_EFFECT_SIZE="-0.0029147390072172936" MODIFIED="2014-07-25 19:55:43 +0100" MODIFIED_BY="[Empty name]" ORDER="280" O_E="0.0" SE="0.25579001704491355" STUDY_ID="STD-Garcia_x002d_Carbonero-2001" TOTAL_1="104" TOTAL_2="99" VAR="0.06542853281983717" WEIGHT="15.61082638483567"/>
<DICH_DATA CI_END="0.8130748301230439" CI_START="0.3944753449233908" EFFECT_SIZE="0.5663373323923783" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="52" LOG_CI_END="-0.08986948292499009" LOG_CI_START="-0.40398013541611133" LOG_EFFECT_SIZE="-0.2469248091705507" MODIFIED="2014-07-25 19:55:43 +0100" MODIFIED_BY="[Empty name]" ORDER="277" O_E="0.0" SE="0.18451015214609112" STUDY_ID="STD-Maher-1994" TOTAL_1="109" TOTAL_2="107" VAR="0.034043996244973694" WEIGHT="17.938878780839417"/>
<DICH_DATA CI_END="0.606460826035732" CI_START="0.03279392596006056" EFFECT_SIZE="0.14102564102564102" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="-0.21719724687651348" LOG_CI_START="-1.4842065881879973" LOG_EFFECT_SIZE="-0.8507019175322553" MODIFIED="2014-07-25 19:55:43 +0100" MODIFIED_BY="[Empty name]" ORDER="275" O_E="0.0" SE="0.7442475588837554" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="22" VAR="0.5539044289044289" WEIGHT="5.169358753030642"/>
<DICH_DATA CI_END="0.5839566004470578" CI_START="0.010132875899996046" EFFECT_SIZE="0.07692307692307693" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="-0.23361942837859279" LOG_CI_START="-1.9942672762350806" LOG_EFFECT_SIZE="-1.1139433523068367" MODIFIED="2014-07-25 19:55:43 +0100" MODIFIED_BY="[Empty name]" ORDER="278" O_E="0.0" SE="1.0342132611783073" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="21" VAR="1.0695970695970696" WEIGHT="3.029877404976317"/>
<DICH_DATA CI_END="1.6994623450112405" CI_START="0.8058091452909492" EFFECT_SIZE="1.1702317290552584" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="33" LOG_CI_END="0.23031154636244203" LOG_CI_START="-0.09376780802376854" LOG_EFFECT_SIZE="0.06827186916933672" MODIFIED="2014-07-25 19:55:43 +0100" MODIFIED_BY="[Empty name]" ORDER="274" O_E="0.0" SE="0.19036581698513677" STUDY_ID="STD-Yoshida-1999" TOTAL_1="102" TOTAL_2="101" VAR="0.03623914427641859" WEIGHT="17.753694680565047"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.1159026328760566" CI_END="1.5325943276936032" CI_START="0.24046129626589444" DF="1" EFFECT_SIZE="0.6070664038529564" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="33" I2="67.90657097404309" ID="CMP-002.01.02" LOG_CI_END="0.18542721385023386" LOG_CI_START="-0.6189548160503165" LOG_EFFECT_SIZE="-0.21676380110004137" MODIFIED="2014-10-10 20:25:47 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.07753179803983601" P_Z="0.2908143008484625" STUDIES="2" TAU2="0.30732456302640393" TOTAL_1="122" TOTAL_2="122" WEIGHT="24.113429287086994" Z="1.0563369829647014">
<NAME>Children</NAME>
<DICH_DATA CI_END="1.679725007800233" CI_START="0.5086682046226763" EFFECT_SIZE="0.9243498817966903" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" LOG_CI_END="0.22523818805306842" LOG_CI_START="-0.29356540801141945" LOG_EFFECT_SIZE="-0.03416360997917553" MODIFIED="2014-07-25 19:55:43 +0100" MODIFIED_BY="[Empty name]" ORDER="272" O_E="0.0" SE="0.3047478004474988" STUDY_ID="STD-Mitchell-1997" TOTAL_1="94" TOTAL_2="92" VAR="0.09287122187758853" WEIGHT="14.019889369167453"/>
<DICH_DATA CI_END="0.8535681487055642" CI_START="0.1494327319987213" EFFECT_SIZE="0.35714285714285715" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="15" LOG_CI_END="-0.06876179918281475" LOG_CI_START="-0.8255542635016236" LOG_EFFECT_SIZE="-0.4471580313422192" MODIFIED="2014-10-10 20:25:47 +0100" MODIFIED_BY="[Empty name]" ORDER="273" O_E="0.0" SE="0.4445436397239844" STUDY_ID="STD-Riikonen-1994" TOTAL_1="28" TOTAL_2="30" VAR="0.19761904761904764" WEIGHT="10.093539917919543"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="16.494664034933436" CI_END="0.8109325012265797" CI_START="0.33556954675676975" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5216552998742915" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="172" I2="69.68716677459639" I2_Q="81.47049239952848" ID="CMP-002.02" LOG_CI_END="-0.09101529321769991" LOG_CI_START="-0.47421745867645376" LOG_EFFECT_SIZE="-0.28261637594707684" METHOD="MH" MODIFIED="2014-07-25 20:05:31 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.00556493811357428" P_Q="0.020173810630111144" P_Z="0.003840232981253106" Q="5.3967974841088235" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.14227012657533417" TOTALS="YES" TOTAL_1="419" TOTAL_2="375" WEIGHT="100.0" Z="2.890995762690302">
<NAME>Time to neutrophil recovery</NAME>
<GROUP_LABEL_1>CSF + ATB</GROUP_LABEL_1>
<GROUP_LABEL_2>ATB alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors CSF plus ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ATB alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.144108580946676" CI_END="0.7018449529280903" CI_START="0.2894904657102907" DF="4" EFFECT_SIZE="0.4507520629787177" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="101" I2="34.8969838781123" ID="CMP-002.02.01" LOG_CI_END="-0.15375881881741074" LOG_CI_START="-0.5383657350715886" LOG_EFFECT_SIZE="-0.34606227694449965" MODIFIED="2014-07-25 20:05:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.18864170960430182" P_Z="4.2017046472201926E-4" STUDIES="4" TAU2="0.0759896366944119" TOTAL_1="325" TOTAL_2="283" WEIGHT="66.68531306185659" Z="3.5270795742575394">
<NAME>Adults</NAME>
<DICH_DATA CI_END="1.0933934015424545" CI_START="0.051797318736123366" EFFECT_SIZE="0.23798076923076922" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.03877644866442071" LOG_CI_START="-1.2856927207228064" LOG_EFFECT_SIZE="-0.6234581360291929" MODIFIED="2014-07-25 20:03:49 +0100" MODIFIED_BY="[Empty name]" ORDER="268" O_E="0.0" SE="0.7779997463261832" STUDY_ID="STD-Garcia_x002d_Carbonero-2001" TOTAL_1="104" TOTAL_2="99" VAR="0.6052836052836054" WEIGHT="6.777799217537966"/>
<DICH_DATA CI_END="0.7408162874866677" CI_START="0.3715963486500309" EFFECT_SIZE="0.5246757355267321" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="58" LOG_CI_END="-0.13028947788143516" LOG_CI_START="-0.429928562086722" LOG_EFFECT_SIZE="-0.28010901998407856" MODIFIED="2014-07-25 20:03:49 +0100" MODIFIED_BY="[Empty name]" ORDER="269" O_E="0.0" SE="0.17600948129957372" STUDY_ID="STD-Maher-1994" TOTAL_1="109" TOTAL_2="107" VAR="0.030979337507344988" WEIGHT="29.245510949708407"/>
<DICH_DATA CI_END="1.134013013337193" CI_START="0.003599420884461303" EFFECT_SIZE="0.06388888888888888" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.054618038320650084" LOG_CI_START="-2.443767367820039" LOG_EFFECT_SIZE="-1.1945746647496944" MODIFIED="2014-07-25 20:03:49 +0100" MODIFIED_BY="[Empty name]" ORDER="267" O_E="0.0" SE="1.467563954774257" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="22" VAR="2.153743961352657" WEIGHT="2.2067674259932564"/>
<DICH_DATA CI_END="0.8626033503367427" CI_START="0.002898203443128352" EFFECT_SIZE="0.05" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="-0.06418885939440955" LOG_CI_START="-2.537871131933553" LOG_EFFECT_SIZE="-1.3010299956639813" MODIFIED="2014-07-25 20:03:49 +0100" MODIFIED_BY="[Empty name]" ORDER="271" O_E="0.0" SE="1.4530532118142254" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="21" VAR="2.1113636363636363" WEIGHT="2.248266414083856"/>
<DICH_DATA CI_END="0.8385104838080086" CI_START="0.3457808029848721" EFFECT_SIZE="0.5384615384615384" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="26" LOG_CI_END="-0.07649150308591675" LOG_CI_START="-0.46119912149924314" LOG_EFFECT_SIZE="-0.26884531229257996" MODIFIED="2014-07-25 20:03:49 +0100" MODIFIED_BY="[Empty name]" ORDER="266" O_E="0.0" SE="0.2259791593894118" STUDY_ID="STD-Ravaud-1998" TOTAL_1="34" TOTAL_2="34" VAR="0.051066580478345176" WEIGHT="26.206969054533108"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9708937884569786" CI_START="0.658396501621064" DF="0" EFFECT_SIZE="0.7995205274198381" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="71" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="-0.012828277414351085" LOG_CI_START="-0.1815124854062118" LOG_EFFECT_SIZE="-0.0971703814102814" MODIFIED="2014-07-25 20:05:31 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.023941241567093995" STUDIES="1" TAU2="0.0" TOTAL_1="94" TOTAL_2="92" WEIGHT="33.31468693814342" Z="2.2580708673969236">
<NAME>Children</NAME>
<DICH_DATA CI_END="0.9708937884569786" CI_START="0.658396501621064" EFFECT_SIZE="0.7995205274198381" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="71" LOG_CI_END="-0.012828277414351085" LOG_CI_START="-0.1815124854062118" LOG_EFFECT_SIZE="-0.0971703814102814" MODIFIED="2014-07-25 20:05:31 +0100" MODIFIED_BY="[Empty name]" ORDER="270" O_E="0.0" SE="0.09908593877471525" STUDY_ID="STD-Mitchell-1997" TOTAL_1="94" TOTAL_2="92" VAR="0.00981802326286662" WEIGHT="33.31468693814342"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="373.1754047514254" CI_END="-0.7568572778884834" CI_START="-2.6483944819768244" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="SMD" EFFECT_SIZE="-1.702625879932654" ESTIMABLE="YES" I2="97.588265495151" I2_Q="0.0" ID="CMP-002.03" MODIFIED="2014-10-10 20:31:29 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.3322676295501878E-15" P_Q="0.8074045609144448" P_Z="4.1802064371266673E-4" Q="0.05942658110596988" RANDOM="YES" SCALE="15.404019975367234" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="2.2550262379819737" TOTALS="YES" TOTAL_1="588" TOTAL_2="547" UNITS="" WEIGHT="100.0" Z="3.5284375021554877">
<NAME>Duration of grade IV neutropenia</NAME>
<GROUP_LABEL_1>CSF plus ATB</GROUP_LABEL_1>
<GROUP_LABEL_2>ATB alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors CSF plus ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ATB alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="310.3703790309845" CI_END="-0.5467877696233412" CI_START="-2.7484897557948114" DF="7" EFFECT_SIZE="-1.6476387627090763" ESTIMABLE="YES" I2="97.74463013453317" ID="CMP-002.03.01" MODIFIED="2014-10-10 20:31:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="-6.661338147750939E-16" P_Z="0.0033519676051528436" STUDIES="7" TAU2="2.4470674437505755" TOTAL_1="466" TOTAL_2="425" WEIGHT="79.89016812234323" Z="2.9334693384706108">
<NAME>Adults</NAME>
<CONT_DATA CI_END="-3.8630621429187046" CI_START="-5.2417012038127035" EFFECT_SIZE="-4.552381673365704" ESTIMABLE="YES" MEAN_1="7.5" MEAN_2="14.8" MODIFIED="2014-07-14 22:17:39 +0100" MODIFIED_BY="[Empty name]" ORDER="378" SD_1="2.0" SD_2="1.0" SE="0.35170010055504286" STUDY_ID="STD-Aviles-1996" TOTAL_1="61" TOTAL_2="58" WEIGHT="9.788821840497"/>
<CONT_DATA CI_END="0.6135351786365997" CI_START="-0.8189056257095417" EFFECT_SIZE="-0.10268522353647108" ESTIMABLE="YES" MEAN_1="6.3" MEAN_2="6.7" MODIFIED="2014-10-10 20:31:29 +0100" MODIFIED_BY="[Empty name]" ORDER="379" SD_1="3.2" SD_2="4.3" SE="0.3654252873126883" STUDY_ID="STD-Biesma-1990" TOTAL_1="15" TOTAL_2="15" WEIGHT="9.748484497506666"/>
<CONT_DATA CI_END="-3.7799163925878263" CI_START="-4.785322438261804" EFFECT_SIZE="-4.282619415424815" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="3.0" MODIFIED="2014-07-14 22:17:39 +0100" MODIFIED_BY="[Empty name]" ORDER="380" SD_1="0.01" SD_2="0.333" SE="0.2564858470881332" STUDY_ID="STD-Garcia_x002d_Carbonero-2001" TOTAL_1="104" TOTAL_2="99" WEIGHT="10.03306868152967"/>
<CONT_DATA CI_END="-0.17062327540468808" CI_START="-0.7106335211190538" EFFECT_SIZE="-0.4406283982618709" ESTIMABLE="YES" MEAN_1="3.3" MEAN_2="4.3" MODIFIED="2014-07-14 22:17:39 +0100" MODIFIED_BY="[Empty name]" ORDER="382" SD_1="2.0" SD_2="2.5" SE="0.13776024712032914" STUDY_ID="STD-Maher-1994" TOTAL_1="109" TOTAL_2="107" WEIGHT="10.239584969265689"/>
<CONT_DATA CI_END="-0.9261965054835081" CI_START="-2.1284423199057416" EFFECT_SIZE="-1.5273194126946248" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="5.75" MODIFIED="2014-07-14 22:17:39 +0100" MODIFIED_BY="[Empty name]" ORDER="391" SD_1="1.25" SD_2="3.75" SE="0.30670099652478183" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="21" WEIGHT="9.912281438692181">
<FOOTNOTE>G-CSF</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="-0.9184367897784403" CI_START="-2.1014068041701104" EFFECT_SIZE="-1.5099217969742753" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="5.75" MODIFIED="2014-07-14 22:17:39 +0100" MODIFIED_BY="[Empty name]" ORDER="383" SD_1="1.25" SD_2="3.75" SE="0.3017836102404907" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="22" WEIGHT="9.924923302382883">
<FOOTNOTE>GM-CSF</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="-0.04207115863029898" CI_START="-1.0100926580195093" EFFECT_SIZE="-0.5260819083249041" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="4.2" MODIFIED="2014-07-14 22:17:39 +0100" MODIFIED_BY="[Empty name]" ORDER="385" SD_1="1.75" SD_2="2.0" SE="0.24694879779037784" STUDY_ID="STD-Ravaud-1998" TOTAL_1="34" TOTAL_2="34" WEIGHT="10.05386806642248"/>
<CONT_DATA CI_END="0.03487441074032699" CI_START="-0.6467558878969464" EFFECT_SIZE="-0.3059407385783097" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="4.0" MODIFIED="2014-07-14 22:17:39 +0100" MODIFIED_BY="[Empty name]" ORDER="388" SD_1="3.25" SD_2="3.25" SE="0.17388847550615374" STUDY_ID="STD-Vellenga-1996" TOTAL_1="65" TOTAL_2="69" WEIGHT="10.189135326046655"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="32.20505249489964" CI_END="0.015031840768036764" CI_START="-3.8652024288272244" DF="1" EFFECT_SIZE="-1.925085294029594" ESTIMABLE="YES" I2="96.8948971588903" ID="CMP-002.03.02" MODIFIED="2014-07-14 22:18:23 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.387352244197615E-8" P_Z="0.05180165821680148" STUDIES="2" TAU2="1.8989786499166994" TOTAL_1="122" TOTAL_2="122" WEIGHT="20.10983187765678" Z="1.9447783722910466">
<NAME>Children</NAME>
<CONT_DATA CI_END="-2.492393359241935" CI_START="-3.3212864295189966" EFFECT_SIZE="-2.906839894380466" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="5.0" MODIFIED="2014-07-14 22:18:23 +0100" MODIFIED_BY="[Empty name]" ORDER="384" SD_1="0.5" SD_2="0.833" SE="0.21145619940347488" STUDY_ID="STD-Mitchell-1997" TOTAL_1="94" TOTAL_2="92" WEIGHT="10.1249962287054"/>
<CONT_DATA CI_END="-0.3831713165037638" CI_START="-1.4708786961640392" EFFECT_SIZE="-0.9270250063339015" ESTIMABLE="YES" MEAN_1="4.5" MEAN_2="8.58" MODIFIED="2014-07-14 22:18:23 +0100" MODIFIED_BY="[Empty name]" ORDER="386" SD_1="3.5" SD_2="5.0" SE="0.27748147114946303" STUDY_ID="STD-Riikonen-1994" TOTAL_1="28" TOTAL_2="30" WEIGHT="9.98483564895138"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="78.71718682070322" CI_END="-0.0857905777666757" CI_START="-0.8973135166356314" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.49155204720115353" ESTIMABLE="YES" I2="88.56666458304765" I2_Q="23.623721451110118" ID="CMP-002.04" MODIFIED="2014-10-17 18:13:38 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="2.907674101493285E-13" P_Q="0.27000723985334696" P_Z="0.017579341924318176" Q="2.618614101130579" RANDOM="YES" SCALE="3.86" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.3638736341310852" TOTALS="YES" TOTAL_1="502" TOTAL_2="464" UNITS="" WEIGHT="100.0" Z="2.3743612482080856">
<NAME>Time to recovering from fever</NAME>
<GROUP_LABEL_1>CSF plus ATB</GROUP_LABEL_1>
<GROUP_LABEL_2>ATB alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors CSF plus ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ATB alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="75.76880002410587" CI_END="0.031068039416781157" CI_START="-1.1519063573369812" DF="6" EFFECT_SIZE="-0.5604191589601001" ESTIMABLE="YES" I2="92.08117325589016" ID="CMP-002.04.01" MODIFIED="2014-07-14 22:20:07 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="2.5979218776228663E-14" P_Z="0.06330883528612256" STUDIES="6" TAU2="0.5707349683764905" TOTAL_1="359" TOTAL_2="323" WEIGHT="69.8793899279238" Z="1.8570162986150531">
<NAME>Adults</NAME>
<CONT_DATA CI_END="-1.4785229543463472" CI_START="-2.351260966229865" EFFECT_SIZE="-1.914891960288106" ESTIMABLE="YES" MEAN_1="6.1" MEAN_2="11.4" MODIFIED="2014-07-14 22:19:21 +0100" MODIFIED_BY="[Empty name]" ORDER="131" SD_1="2.75" SD_2="2.75" SE="0.22264133901631958" STUDY_ID="STD-Aviles-1996" TOTAL_1="61" TOTAL_2="58" WEIGHT="10.366448489875692"/>
<CONT_DATA CI_END="0.9573715089499887" CI_START="-0.6458332784416482" EFFECT_SIZE="0.15576911525417028" ESTIMABLE="YES" MEAN_1="2.9" MEAN_2="2.4" MODIFIED="2014-07-14 22:19:21 +0100" MODIFIED_BY="[Empty name]" ORDER="132" SD_1="3.6" SD_2="2.5" SE="0.4089883283666209" STUDY_ID="STD-Biesma-1990" TOTAL_1="12" TOTAL_2="12" WEIGHT="8.06923305013816"/>
<CONT_DATA CI_END="0.26672874944371977" CI_START="-0.26672874944371977" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="3.0" MODIFIED="2014-07-14 22:19:21 +0100" MODIFIED_BY="[Empty name]" ORDER="134" SD_1="3.0" SD_2="4.667" SE="0.1360885973148701" STUDY_ID="STD-Maher-1994" TOTAL_1="109" TOTAL_2="107" WEIGHT="11.208168534227529"/>
<CONT_DATA CI_END="-0.4744141771913817" CI_START="-1.5858673409668602" EFFECT_SIZE="-1.030140759079121" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="4.0" MODIFIED="2014-07-14 22:19:21 +0100" MODIFIED_BY="[Empty name]" ORDER="352" SD_1="1.5" SD_2="2.5" SE="0.2835391804498652" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="22" WEIGHT="9.64717808893595">
<FOOTNOTE>GM-CSF</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="-0.541557311039923" CI_START="-1.6794088928093511" EFFECT_SIZE="-1.110483101924637" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="4.0" MODIFIED="2014-07-14 22:19:21 +0100" MODIFIED_BY="[Empty name]" ORDER="135" SD_1="2.75" SD_2="2.5" SE="0.2902735945008827" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="21" WEIGHT="9.563989456551168">
<FOOTNOTE>G-CSF</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="0.4753610900391237" CI_START="-0.4753610900391237" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="2.0" MODIFIED="2014-07-14 22:19:21 +0100" MODIFIED_BY="[Empty name]" ORDER="137" SD_1="2.0" SD_2="2.75" SE="0.24253562503633297" STUDY_ID="STD-Ravaud-1998" TOTAL_1="34" TOTAL_2="34" WEIGHT="10.139489589844814"/>
<CONT_DATA CI_END="0.3387811723135764" CI_START="-0.3387811723135764" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="3.0" MODIFIED="2014-07-14 22:19:21 +0100" MODIFIED_BY="[Empty name]" ORDER="140" SD_1="3.25" SD_2="3.25" SE="0.17285071306709668" STUDY_ID="STD-Vellenga-1996" TOTAL_1="65" TOTAL_2="69" WEIGHT="10.884882718350477"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.1999641054125646" CI_END="0.04174154974766914" CI_START="-0.46176819195935576" DF="1" EFFECT_SIZE="-0.2100133211058433" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.02" MODIFIED="2014-07-14 22:20:07 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6547498307377126" P_Z="0.10204960402163259" STUDIES="2" TAU2="0.0" TOTAL_1="122" TOTAL_2="122" WEIGHT="21.014219936388407" Z="1.6349973458134412">
<NAME>Children</NAME>
<CONT_DATA CI_END="0.04634806532418545" CI_START="-0.5306797207087747" EFFECT_SIZE="-0.2421658276922946" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="3.0" MODIFIED="2014-07-14 22:20:07 +0100" MODIFIED_BY="[Empty name]" ORDER="136" SD_1="3.0" SD_2="5.0" SE="0.14720367072672805" STUDY_ID="STD-Mitchell-1997" TOTAL_1="94" TOTAL_2="92" WEIGHT="11.116628854499952"/>
<CONT_DATA CI_END="0.4080141339145007" CI_START="-0.6228174197788947" EFFECT_SIZE="-0.10740164293219699" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="2.3" MODIFIED="2014-07-14 22:20:07 +0100" MODIFIED_BY="[Empty name]" ORDER="138" SD_1="1.25" SD_2="2.25" SE="0.2629720652584596" STUDY_ID="STD-Riikonen-1994" TOTAL_1="28" TOTAL_2="30" WEIGHT="9.897591081888455"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.04563846942141192" CI_START="-1.326546961042164" DF="0" EFFECT_SIZE="-0.6860927152317879" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.03" MODIFIED="2014-10-17 18:13:38 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.0357613928680626" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="19" WEIGHT="9.106390135687805" Z="2.099630099583632">
<NAME>Adults and Children</NAME>
<CONT_DATA CI_END="-0.04563846942141192" CI_START="-1.326546961042164" EFFECT_SIZE="-0.6860927152317879" ESTIMABLE="YES" MEAN_1="5.5" MEAN_2="7.6" MODIFIED="2014-10-17 18:13:37 +0100" MODIFIED_BY="[Empty name]" ORDER="517" SD_1="3.0" SD_2="3.0" SE="0.326768374756984" STUDY_ID="STD-Lopez_x002d_Hernandez-2000" TOTAL_1="21" TOTAL_2="19" WEIGHT="9.106390135687805"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2014-10-10 20:39:21 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Subgroup analysis - Type of CSF (G-CSF vs. GM-CSF)</NAME>
<DICH_OUTCOME CHI2="22.50132488405293" CI_END="0.9526698015390064" CI_START="0.4448012801323497" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6509598660961992" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="182" I2="68.89072071946742" I2_Q="50.0158691487829" ID="CMP-003.01" LOG_CI_END="-0.021057601165146364" LOG_CI_START="-0.3518339715302805" LOG_EFFECT_SIZE="-0.18644578634771344" METHOD="MH" MODIFIED="2014-10-10 20:34:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.002080920096340977" P_Q="0.1572336872290785" P_Z="0.02713911316396967" Q="2.000634967479184" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.17640597149618625" TOTALS="YES" TOTAL_1="565" TOTAL_2="522" WEIGHT="100.0" Z="2.209511071830095">
<NAME>Patients with hospitalization for greater than 10 days</NAME>
<GROUP_LABEL_1>CSF plus ATB</GROUP_LABEL_1>
<GROUP_LABEL_2>ATB</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors CSF plus ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ATB alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="13.551034946878449" CI_END="1.2322804584934912" CI_START="0.5086878657052302" DF="4" EFFECT_SIZE="0.7917361406310289" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="133" I2="70.48195938036879" ID="CMP-003.01.01" LOG_CI_END="0.09070956149275497" LOG_CI_START="-0.2935486219521202" LOG_EFFECT_SIZE="-0.10141953022968267" MODIFIED="2014-07-25 19:57:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.008874833046356612" P_Z="0.3008512255882929" STUDIES="5" TAU2="0.15804138867486384" TOTAL_1="448" TOTAL_2="420" WEIGHT="68.3531666203839" Z="1.0346097241031984">
<NAME>G-CSF</NAME>
<DICH_DATA CI_END="1.63988773696822" CI_START="0.6016672931718803" EFFECT_SIZE="0.9933110367892977" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" LOG_CI_END="0.21481411824036745" LOG_CI_START="-0.22064359625480207" LOG_EFFECT_SIZE="-0.0029147390072172936" MODIFIED="2014-07-25 19:57:24 +0100" MODIFIED_BY="[Empty name]" ORDER="288" O_E="0.0" SE="0.25579001704491355" STUDY_ID="STD-Garcia_x002d_Carbonero-2001" TOTAL_1="104" TOTAL_2="99" VAR="0.06542853281983717" WEIGHT="15.610826384835667"/>
<DICH_DATA CI_END="0.8130748301230439" CI_START="0.3944753449233908" EFFECT_SIZE="0.5663373323923783" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="52" LOG_CI_END="-0.08986948292499009" LOG_CI_START="-0.40398013541611133" LOG_EFFECT_SIZE="-0.2469248091705507" MODIFIED="2014-07-25 19:57:24 +0100" MODIFIED_BY="[Empty name]" ORDER="289" O_E="0.0" SE="0.18451015214609112" STUDY_ID="STD-Maher-1994" TOTAL_1="109" TOTAL_2="107" VAR="0.034043996244973694" WEIGHT="17.938878780839413"/>
<DICH_DATA CI_END="0.5839566004470578" CI_START="0.010132875899996046" EFFECT_SIZE="0.07692307692307693" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="-0.23361942837859279" LOG_CI_START="-1.9942672762350806" LOG_EFFECT_SIZE="-1.1139433523068367" MODIFIED="2014-07-25 19:57:24 +0100" MODIFIED_BY="[Empty name]" ORDER="286" O_E="0.0" SE="1.0342132611783073" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="21" VAR="1.0695970695970696" WEIGHT="3.029877404976317"/>
<DICH_DATA CI_END="1.679725007800233" CI_START="0.5086682046226763" EFFECT_SIZE="0.9243498817966903" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" LOG_CI_END="0.22523818805306842" LOG_CI_START="-0.29356540801141945" LOG_EFFECT_SIZE="-0.03416360997917553" MODIFIED="2014-07-25 19:57:24 +0100" MODIFIED_BY="[Empty name]" ORDER="287" O_E="0.0" SE="0.3047478004474988" STUDY_ID="STD-Mitchell-1997" TOTAL_1="94" TOTAL_2="92" VAR="0.09287122187758853" WEIGHT="14.019889369167453"/>
<DICH_DATA CI_END="1.6994623450112405" CI_START="0.8058091452909492" EFFECT_SIZE="1.1702317290552584" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="33" LOG_CI_END="0.23031154636244203" LOG_CI_START="-0.09376780802376854" LOG_EFFECT_SIZE="0.06827186916933672" MODIFIED="2014-07-25 19:57:24 +0100" MODIFIED_BY="[Empty name]" ORDER="285" O_E="0.0" SE="0.19036581698513677" STUDY_ID="STD-Yoshida-1999" TOTAL_1="102" TOTAL_2="101" VAR="0.03623914427641859" WEIGHT="17.753694680565047"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.5685761842720645" CI_END="0.9203460517504297" CI_START="0.17569310778617114" DF="2" EFFECT_SIZE="0.4021174680000426" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="49" I2="64.0841763887721" ID="CMP-003.01.02" LOG_CI_END="-0.036048846450339886" LOG_CI_START="-0.7552452749824733" LOG_EFFECT_SIZE="-0.3956470607164066" MODIFIED="2014-10-10 20:34:42 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.06177309606333159" P_Z="0.03104888668175112" STUDIES="3" TAU2="0.33237958360424297" TOTAL_1="117" TOTAL_2="102" WEIGHT="31.646833379616105" Z="2.1564456074287692">
<NAME>GM-CSF</NAME>
<DICH_DATA CI_END="1.091771683962423" CI_START="0.43900198903207566" EFFECT_SIZE="0.6923076923076923" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="26" LOG_CI_END="0.038131826315114824" LOG_CI_START="-0.3575335120501386" LOG_EFFECT_SIZE="-0.1597008428675119" MODIFIED="2014-07-25 19:57:24 +0100" MODIFIED_BY="[Empty name]" ORDER="281" O_E="0.0" SE="0.23241577833076224" STUDY_ID="STD-Anaissie-1996" TOTAL_1="50" TOTAL_2="50" VAR="0.05401709401709401" WEIGHT="16.38393470866592"/>
<DICH_DATA CI_END="0.606460826035732" CI_START="0.03279392596006056" EFFECT_SIZE="0.14102564102564102" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="-0.21719724687651348" LOG_CI_START="-1.4842065881879973" LOG_EFFECT_SIZE="-0.8507019175322553" MODIFIED="2014-07-25 19:57:24 +0100" MODIFIED_BY="[Empty name]" ORDER="282" O_E="0.0" SE="0.7442475588837554" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="22" VAR="0.5539044289044289" WEIGHT="5.169358753030642"/>
<DICH_DATA CI_END="0.8535681487055642" CI_START="0.1494327319987213" EFFECT_SIZE="0.35714285714285715" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="15" LOG_CI_END="-0.06876179918281475" LOG_CI_START="-0.8255542635016236" LOG_EFFECT_SIZE="-0.4471580313422192" MODIFIED="2014-10-10 20:34:42 +0100" MODIFIED_BY="[Empty name]" ORDER="283" O_E="0.0" SE="0.4445436397239844" STUDY_ID="STD-Riikonen-1994" TOTAL_1="28" TOTAL_2="30" VAR="0.19761904761904764" WEIGHT="10.093539917919543"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="16.494664034933447" CI_END="0.8109325012265797" CI_START="0.33556954675676964" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5216552998742914" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="172" I2="69.68716677459642" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-0.09101529321769991" LOG_CI_START="-0.47421745867645393" LOG_EFFECT_SIZE="-0.28261637594707695" METHOD="MH" MODIFIED="2014-07-25 20:20:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.005564938113574391" P_Q="0.5587488698459127" P_Z="0.003840232981253106" Q="0.3418754213249856" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.14227012657533428" TOTALS="YES" TOTAL_1="419" TOTAL_2="375" WEIGHT="100.0" Z="2.890995762690302">
<NAME>Time to neutrophil recovery</NAME>
<GROUP_LABEL_1>CSF + ATB</GROUP_LABEL_1>
<GROUP_LABEL_2>ATB alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors CSF plus ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ATB alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="11.953536538529542" CI_END="0.9406923359217827" CI_START="0.30658941314985755" DF="3" EFFECT_SIZE="0.5370347393091326" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="142" I2="74.90282486417159" ID="CMP-003.02.01" LOG_CI_END="-0.026552394276795496" LOG_CI_START="-0.513442845861227" LOG_EFFECT_SIZE="-0.2699976200690113" MODIFIED="2014-07-25 20:20:16 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.007544042638515269" P_Z="0.029724979771227726" STUDIES="4" TAU2="0.17069104719118203" TOTAL_1="346" TOTAL_2="319" WEIGHT="71.58626351947365" Z="2.1737358353392358">
<NAME>G-CSF</NAME>
<DICH_DATA CI_END="1.0933934015424545" CI_START="0.051797318736123366" EFFECT_SIZE="0.23798076923076922" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.03877644866442071" LOG_CI_START="-1.2856927207228064" LOG_EFFECT_SIZE="-0.6234581360291929" MODIFIED="2014-07-25 20:10:16 +0100" MODIFIED_BY="[Empty name]" ORDER="268" O_E="0.0" SE="0.7779997463261832" STUDY_ID="STD-Garcia_x002d_Carbonero-2001" TOTAL_1="104" TOTAL_2="99" VAR="0.6052836052836054" WEIGHT="6.77779921753797"/>
<DICH_DATA CI_END="0.7408162874866677" CI_START="0.3715963486500309" EFFECT_SIZE="0.5246757355267321" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="58" LOG_CI_END="-0.13028947788143516" LOG_CI_START="-0.429928562086722" LOG_EFFECT_SIZE="-0.28010901998407856" MODIFIED="2014-07-25 20:10:16 +0100" MODIFIED_BY="[Empty name]" ORDER="269" O_E="0.0" SE="0.17600948129957372" STUDY_ID="STD-Maher-1994" TOTAL_1="109" TOTAL_2="107" VAR="0.030979337507344988" WEIGHT="29.245510949708404"/>
<DICH_DATA CI_END="0.8626033503367427" CI_START="0.002898203443128352" EFFECT_SIZE="0.05" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="-0.06418885939440955" LOG_CI_START="-2.537871131933553" LOG_EFFECT_SIZE="-1.3010299956639813" MODIFIED="2014-07-25 20:10:16 +0100" MODIFIED_BY="[Empty name]" ORDER="271" O_E="0.0" SE="1.4530532118142254" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="21" VAR="2.1113636363636363" WEIGHT="2.2482664140838575"/>
<DICH_DATA CI_END="0.9708937884569786" CI_START="0.658396501621064" EFFECT_SIZE="0.7995205274198381" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="71" LOG_CI_END="-0.012828277414351085" LOG_CI_START="-0.1815124854062118" LOG_EFFECT_SIZE="-0.0971703814102814" MODIFIED="2014-07-25 20:10:16 +0100" MODIFIED_BY="[Empty name]" ORDER="270" O_E="0.0" SE="0.09908593877471525" STUDY_ID="STD-Mitchell-1997" TOTAL_1="94" TOTAL_2="92" VAR="0.00981802326286662" WEIGHT="33.31468693814341"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.3668042377135308" CI_END="2.211096115283515" CI_START="0.036726929694790335" DF="1" EFFECT_SIZE="0.28496801851162473" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="30" I2="57.7489348689836" ID="CMP-003.02.02" LOG_CI_END="0.3446076215610678" LOG_CI_START="-1.4350153763741285" LOG_EFFECT_SIZE="-0.5452038774065303" MODIFIED="2014-07-25 20:20:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.12394071180606636" P_Z="0.22978769019037026" STUDIES="2" TAU2="1.5067721959650344" TOTAL_1="73" TOTAL_2="56" WEIGHT="28.413736480526357" Z="1.200905995470061">
<NAME>GM-CSF</NAME>
<DICH_DATA CI_END="1.134013013337193" CI_START="0.003599420884461303" EFFECT_SIZE="0.06388888888888888" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.054618038320650084" LOG_CI_START="-2.443767367820039" LOG_EFFECT_SIZE="-1.1945746647496944" MODIFIED="2014-07-25 20:16:48 +0100" MODIFIED_BY="[Empty name]" ORDER="267" O_E="0.0" SE="1.467563954774257" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="22" VAR="2.153743961352657" WEIGHT="2.2067674259932573"/>
<DICH_DATA CI_END="0.8385104838080086" CI_START="0.3457808029848721" EFFECT_SIZE="0.5384615384615384" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="26" LOG_CI_END="-0.07649150308591675" LOG_CI_START="-0.46119912149924314" LOG_EFFECT_SIZE="-0.26884531229257996" MODIFIED="2014-07-25 20:20:16 +0100" MODIFIED_BY="[Empty name]" ORDER="266" O_E="0.0" SE="0.2259791593894118" STUDY_ID="STD-Ravaud-1998" TOTAL_1="34" TOTAL_2="34" VAR="0.051066580478345176" WEIGHT="26.2069690545331"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="373.1754047514254" CI_END="-0.7568572778884837" CI_START="-2.6483944819768244" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="SMD" EFFECT_SIZE="-1.7026258799326541" ESTIMABLE="YES" I2="97.588265495151" I2_Q="81.23146554698451" ID="CMP-003.03" MODIFIED="2014-10-10 20:39:21 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.3322676295501878E-15" P_Q="0.02098471521225309" P_Z="4.180206437126659E-4" Q="5.328066517411713" RANDOM="YES" SCALE="15.404019975367234" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="2.2550262379819737" TOTALS="YES" TOTAL_1="588" TOTAL_2="547" UNITS="" WEIGHT="100.00000000000001" Z="3.528437502155488">
<NAME>Duration of grade IV neutropenia</NAME>
<GROUP_LABEL_1>CSF plus ATB</GROUP_LABEL_1>
<GROUP_LABEL_2>ATB alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors CSF plus ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ATB alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="279.53742026592437" CI_END="-1.038448046639484" CI_START="-4.42672440674871" DF="4" EFFECT_SIZE="-2.7325862266940972" ESTIMABLE="YES" I2="98.56906456523967" ID="CMP-003.03.01" MODIFIED="2014-05-01 20:11:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="-2.220446049250313E-16" P_Z="0.00157037496472297" STUDIES="5" TAU2="3.666607975529725" TOTAL_1="407" TOTAL_2="377" WEIGHT="50.098753158689945" Z="3.161354045393147">
<NAME>G-CSF</NAME>
<CONT_DATA CI_END="-3.8630621429187046" CI_START="-5.2417012038127035" EFFECT_SIZE="-4.552381673365704" ESTIMABLE="YES" MEAN_1="7.5" MEAN_2="14.8" MODIFIED="2014-05-01 20:06:57 +0100" MODIFIED_BY="[Empty name]" ORDER="378" SD_1="2.0" SD_2="1.0" SE="0.35170010055504286" STUDY_ID="STD-Aviles-1996" TOTAL_1="61" TOTAL_2="58" WEIGHT="9.788821840497002"/>
<CONT_DATA CI_END="-3.7799163925878263" CI_START="-4.785322438261804" EFFECT_SIZE="-4.282619415424815" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="3.0" MODIFIED="2014-05-01 20:06:57 +0100" MODIFIED_BY="[Empty name]" ORDER="380" SD_1="0.01" SD_2="0.333" SE="0.2564858470881332" STUDY_ID="STD-Garcia_x002d_Carbonero-2001" TOTAL_1="104" TOTAL_2="99" WEIGHT="10.03306868152967"/>
<CONT_DATA CI_END="-0.17062327540468808" CI_START="-0.7106335211190538" EFFECT_SIZE="-0.4406283982618709" ESTIMABLE="YES" MEAN_1="3.3" MEAN_2="4.3" MODIFIED="2014-05-01 20:06:57 +0100" MODIFIED_BY="[Empty name]" ORDER="382" SD_1="2.0" SD_2="2.5" SE="0.13776024712032914" STUDY_ID="STD-Maher-1994" TOTAL_1="109" TOTAL_2="107" WEIGHT="10.23958496926569"/>
<CONT_DATA CI_END="-0.9261965054835081" CI_START="-2.1284423199057416" EFFECT_SIZE="-1.5273194126946248" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="5.75" MODIFIED="2014-05-01 20:09:10 +0100" MODIFIED_BY="[Empty name]" ORDER="391" SD_1="1.25" SD_2="3.75" SE="0.30670099652478183" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="21" WEIGHT="9.912281438692183">
<FOOTNOTE>G-CSF</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="-2.492393359241935" CI_START="-3.3212864295189966" EFFECT_SIZE="-2.906839894380466" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="5.0" MODIFIED="2014-05-01 20:06:57 +0100" MODIFIED_BY="[Empty name]" ORDER="384" SD_1="0.5" SD_2="0.833" SE="0.21145619940347488" STUDY_ID="STD-Mitchell-1997" TOTAL_1="94" TOTAL_2="92" WEIGHT="10.124996228705403"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="15.279321748976939" CI_END="-0.2190473402198141" CI_START="-1.117752572878071" DF="4" EFFECT_SIZE="-0.6683999565489426" ESTIMABLE="YES" I2="73.82082748360325" ID="CMP-003.03.02" MODIFIED="2014-10-10 20:39:21 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0041556151497620375" P_Z="0.0035523995922561963" STUDIES="5" TAU2="0.1885512052605756" TOTAL_1="181" TOTAL_2="170" WEIGHT="49.90124684131007" Z="2.915393823243093">
<NAME>GM-CSF</NAME>
<CONT_DATA CI_END="0.6135351786365997" CI_START="-0.8189056257095417" EFFECT_SIZE="-0.10268522353647108" ESTIMABLE="YES" MEAN_1="6.3" MEAN_2="6.7" MODIFIED="2014-10-10 20:39:21 +0100" MODIFIED_BY="[Empty name]" ORDER="379" SD_1="3.2" SD_2="4.3" SE="0.3654252873126883" STUDY_ID="STD-Biesma-1990" TOTAL_1="15" TOTAL_2="15" WEIGHT="9.748484497506668"/>
<CONT_DATA CI_END="-0.9184367897784403" CI_START="-2.1014068041701104" EFFECT_SIZE="-1.5099217969742753" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="5.75" MODIFIED="2014-05-01 20:09:34 +0100" MODIFIED_BY="[Empty name]" ORDER="383" SD_1="1.25" SD_2="3.75" SE="0.3017836102404907" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="22" WEIGHT="9.924923302382883">
<FOOTNOTE>GM-CSF</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="-0.04207115863029898" CI_START="-1.0100926580195093" EFFECT_SIZE="-0.5260819083249041" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="4.2" MODIFIED="2014-05-01 20:09:42 +0100" MODIFIED_BY="[Empty name]" ORDER="385" SD_1="1.75" SD_2="2.0" SE="0.24694879779037784" STUDY_ID="STD-Ravaud-1998" TOTAL_1="34" TOTAL_2="34" WEIGHT="10.053868066422481"/>
<CONT_DATA CI_END="-0.3831713165037638" CI_START="-1.4708786961640392" EFFECT_SIZE="-0.9270250063339015" ESTIMABLE="YES" MEAN_1="4.5" MEAN_2="8.58" MODIFIED="2014-05-01 20:09:51 +0100" MODIFIED_BY="[Empty name]" ORDER="386" SD_1="3.5" SD_2="5.0" SE="0.27748147114946303" STUDY_ID="STD-Riikonen-1994" TOTAL_1="28" TOTAL_2="30" WEIGHT="9.984835648951382"/>
<CONT_DATA CI_END="0.03487441074032699" CI_START="-0.6467558878969464" EFFECT_SIZE="-0.3059407385783097" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="4.0" MODIFIED="2014-05-01 20:09:51 +0100" MODIFIED_BY="[Empty name]" ORDER="388" SD_1="3.25" SD_2="3.25" SE="0.17388847550615374" STUDY_ID="STD-Vellenga-1996" TOTAL_1="65" TOTAL_2="69" WEIGHT="10.189135326046657"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="78.7171868207032" CI_END="-0.08579057776667554" CI_START="-0.8973135166356312" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.49155204720115336" ESTIMABLE="YES" I2="88.56666458304767" I2_Q="51.072089620192884" ID="CMP-003.04" MODIFIED="2014-07-25 20:10:24 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="2.9054536554440347E-13" P_Q="0.15282555081156757" P_Z="0.017579341924318218" Q="2.043823233482513" RANDOM="YES" SCALE="3.86" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.3638736341310852" TOTALS="YES" TOTAL_1="502" TOTAL_2="464" UNITS="" WEIGHT="100.0" Z="2.3743612482080847">
<NAME>Time to recovering from fever</NAME>
<GROUP_LABEL_1>CSF plus ATB</GROUP_LABEL_1>
<GROUP_LABEL_2>ATB alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors CSF plus ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ATB alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="61.68746720553773" CI_END="-0.0835635791617475" CI_START="-1.4673207506704038" DF="4" EFFECT_SIZE="-0.7754421649160756" ESTIMABLE="YES" I2="93.5157007068027" ID="CMP-003.04.01" MODIFIED="2014-05-01 20:02:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.2826406603494434E-12" P_Z="0.028043012423189503" STUDIES="5" TAU2="0.5688004263309395" TOTAL_1="324" TOTAL_2="297" WEIGHT="51.36162547084215" Z="2.196684138839558">
<NAME>G-CSF</NAME>
<CONT_DATA CI_END="-1.4785229543463472" CI_START="-2.351260966229865" EFFECT_SIZE="-1.914891960288106" ESTIMABLE="YES" MEAN_1="6.1" MEAN_2="11.4" MODIFIED="2014-04-30 22:24:57 +0100" MODIFIED_BY="[Empty name]" ORDER="131" SD_1="2.75" SD_2="2.75" SE="0.22264133901631958" STUDY_ID="STD-Aviles-1996" TOTAL_1="61" TOTAL_2="58" WEIGHT="10.366448489875692"/>
<CONT_DATA CI_END="-0.04563846942141192" CI_START="-1.326546961042164" EFFECT_SIZE="-0.6860927152317879" ESTIMABLE="YES" MEAN_1="5.5" MEAN_2="7.6" MODIFIED="2014-05-01 20:02:02 +0100" MODIFIED_BY="[Empty name]" ORDER="517" SD_1="3.0" SD_2="3.0" SE="0.326768374756984" STUDY_ID="STD-Lopez_x002d_Hernandez-2000" TOTAL_1="21" TOTAL_2="19" WEIGHT="9.106390135687805"/>
<CONT_DATA CI_END="0.26672874944371977" CI_START="-0.26672874944371977" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="3.0" MODIFIED="2014-04-30 22:24:57 +0100" MODIFIED_BY="[Empty name]" ORDER="134" SD_1="3.0" SD_2="4.667" SE="0.1360885973148701" STUDY_ID="STD-Maher-1994" TOTAL_1="109" TOTAL_2="107" WEIGHT="11.208168534227529"/>
<CONT_DATA CI_END="-0.541557311039923" CI_START="-1.6794088928093511" EFFECT_SIZE="-1.110483101924637" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="4.0" MODIFIED="2014-05-01 15:01:48 +0100" MODIFIED_BY="[Empty name]" ORDER="135" SD_1="2.75" SD_2="2.5" SE="0.2902735945008827" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="21" WEIGHT="9.563989456551168"/>
<CONT_DATA CI_END="0.04634806532418545" CI_START="-0.5306797207087747" EFFECT_SIZE="-0.2421658276922946" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="3.0" MODIFIED="2014-04-30 22:24:57 +0100" MODIFIED_BY="[Empty name]" ORDER="136" SD_1="3.0" SD_2="5.0" SE="0.14720367072672805" STUDY_ID="STD-Mitchell-1997" TOTAL_1="94" TOTAL_2="92" WEIGHT="11.116628854499952"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="11.34589380483926" CI_END="0.18485677913477389" CI_START="-0.5818372786496293" DF="4" EFFECT_SIZE="-0.19849024975742774" ESTIMABLE="YES" I2="64.74495470516464" ID="CMP-003.04.02" MODIFIED="2014-05-01 15:01:52 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.022939758839706448" P_Z="0.31018480076047683" STUDIES="5" TAU2="0.11916358905991933" TOTAL_1="178" TOTAL_2="167" WEIGHT="48.63837452915786" Z="1.0148343706514447">
<NAME>GM-CSF</NAME>
<CONT_DATA CI_END="0.9573715089499887" CI_START="-0.6458332784416482" EFFECT_SIZE="0.15576911525417028" ESTIMABLE="YES" MEAN_1="2.9" MEAN_2="2.4" MODIFIED="2014-04-30 22:25:41 +0100" MODIFIED_BY="[Empty name]" ORDER="132" SD_1="3.6" SD_2="2.5" SE="0.4089883283666209" STUDY_ID="STD-Biesma-1990" TOTAL_1="12" TOTAL_2="12" WEIGHT="8.06923305013816"/>
<CONT_DATA CI_END="-0.4744141771913817" CI_START="-1.5858673409668602" EFFECT_SIZE="-1.030140759079121" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="4.0" MODIFIED="2014-05-01 15:01:52 +0100" MODIFIED_BY="[Empty name]" ORDER="352" SD_1="1.5" SD_2="2.5" SE="0.2835391804498652" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="22" WEIGHT="9.64717808893595"/>
<CONT_DATA CI_END="0.4753610900391237" CI_START="-0.4753610900391237" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="2.0" MODIFIED="2014-04-30 22:27:14 +0100" MODIFIED_BY="[Empty name]" ORDER="137" SD_1="2.0" SD_2="2.75" SE="0.24253562503633297" STUDY_ID="STD-Ravaud-1998" TOTAL_1="34" TOTAL_2="34" WEIGHT="10.139489589844814"/>
<CONT_DATA CI_END="0.4080141339145007" CI_START="-0.6228174197788947" EFFECT_SIZE="-0.10740164293219699" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="2.3" MODIFIED="2014-04-30 22:27:21 +0100" MODIFIED_BY="[Empty name]" ORDER="138" SD_1="1.25" SD_2="2.25" SE="0.2629720652584596" STUDY_ID="STD-Riikonen-1994" TOTAL_1="28" TOTAL_2="30" WEIGHT="9.897591081888455"/>
<CONT_DATA CI_END="0.3387811723135764" CI_START="-0.3387811723135764" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="3.0" MODIFIED="2014-04-30 22:27:26 +0100" MODIFIED_BY="[Empty name]" ORDER="140" SD_1="3.25" SD_2="3.25" SE="0.17285071306709668" STUDY_ID="STD-Vellenga-1996" TOTAL_1="65" TOTAL_2="69" WEIGHT="10.884882718350477"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="69.92355953989522" CI_END="-0.17641390257494383" CI_START="-2.831457948579276" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-1.5039359255771099" ESTIMABLE="YES" I2="97.13973371327172" I2_Q="12.731838487650107" ID="CMP-003.05" MODIFIED="2014-07-25 20:10:21 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="5.551115123125783E-16" P_Q="0.2844105267327389" P_Z="0.02639007659177784" Q="1.1458932818912237" RANDOM="YES" SCALE="5.62" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="1.3340487867611612" TOTALS="YES" TOTAL_1="232" TOTAL_2="225" UNITS="" WEIGHT="99.99999999999997" Z="2.220422861626784">
<NAME>Time to withdrawal from antibiotics</NAME>
<GROUP_LABEL_1>CSF plus ATB</GROUP_LABEL_1>
<GROUP_LABEL_2>ATB alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors CSF plus ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ATB alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="60.95743714302142" CI_END="0.06983590445379817" CI_START="-3.795331918874779" DF="1" EFFECT_SIZE="-1.8627480072104905" ESTIMABLE="YES" I2="98.35951108368656" ID="CMP-003.05.01" MODIFIED="2014-04-30 22:24:18 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="5.88418203051333E-15" P_Z="0.05887324963084128" STUDIES="2" TAU2="1.9126466007779144" TOTAL_1="198" TOTAL_2="191" WEIGHT="67.17361616343382" Z="1.8891386730329587">
<NAME>G-CSF</NAME>
<CONT_DATA CI_END="-2.4601945378835355" CI_START="-3.2457579703388557" EFFECT_SIZE="-2.8529762541111956" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="6.0" MODIFIED="2014-04-30 22:22:50 +0100" MODIFIED_BY="[Empty name]" ORDER="128" SD_1="0.01" SD_2="0.5" SE="0.200402517253313" STUDY_ID="STD-Garcia_x002d_Carbonero-2001" TOTAL_1="104" TOTAL_2="99" WEIGHT="33.38367906037894"/>
<CONT_DATA CI_END="-0.5795539071722889" CI_START="-1.1822417345671852" EFFECT_SIZE="-0.8808978208697371" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="6.0" MODIFIED="2014-04-30 22:22:50 +0100" MODIFIED_BY="[Empty name]" ORDER="126" SD_1="1.0" SD_2="1.25" SE="0.1537497199307796" STUDY_ID="STD-Mitchell-1997" TOTAL_1="94" TOTAL_2="92" WEIGHT="33.78993710305489"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.27945786413677176" CI_START="-1.2671801748601952" DF="0" EFFECT_SIZE="-0.7733190194984835" ESTIMABLE="YES" I2="0.0" ID="CMP-003.05.02" MODIFIED="2014-04-30 22:24:18 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.0021475105797839115" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="34" WEIGHT="32.82638383656616" Z="3.069035518022772">
<NAME>GM-CSF</NAME>
<CONT_DATA CI_END="-0.27945786413677176" CI_START="-1.2671801748601952" EFFECT_SIZE="-0.7733190194984835" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="7.8" MODIFIED="2014-04-30 22:24:18 +0100" MODIFIED_BY="[Empty name]" ORDER="127" SD_1="2.75" SD_2="4.25" SE="0.2519746073179025" STUDY_ID="STD-Ravaud-1998" TOTAL_1="34" TOTAL_2="34" WEIGHT="32.82638383656616"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2014-10-10 20:40:14 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Subgroup analysis - Hospital discharge criteria (fever resolution)</NAME>
<DICH_OUTCOME CHI2="15.047888103435076" CI_END="0.8846691701708848" CI_START="0.3174554183224463" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5299462439659042" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="123" I2="66.77274601172361" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-0.05321910718989426" LOG_CI_START="-0.498317255997228" LOG_EFFECT_SIZE="-0.27576818159356115" METHOD="MH" MODIFIED="2014-10-10 20:35:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.010159683434236455" P_Q="0.6977497139850366" P_Z="0.015154798832218937" Q="0.7197899578267606" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.2305600338347673" TOTALS="YES" TOTAL_1="413" TOTAL_2="371" WEIGHT="100.0" Z="2.4286585125270497">
<NAME>Patients with hospitalization for greater than 10 days</NAME>
<GROUP_LABEL_1>CSF plus ATB</GROUP_LABEL_1>
<GROUP_LABEL_2>ATB alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors CSF plus ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ATB alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="11.661194434227658" CI_END="1.5699654792505422" CI_START="0.043986258977011077" DF="2" EFFECT_SIZE="0.26278681122781195" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="38" I2="82.8490982524942" ID="CMP-004.01.01" LOG_CI_END="0.19589010315074643" LOG_CI_START="-1.3566829731158685" LOG_EFFECT_SIZE="-0.580396434982561" MODIFIED="2014-07-25 19:58:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.002936337492180141" P_Z="0.14281679952870277" STUDIES="2" TAU2="1.9983251741550443" TOTAL_1="182" TOTAL_2="142" WEIGHT="37.06623440668722" Z="1.4653817288351798">
<NAME>Discharge after 48h of resolution of fever</NAME>
<DICH_DATA CI_END="1.63988773696822" CI_START="0.6016672931718803" EFFECT_SIZE="0.9933110367892977" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" LOG_CI_END="0.21481411824036745" LOG_CI_START="-0.22064359625480207" LOG_EFFECT_SIZE="-0.0029147390072172936" MODIFIED="2014-07-25 19:58:38 +0100" MODIFIED_BY="[Empty name]" ORDER="294" O_E="0.0" SE="0.25579001704491355" STUDY_ID="STD-Garcia_x002d_Carbonero-2001" TOTAL_1="104" TOTAL_2="99" VAR="0.06542853281983717" WEIGHT="23.094674439906147"/>
<DICH_DATA CI_END="0.5839566004470578" CI_START="0.010132875899996046" EFFECT_SIZE="0.07692307692307693" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="-0.23361942837859279" LOG_CI_START="-1.9942672762350806" LOG_EFFECT_SIZE="-1.1139433523068367" MODIFIED="2014-07-25 19:58:38 +0100" MODIFIED_BY="[Empty name]" ORDER="295" O_E="0.0" SE="1.0342132611783073" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="21" VAR="1.0695970695970696" WEIGHT="5.257641224109905"/>
<DICH_DATA CI_END="0.606460826035732" CI_START="0.03279392596006056" EFFECT_SIZE="0.14102564102564102" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="-0.21719724687651348" LOG_CI_START="-1.4842065881879973" LOG_EFFECT_SIZE="-0.8507019175322553" MODIFIED="2014-07-25 19:58:38 +0100" MODIFIED_BY="[Empty name]" ORDER="296" O_E="0.0" SE="0.7442475588837554" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="22" VAR="0.5539044289044289" WEIGHT="8.713918742671169"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.1159026328760566" CI_END="1.5325943276936032" CI_START="0.24046129626589444" DF="1" EFFECT_SIZE="0.6070664038529564" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="33" I2="67.90657097404309" ID="CMP-004.01.02" LOG_CI_END="0.18542721385023386" LOG_CI_START="-0.6189548160503165" LOG_EFFECT_SIZE="-0.21676380110004137" MODIFIED="2014-10-10 20:35:29 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.07753179803983601" P_Z="0.2908143008484625" STUDIES="2" TAU2="0.30732456302640393" TOTAL_1="122" TOTAL_2="122" WEIGHT="37.09984468605174" Z="1.0563369829647014">
<NAME>Discharge after 72 hours of the resolution of fever</NAME>
<DICH_DATA CI_END="1.679725007800233" CI_START="0.5086682046226763" EFFECT_SIZE="0.9243498817966903" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" LOG_CI_END="0.22523818805306842" LOG_CI_START="-0.29356540801141945" LOG_EFFECT_SIZE="-0.03416360997917553" MODIFIED="2014-07-25 19:58:38 +0100" MODIFIED_BY="[Empty name]" ORDER="291" O_E="0.0" SE="0.3047478004474988" STUDY_ID="STD-Mitchell-1997" TOTAL_1="94" TOTAL_2="92" VAR="0.09287122187758853" WEIGHT="21.13512365948313"/>
<DICH_DATA CI_END="0.8535681487055642" CI_START="0.1494327319987213" EFFECT_SIZE="0.35714285714285715" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="15" LOG_CI_END="-0.06876179918281475" LOG_CI_START="-0.8255542635016236" LOG_EFFECT_SIZE="-0.4471580313422192" MODIFIED="2014-10-10 20:35:29 +0100" MODIFIED_BY="[Empty name]" ORDER="293" O_E="0.0" SE="0.4445436397239844" STUDY_ID="STD-Riikonen-1994" TOTAL_1="28" TOTAL_2="30" VAR="0.19761904761904764" WEIGHT="15.964721026568604"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8130748301230439" CI_START="0.3944753449233908" DF="0" EFFECT_SIZE="0.5663373323923783" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="52" I2="0.0" ID="CMP-004.01.03" LOG_CI_END="-0.08986948292499009" LOG_CI_START="-0.40398013541611133" LOG_EFFECT_SIZE="-0.2469248091705507" MODIFIED="2014-07-25 19:58:38 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.0020597040973736316" STUDIES="1" TAU2="0.0" TOTAL_1="109" TOTAL_2="107" WEIGHT="25.833920907261042" Z="3.0814856422443997">
<NAME>Discharge after 96 hours of the resolution of fever</NAME>
<DICH_DATA CI_END="0.8130748301230439" CI_START="0.3944753449233908" EFFECT_SIZE="0.5663373323923783" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="52" LOG_CI_END="-0.08986948292499009" LOG_CI_START="-0.40398013541611133" LOG_EFFECT_SIZE="-0.2469248091705507" MODIFIED="2014-07-25 19:58:38 +0100" MODIFIED_BY="[Empty name]" ORDER="290" O_E="0.0" SE="0.18451015214609112" STUDY_ID="STD-Maher-1994" TOTAL_1="109" TOTAL_2="107" VAR="0.034043996244973694" WEIGHT="25.833920907261042"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="16.494664034933447" CI_END="0.8109325012265796" CI_START="0.33556954675676953" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5216552998742913" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="172" I2="69.68716677459642" I2_Q="75.60516934373577" ID="CMP-004.02" LOG_CI_END="-0.09101529321769997" LOG_CI_START="-0.47421745867645404" LOG_EFFECT_SIZE="-0.282616375947077" METHOD="MH" MODIFIED="2014-07-25 20:24:28 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.005564938113574391" P_Q="0.006429983886209634" P_Z="0.003840232981253106" Q="12.297687334958582" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.14227012657533436" TOTALS="YES" TOTAL_1="419" TOTAL_2="375" WEIGHT="100.00000000000001" Z="2.890995762690302">
<NAME>Time to neutrophil recovery</NAME>
<GROUP_LABEL_1>CSF + ATB</GROUP_LABEL_1>
<GROUP_LABEL_2>ATB alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors CSF plus ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ATB alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8385104838080086" CI_START="0.3457808029848721" DF="0" EFFECT_SIZE="0.5384615384615384" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="26" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="-0.07649150308591675" LOG_CI_START="-0.46119912149924314" LOG_EFFECT_SIZE="-0.26884531229257996" MODIFIED="2014-07-25 20:24:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.006155814872758767" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="34" WEIGHT="26.206969054533108" Z="2.739364152335317">
<NAME>Discharge after 24h of resolution of fever</NAME>
<DICH_DATA CI_END="0.8385104838080086" CI_START="0.3457808029848721" EFFECT_SIZE="0.5384615384615384" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="26" LOG_CI_END="-0.07649150308591675" LOG_CI_START="-0.46119912149924314" LOG_EFFECT_SIZE="-0.26884531229257996" MODIFIED="2014-07-25 20:21:01 +0100" MODIFIED_BY="[Empty name]" ORDER="266" O_E="0.0" SE="0.2259791593894118" STUDY_ID="STD-Ravaud-1998" TOTAL_1="34" TOTAL_2="34" VAR="0.051066580478345176" WEIGHT="26.206969054533108"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2817463357698375" CI_END="0.4777076546660998" CI_START="0.04181684835117956" DF="2" EFFECT_SIZE="0.1413372864865105" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="17" I2="0.0" ID="CMP-004.02.02" LOG_CI_END="-0.32083779963644243" LOG_CI_START="-1.37864870215608" LOG_EFFECT_SIZE="-0.8497432508962613" MODIFIED="2014-07-25 20:24:17 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5268322384611903" P_Z="0.0016389072688372994" STUDIES="2" TAU2="0.0" TOTAL_1="182" TOTAL_2="142" WEIGHT="11.232833057615089" Z="3.1488920446851543">
<NAME>Discharge after 48h of resolution of fever</NAME>
<DICH_DATA CI_END="1.0933934015424545" CI_START="0.051797318736123366" EFFECT_SIZE="0.23798076923076922" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.03877644866442071" LOG_CI_START="-1.2856927207228064" LOG_EFFECT_SIZE="-0.6234581360291929" MODIFIED="2014-07-25 20:24:02 +0100" MODIFIED_BY="[Empty name]" ORDER="268" O_E="0.0" SE="0.7779997463261832" STUDY_ID="STD-Garcia_x002d_Carbonero-2001" TOTAL_1="104" TOTAL_2="99" VAR="0.6052836052836054" WEIGHT="6.7777992175379715"/>
<DICH_DATA CI_END="1.134013013337193" CI_START="0.003599420884461303" EFFECT_SIZE="0.06388888888888888" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.054618038320650084" LOG_CI_START="-2.443767367820039" LOG_EFFECT_SIZE="-1.1945746647496944" MODIFIED="2014-07-25 20:24:17 +0100" MODIFIED_BY="[Empty name]" ORDER="267" O_E="0.0" SE="1.467563954774257" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="22" VAR="2.153743961352657" WEIGHT="2.206767425993258"/>
<DICH_DATA CI_END="0.8626033503367427" CI_START="0.002898203443128352" EFFECT_SIZE="0.05" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="-0.06418885939440955" LOG_CI_START="-2.537871131933553" LOG_EFFECT_SIZE="-1.3010299956639813" MODIFIED="2014-07-25 20:24:17 +0100" MODIFIED_BY="[Empty name]" ORDER="271" O_E="0.0" SE="1.4530532118142254" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="21" VAR="2.1113636363636363" WEIGHT="2.2482664140838584"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9708937884569786" CI_START="0.658396501621064" DF="0" EFFECT_SIZE="0.7995205274198381" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="71" I2="0.0" ID="CMP-004.02.03" LOG_CI_END="-0.012828277414351085" LOG_CI_START="-0.1815124854062118" LOG_EFFECT_SIZE="-0.0971703814102814" MODIFIED="2014-07-25 20:24:28 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.023941241567093995" STUDIES="1" TAU2="0.0" TOTAL_1="94" TOTAL_2="92" WEIGHT="33.31468693814341" Z="2.2580708673969236">
<NAME>Discharge after 72h of resolution of fever</NAME>
<DICH_DATA CI_END="0.9708937884569786" CI_START="0.658396501621064" EFFECT_SIZE="0.7995205274198381" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="71" LOG_CI_END="-0.012828277414351085" LOG_CI_START="-0.1815124854062118" LOG_EFFECT_SIZE="-0.0971703814102814" MODIFIED="2014-07-25 20:24:28 +0100" MODIFIED_BY="[Empty name]" ORDER="270" O_E="0.0" SE="0.09908593877471525" STUDY_ID="STD-Mitchell-1997" TOTAL_1="94" TOTAL_2="92" VAR="0.00981802326286662" WEIGHT="33.31468693814341"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7408162874866677" CI_START="0.3715963486500309" DF="0" EFFECT_SIZE="0.5246757355267321" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="58" I2="0.0" ID="CMP-004.02.04" LOG_CI_END="-0.13028947788143516" LOG_CI_START="-0.429928562086722" LOG_EFFECT_SIZE="-0.28010901998407856" MODIFIED="2014-07-25 20:24:12 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="2.478876552179976E-4" STUDIES="1" TAU2="0.0" TOTAL_1="109" TOTAL_2="107" WEIGHT="29.245510949708407" Z="3.6644324445837264">
<NAME>Discharge after 96h of resolution of fever</NAME>
<DICH_DATA CI_END="0.7408162874866677" CI_START="0.3715963486500309" EFFECT_SIZE="0.5246757355267321" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="58" LOG_CI_END="-0.13028947788143516" LOG_CI_START="-0.429928562086722" LOG_EFFECT_SIZE="-0.28010901998407856" MODIFIED="2014-07-25 20:24:12 +0100" MODIFIED_BY="[Empty name]" ORDER="269" O_E="0.0" SE="0.17600948129957372" STUDY_ID="STD-Maher-1994" TOTAL_1="109" TOTAL_2="107" VAR="0.030979337507344988" WEIGHT="29.245510949708407"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="286.04840028779023" CI_END="-0.49521669142614233" CI_START="-2.2920696326562675" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="SMD" EFFECT_SIZE="-1.3936431620412049" ESTIMABLE="YES" I2="97.20327049829635" I2_Q="14.224079999018345" ID="CMP-004.03" MODIFIED="2014-10-10 20:40:14 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="-6.661338147750939E-16" P_Q="0.32108857086016884" P_Z="0.0023633875387271573" Q="3.4974850750253297" RANDOM="YES" SCALE="15.404019975367234" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="1.8231859915448883" TOTALS="YES" TOTAL_1="527" TOTAL_2="489" UNITS="" WEIGHT="100.00000000000001" Z="3.040304904452896">
<NAME>Duration of grade IV neutropenia</NAME>
<GROUP_LABEL_1>CSF plus ATB</GROUP_LABEL_1>
<GROUP_LABEL_2>ATB alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors CSF plus ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ATB alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.04207115863029898" CI_START="-1.0100926580195093" DF="0" EFFECT_SIZE="-0.5260819083249041" ESTIMABLE="YES" I2="0.0" ID="CMP-004.03.01" MODIFIED="2014-07-14 21:36:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.03314455353429892" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="34" WEIGHT="11.151900369648148" Z="2.1303278778116104">
<NAME>Discharge after 24 hours of resolution of fever</NAME>
<CONT_DATA CI_END="-0.04207115863029898" CI_START="-1.0100926580195093" EFFECT_SIZE="-0.5260819083249041" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="4.2" MODIFIED="2014-07-14 21:36:35 +0100" MODIFIED_BY="[Empty name]" ORDER="385" SD_1="1.75" SD_2="2.0" SE="0.24694879779037784" STUDY_ID="STD-Ravaud-1998" TOTAL_1="34" TOTAL_2="34" WEIGHT="11.151900369648148"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="108.87751101011509" CI_END="-0.07242758582413056" CI_START="-3.6592571748544866" DF="3" EFFECT_SIZE="-1.8658423803393087" ESTIMABLE="YES" I2="97.24461004649409" ID="CMP-004.03.02" MODIFIED="2014-10-10 20:40:14 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.041438281234845005" STUDIES="3" TAU2="3.2531383287415725" TOTAL_1="197" TOTAL_2="157" WEIGHT="43.79804555499237" Z="2.039117708562307">
<NAME>Discharge after 48 hours of resolution of fever</NAME>
<CONT_DATA CI_END="0.6135351786365997" CI_START="-0.8189056257095417" EFFECT_SIZE="-0.10268522353647108" ESTIMABLE="YES" MEAN_1="6.3" MEAN_2="6.7" MODIFIED="2014-10-10 20:40:14 +0100" MODIFIED_BY="[Empty name]" ORDER="379" SD_1="3.2" SD_2="4.3" SE="0.3654252873126883" STUDY_ID="STD-Biesma-1990" TOTAL_1="15" TOTAL_2="15" WEIGHT="10.73840674713794"/>
<CONT_DATA CI_END="-3.7799163925878263" CI_START="-4.785322438261804" EFFECT_SIZE="-4.282619415424815" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="3.0" MODIFIED="2014-07-14 21:36:35 +0100" MODIFIED_BY="[Empty name]" ORDER="380" SD_1="0.01" SD_2="0.333" SE="0.2564858470881332" STUDY_ID="STD-Garcia_x002d_Carbonero-2001" TOTAL_1="104" TOTAL_2="99" WEIGHT="11.123555091619442"/>
<CONT_DATA CI_END="-0.9184367897784403" CI_START="-2.1014068041701104" EFFECT_SIZE="-1.5099217969742753" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="5.75" MODIFIED="2014-07-14 21:36:35 +0100" MODIFIED_BY="[Empty name]" ORDER="383" SD_1="1.25" SD_2="3.75" SE="0.3017836102404907" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="22" WEIGHT="10.976607165699278">
<FOOTNOTE>GM-CSF</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="-0.9261965054835081" CI_START="-2.1284423199057416" EFFECT_SIZE="-1.5273194126946248" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="5.75" MODIFIED="2014-07-14 21:36:35 +0100" MODIFIED_BY="[Empty name]" ORDER="391" SD_1="1.25" SD_2="3.75" SE="0.30670099652478183" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="21" WEIGHT="10.959476550535713">
<FOOTNOTE>G-CSF</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="92.18398180400118" CI_END="0.284991946915927" CI_START="-3.0444761538823117" DF="2" EFFECT_SIZE="-1.3797421034831923" ESTIMABLE="YES" I2="97.83042567606557" ID="CMP-004.03.03" MODIFIED="2014-07-14 21:36:35 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.10428395375704412" STUDIES="3" TAU2="2.1138135904401705" TOTAL_1="187" TOTAL_2="191" WEIGHT="33.64386321651246" Z="1.6244305389994587">
<NAME>Discharge after 72 hours of resolution of fever</NAME>
<CONT_DATA CI_END="-2.492393359241935" CI_START="-3.3212864295189966" EFFECT_SIZE="-2.906839894380466" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="5.0" MODIFIED="2014-07-14 21:36:35 +0100" MODIFIED_BY="[Empty name]" ORDER="384" SD_1="0.5" SD_2="0.833" SE="0.21145619940347488" STUDY_ID="STD-Mitchell-1997" TOTAL_1="94" TOTAL_2="92" WEIGHT="11.249036872331814"/>
<CONT_DATA CI_END="-0.3831713165037638" CI_START="-1.4708786961640392" EFFECT_SIZE="-0.9270250063339015" ESTIMABLE="YES" MEAN_1="4.5" MEAN_2="8.58" MODIFIED="2014-07-14 21:36:35 +0100" MODIFIED_BY="[Empty name]" ORDER="386" SD_1="3.5" SD_2="5.0" SE="0.27748147114946303" STUDY_ID="STD-Riikonen-1994" TOTAL_1="28" TOTAL_2="30" WEIGHT="11.057926681365263"/>
<CONT_DATA CI_END="0.03487441074032699" CI_START="-0.6467558878969464" EFFECT_SIZE="-0.3059407385783097" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="4.0" MODIFIED="2014-07-14 21:36:35 +0100" MODIFIED_BY="[Empty name]" ORDER="388" SD_1="3.25" SD_2="3.25" SE="0.17388847550615374" STUDY_ID="STD-Vellenga-1996" TOTAL_1="65" TOTAL_2="69" WEIGHT="11.33689966281538"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.17062327540468808" CI_START="-0.7106335211190538" DF="0" EFFECT_SIZE="-0.4406283982618709" ESTIMABLE="YES" I2="0.0" ID="CMP-004.03.04" MODIFIED="2014-07-14 21:36:35 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.0013813671556783293" STUDIES="1" TAU2="0.0" TOTAL_1="109" TOTAL_2="107" WEIGHT="11.406190858847031" Z="3.1985163170983295">
<NAME>Discharge after 96 hours of resolution of fever</NAME>
<CONT_DATA CI_END="-0.17062327540468808" CI_START="-0.7106335211190538" EFFECT_SIZE="-0.4406283982618709" ESTIMABLE="YES" MEAN_1="3.3" MEAN_2="4.3" MODIFIED="2014-07-14 21:36:35 +0100" MODIFIED_BY="[Empty name]" ORDER="382" SD_1="2.0" SD_2="2.5" SE="0.13776024712032914" STUDY_ID="STD-Maher-1994" TOTAL_1="109" TOTAL_2="107" WEIGHT="11.406190858847031"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="23.54334097538268" CI_END="0.007597641490140639" CI_START="-0.5465931680829695" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.26949776329641445" ESTIMABLE="YES" I2="70.26760132591495" I2_Q="22.141565266935213" ID="CMP-004.04" MODIFIED="2014-07-25 20:21:06 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.001370122788381667" P_Q="0.2777645131496088" P_Z="0.05662115013779309" Q="3.853147074283482" RANDOM="YES" SCALE="3.86" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.10368426256208235" TOTALS="YES" TOTAL_1="420" TOTAL_2="387" UNITS="" WEIGHT="100.0" Z="1.9062239966842707">
<NAME>Time to recovering from fever</NAME>
<GROUP_LABEL_1>CSF plus ATB</GROUP_LABEL_1>
<GROUP_LABEL_2>ATB alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors CSF plus ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ATB alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4753610900391237" CI_START="-0.4753610900391237" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-004.04.01" MODIFIED="2014-07-14 21:49:16 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="34" WEIGHT="12.299523196311478" Z="0.0">
<NAME>Discharge after 24 hours of resolution of fever</NAME>
<CONT_DATA CI_END="0.4753610900391237" CI_START="-0.4753610900391237" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="2.0" MODIFIED="2014-07-14 21:45:40 +0100" MODIFIED_BY="[Empty name]" ORDER="137" SD_1="2.0" SD_2="2.75" SE="0.24253562503633297" STUDY_ID="STD-Ravaud-1998" TOTAL_1="34" TOTAL_2="34" WEIGHT="12.299523196311478"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.241106523126632" CI_END="-0.022543815449882043" CI_START="-1.4133264901245228" DF="2" EFFECT_SIZE="-0.7179351527872024" ESTIMABLE="YES" I2="72.37991191522451" ID="CMP-004.04.02" MODIFIED="2014-07-14 21:49:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.026767921634692105" P_Z="0.04302122788868541" STUDIES="2" TAU2="0.27092344748955866" TOTAL_1="90" TOTAL_2="55" WEIGHT="28.86992971290661" Z="2.0235038418599234">
<NAME>Discharge after 48 hours of resolution of fever</NAME>
<CONT_DATA CI_END="0.9573715089499887" CI_START="-0.6458332784416482" EFFECT_SIZE="0.15576911525417028" ESTIMABLE="YES" MEAN_1="2.9" MEAN_2="2.4" MODIFIED="2014-07-14 21:48:09 +0100" MODIFIED_BY="[Empty name]" ORDER="132" SD_1="3.6" SD_2="2.5" SE="0.4089883283666209" STUDY_ID="STD-Biesma-1990" TOTAL_1="12" TOTAL_2="12" WEIGHT="7.376734440660917"/>
<CONT_DATA CI_END="-0.4744141771913817" CI_START="-1.5858673409668602" EFFECT_SIZE="-1.030140759079121" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="4.0" MODIFIED="2014-07-14 21:49:16 +0100" MODIFIED_BY="[Empty name]" ORDER="352" SD_1="1.5" SD_2="2.5" SE="0.2835391804498652" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="22" WEIGHT="10.85822551766555">
<FOOTNOTE>GM-CSF</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="-0.541557311039923" CI_START="-1.6794088928093511" EFFECT_SIZE="-1.110483101924637" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="4.0" MODIFIED="2014-07-14 21:49:16 +0100" MODIFIED_BY="[Empty name]" ORDER="135" SD_1="2.75" SD_2="2.5" SE="0.2902735945008827" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="21" WEIGHT="10.634969754580144">
<FOOTNOTE>G-CSF</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.150998548190246" CI_END="0.06677118271804822" CI_START="-0.33736741762716094" DF="2" EFFECT_SIZE="-0.13529811745455636" ESTIMABLE="YES" I2="0.0" ID="CMP-004.04.03" MODIFIED="2014-07-14 21:48:35 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.562424174191632" P_Z="0.18941243147365064" STUDIES="3" TAU2="0.0" TOTAL_1="187" TOTAL_2="191" WEIGHT="42.474598647509836" Z="1.3123192744295558">
<NAME>Discharge after 72 hours of resolution of fever</NAME>
<CONT_DATA CI_END="0.04634806532418545" CI_START="-0.5306797207087747" EFFECT_SIZE="-0.2421658276922946" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="3.0" MODIFIED="2014-07-14 21:48:35 +0100" MODIFIED_BY="[Empty name]" ORDER="136" SD_1="3.0" SD_2="5.0" SE="0.14720367072672805" STUDY_ID="STD-Mitchell-1997" TOTAL_1="94" TOTAL_2="92" WEIGHT="15.945094534828424"/>
<CONT_DATA CI_END="0.4080141339145007" CI_START="-0.6228174197788947" EFFECT_SIZE="-0.10740164293219699" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="2.3" MODIFIED="2014-07-14 21:48:35 +0100" MODIFIED_BY="[Empty name]" ORDER="138" SD_1="1.25" SD_2="2.25" SE="0.2629720652584596" STUDY_ID="STD-Riikonen-1994" TOTAL_1="28" TOTAL_2="30" WEIGHT="11.56436529646505"/>
<CONT_DATA CI_END="0.3387811723135764" CI_START="-0.3387811723135764" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="3.0" MODIFIED="2014-07-14 21:48:35 +0100" MODIFIED_BY="[Empty name]" ORDER="140" SD_1="3.25" SD_2="3.25" SE="0.17285071306709668" STUDY_ID="STD-Vellenga-1996" TOTAL_1="65" TOTAL_2="69" WEIGHT="14.965138816216365"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.26672874944371977" CI_START="-0.26672874944371977" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-004.04.04" MODIFIED="2014-07-14 21:48:23 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="109" TOTAL_2="107" WEIGHT="16.35594844327207" Z="0.0">
<NAME>Discharge after 96 hours of resolution of fever</NAME>
<CONT_DATA CI_END="0.26672874944371977" CI_START="-0.26672874944371977" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="3.0" MODIFIED="2014-07-14 21:48:23 +0100" MODIFIED_BY="[Empty name]" ORDER="134" SD_1="3.0" SD_2="4.667" SE="0.1360885973148701" STUDY_ID="STD-Maher-1994" TOTAL_1="109" TOTAL_2="107" WEIGHT="16.35594844327207"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2014-10-17 17:56:55 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Subgroup analysis - Type of malignancy</NAME>
<DICH_OUTCOME CHI2="22.501324884052927" CI_END="0.9526698015390065" CI_START="0.44480128013234976" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6509598660961993" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="182" I2="68.89072071946741" I2_Q="84.11258512227059" ID="CMP-005.01" LOG_CI_END="-0.021057601165146315" LOG_CI_START="-0.35183397153028045" LOG_EFFECT_SIZE="-0.18644578634771336" METHOD="MH" MODIFIED="2014-10-10 20:36:54 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.00208092009634131" P_Q="0.01211285138463103" P_Z="0.02713911316396967" Q="6.294290214588497" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.1764059714961862" TOTALS="YES" TOTAL_1="565" TOTAL_2="522" WEIGHT="100.0" Z="2.209511071830095">
<NAME>Patients with hospitalisation for greater than10 days</NAME>
<GROUP_LABEL_1>CSF plus ATB</GROUP_LABEL_1>
<GROUP_LABEL_2>ATB alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors CSF plus ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ATB alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="15.167427999124433" CI_END="0.8665254074081732" CI_START="0.39264062054885646" DF="6" EFFECT_SIZE="0.5832950142818776" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="149" I2="60.441546184716614" ID="CMP-005.01.01" LOG_CI_END="-0.06221869880649919" LOG_CI_START="-0.4060047725718471" LOG_EFFECT_SIZE="-0.23411173568917312" MODIFIED="2014-10-10 20:36:54 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.01899375595195596" P_Z="0.007598782096892722" STUDIES="6" TAU2="0.14703275857336323" TOTAL_1="463" TOTAL_2="421" WEIGHT="82.24630531943495" Z="2.66939591405398">
<NAME>Mix</NAME>
<DICH_DATA CI_END="1.091771683962423" CI_START="0.43900198903207566" EFFECT_SIZE="0.6923076923076923" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="26" LOG_CI_END="0.038131826315114824" LOG_CI_START="-0.3575335120501386" LOG_EFFECT_SIZE="-0.1597008428675119" MODIFIED="2014-07-25 19:59:54 +0100" MODIFIED_BY="[Empty name]" ORDER="297" O_E="0.0" SE="0.23241577833076224" STUDY_ID="STD-Anaissie-1996" TOTAL_1="50" TOTAL_2="50" VAR="0.05401709401709401" WEIGHT="16.38393470866592"/>
<DICH_DATA CI_END="1.63988773696822" CI_START="0.6016672931718803" EFFECT_SIZE="0.9933110367892977" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" LOG_CI_END="0.21481411824036745" LOG_CI_START="-0.22064359625480207" LOG_EFFECT_SIZE="-0.0029147390072172936" MODIFIED="2014-07-25 19:59:54 +0100" MODIFIED_BY="[Empty name]" ORDER="299" O_E="0.0" SE="0.25579001704491355" STUDY_ID="STD-Garcia_x002d_Carbonero-2001" TOTAL_1="104" TOTAL_2="99" VAR="0.06542853281983717" WEIGHT="15.610826384835667"/>
<DICH_DATA CI_END="0.8130748301230439" CI_START="0.3944753449233908" EFFECT_SIZE="0.5663373323923783" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="52" LOG_CI_END="-0.08986948292499009" LOG_CI_START="-0.40398013541611133" LOG_EFFECT_SIZE="-0.2469248091705507" MODIFIED="2014-07-25 19:59:54 +0100" MODIFIED_BY="[Empty name]" ORDER="298" O_E="0.0" SE="0.18451015214609112" STUDY_ID="STD-Maher-1994" TOTAL_1="109" TOTAL_2="107" VAR="0.034043996244973694" WEIGHT="17.938878780839413"/>
<DICH_DATA CI_END="0.5839566004470578" CI_START="0.010132875899996046" EFFECT_SIZE="0.07692307692307693" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="-0.23361942837859279" LOG_CI_START="-1.9942672762350806" LOG_EFFECT_SIZE="-1.1139433523068367" MODIFIED="2014-07-25 19:59:54 +0100" MODIFIED_BY="[Empty name]" ORDER="300" O_E="0.0" SE="1.0342132611783073" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="21" VAR="1.0695970695970696" WEIGHT="3.029877404976316"/>
<DICH_DATA CI_END="0.606460826035732" CI_START="0.03279392596006056" EFFECT_SIZE="0.14102564102564102" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="-0.21719724687651348" LOG_CI_START="-1.4842065881879973" LOG_EFFECT_SIZE="-0.8507019175322553" MODIFIED="2014-07-25 19:59:54 +0100" MODIFIED_BY="[Empty name]" ORDER="301" O_E="0.0" SE="0.7442475588837554" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="22" VAR="0.5539044289044289" WEIGHT="5.169358753030641"/>
<DICH_DATA CI_END="1.679725007800233" CI_START="0.5086682046226763" EFFECT_SIZE="0.9243498817966903" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" LOG_CI_END="0.22523818805306842" LOG_CI_START="-0.29356540801141945" LOG_EFFECT_SIZE="-0.03416360997917553" MODIFIED="2014-07-25 19:59:54 +0100" MODIFIED_BY="[Empty name]" ORDER="303" O_E="0.0" SE="0.3047478004474988" STUDY_ID="STD-Mitchell-1997" TOTAL_1="94" TOTAL_2="92" VAR="0.09287122187758853" WEIGHT="14.01988936916745"/>
<DICH_DATA CI_END="0.8535681487055642" CI_START="0.1494327319987213" EFFECT_SIZE="0.35714285714285715" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="15" LOG_CI_END="-0.06876179918281475" LOG_CI_START="-0.8255542635016236" LOG_EFFECT_SIZE="-0.4471580313422192" MODIFIED="2014-10-10 20:36:54 +0100" MODIFIED_BY="[Empty name]" ORDER="302" O_E="0.0" SE="0.4445436397239844" STUDY_ID="STD-Riikonen-1994" TOTAL_1="28" TOTAL_2="30" VAR="0.19761904761904764" WEIGHT="10.093539917919541"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6994623450112403" CI_START="0.8058091452909492" DF="0" EFFECT_SIZE="1.1702317290552584" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="33" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="0.23031154636244197" LOG_CI_START="-0.09376780802376854" LOG_EFFECT_SIZE="0.06827186916933672" MODIFIED="2014-07-25 19:59:54 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.40892442712402577" STUDIES="1" TAU2="0.0" TOTAL_1="102" TOTAL_2="101" WEIGHT="17.753694680565047" Z="0.8257878998960636">
<NAME>Hematological malignancies</NAME>
<DICH_DATA CI_END="1.6994623450112405" CI_START="0.8058091452909492" EFFECT_SIZE="1.1702317290552584" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="33" LOG_CI_END="0.23031154636244203" LOG_CI_START="-0.09376780802376854" LOG_EFFECT_SIZE="0.06827186916933672" MODIFIED="2014-07-25 19:59:54 +0100" MODIFIED_BY="[Empty name]" ORDER="305" O_E="0.0" SE="0.19036581698513677" STUDY_ID="STD-Yoshida-1999" TOTAL_1="102" TOTAL_2="101" VAR="0.03623914427641859" WEIGHT="17.753694680565047"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="16.494664034933447" CI_END="0.8109325012265798" CI_START="0.33556954675676964" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5216552998742914" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="172" I2="69.68716677459642" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-0.09101529321769984" LOG_CI_START="-0.47421745867645393" LOG_EFFECT_SIZE="-0.28261637594707695" METHOD="MH" MODIFIED="2014-07-25 20:31:37 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.005564938113574391" P_Q="0.7479028854208838" P_Z="0.0038402329812531133" Q="0.10330171588444478" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.14227012657533436" TOTALS="YES" TOTAL_1="419" TOTAL_2="375" WEIGHT="100.00000000000001" Z="2.8909957626903013">
<NAME>Time to neutrophil recovery</NAME>
<GROUP_LABEL_1>CSF + ATB</GROUP_LABEL_1>
<GROUP_LABEL_2>ATB alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors CSF plus ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ATB alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="15.65365390948484" CI_END="0.8733422389391586" CI_START="0.25948907979872887" DF="4" EFFECT_SIZE="0.47604912974574787" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="146" I2="74.44686062992407" ID="CMP-005.02.01" LOG_CI_END="-0.058815534809365466" LOG_CI_START="-0.5858809140503753" LOG_EFFECT_SIZE="-0.32234822442987043" MODIFIED="2014-07-25 20:31:37 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0035209306458694467" P_Z="0.01651229092526528" STUDIES="4" TAU2="0.2190455653376772" TOTAL_1="385" TOTAL_2="341" WEIGHT="73.79303094546691" Z="2.397391045766575">
<NAME>Mix</NAME>
<DICH_DATA CI_END="1.0933934015424545" CI_START="0.051797318736123366" EFFECT_SIZE="0.23798076923076922" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.03877644866442071" LOG_CI_START="-1.2856927207228064" LOG_EFFECT_SIZE="-0.6234581360291929" MODIFIED="2014-07-25 20:26:23 +0100" MODIFIED_BY="[Empty name]" ORDER="268" O_E="0.0" SE="0.7779997463261832" STUDY_ID="STD-Garcia_x002d_Carbonero-2001" TOTAL_1="104" TOTAL_2="99" VAR="0.6052836052836054" WEIGHT="6.7777992175379715"/>
<DICH_DATA CI_END="0.7408162874866677" CI_START="0.3715963486500309" EFFECT_SIZE="0.5246757355267321" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="58" LOG_CI_END="-0.13028947788143516" LOG_CI_START="-0.429928562086722" LOG_EFFECT_SIZE="-0.28010901998407856" MODIFIED="2014-07-25 20:26:23 +0100" MODIFIED_BY="[Empty name]" ORDER="269" O_E="0.0" SE="0.17600948129957372" STUDY_ID="STD-Maher-1994" TOTAL_1="109" TOTAL_2="107" VAR="0.030979337507344988" WEIGHT="29.245510949708407"/>
<DICH_DATA CI_END="0.8626033503367427" CI_START="0.002898203443128352" EFFECT_SIZE="0.05" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="-0.06418885939440955" LOG_CI_START="-2.537871131933553" LOG_EFFECT_SIZE="-1.3010299956639813" MODIFIED="2014-07-25 20:26:23 +0100" MODIFIED_BY="[Empty name]" ORDER="271" O_E="0.0" SE="1.4530532118142254" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="21" VAR="2.1113636363636363" WEIGHT="2.2482664140838584"/>
<DICH_DATA CI_END="1.134013013337193" CI_START="0.003599420884461303" EFFECT_SIZE="0.06388888888888888" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.054618038320650084" LOG_CI_START="-2.443767367820039" LOG_EFFECT_SIZE="-1.1945746647496944" MODIFIED="2014-07-25 20:26:23 +0100" MODIFIED_BY="[Empty name]" ORDER="267" O_E="0.0" SE="1.467563954774257" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="22" VAR="2.153743961352657" WEIGHT="2.206767425993258"/>
<DICH_DATA CI_END="0.9708937884569786" CI_START="0.658396501621064" EFFECT_SIZE="0.7995205274198381" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="71" LOG_CI_END="-0.012828277414351085" LOG_CI_START="-0.1815124854062118" LOG_EFFECT_SIZE="-0.0971703814102814" MODIFIED="2014-07-25 20:26:23 +0100" MODIFIED_BY="[Empty name]" ORDER="270" O_E="0.0" SE="0.09908593877471525" STUDY_ID="STD-Mitchell-1997" TOTAL_1="94" TOTAL_2="92" VAR="0.00981802326286662" WEIGHT="33.31468693814341"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8385104838080086" CI_START="0.3457808029848721" DF="0" EFFECT_SIZE="0.5384615384615384" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="26" I2="0.0" ID="CMP-005.02.02" LOG_CI_END="-0.07649150308591675" LOG_CI_START="-0.46119912149924314" LOG_EFFECT_SIZE="-0.26884531229257996" MODIFIED="2014-07-25 20:31:37 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.006155814872758767" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="34" WEIGHT="26.206969054533108" Z="2.739364152335317">
<NAME>Solid tumors</NAME>
<DICH_DATA CI_END="0.8385104838080086" CI_START="0.3457808029848721" EFFECT_SIZE="0.5384615384615384" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="26" LOG_CI_END="-0.07649150308591675" LOG_CI_START="-0.46119912149924314" LOG_EFFECT_SIZE="-0.26884531229257996" MODIFIED="2014-07-25 20:31:37 +0100" MODIFIED_BY="[Empty name]" ORDER="266" O_E="0.0" SE="0.2259791593894118" STUDY_ID="STD-Ravaud-1998" TOTAL_1="34" TOTAL_2="34" VAR="0.051066580478345176" WEIGHT="26.206969054533108"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="373.1754047514254" CI_END="-0.7568572778884832" CI_START="-2.6483944819768244" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="SMD" EFFECT_SIZE="-1.7026258799326537" ESTIMABLE="YES" I2="97.588265495151" I2_Q="97.73232527660268" ID="CMP-005.03" MODIFIED="2014-10-10 20:40:38 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.3322676295501878E-15" P_Q="0.0" P_Z="4.180206437126671E-4" Q="88.1960705988603" RANDOM="YES" SCALE="15.404019975367234" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="2.255026237981974" TOTALS="YES" TOTAL_1="588" TOTAL_2="547" UNITS="" WEIGHT="99.99999999999999" Z="3.5284375021554872">
<NAME>Duration of grade IV neutropenia</NAME>
<GROUP_LABEL_1>CSF plus ATB</GROUP_LABEL_1>
<GROUP_LABEL_2>ATB alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors CSF plus ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ATB alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="277.9269448395703" CI_END="-0.5034034602846315" CI_START="-2.5013344163699407" DF="7" EFFECT_SIZE="-1.502368938327286" ESTIMABLE="YES" I2="97.48135251728087" ID="CMP-005.03.01" MODIFIED="2014-10-10 20:40:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="5.551115123125783E-16" P_Z="0.0032021137250066744" STUDIES="7" TAU2="2.0094083845101482" TOTAL_1="493" TOTAL_2="455" WEIGHT="80.15731009308051" Z="2.947638407267792">
<NAME>Mix</NAME>
<CONT_DATA CI_END="0.6135351786365997" CI_START="-0.8189056257095417" EFFECT_SIZE="-0.10268522353647108" ESTIMABLE="YES" MEAN_1="6.3" MEAN_2="6.7" MODIFIED="2014-10-10 20:40:38 +0100" MODIFIED_BY="[Empty name]" ORDER="379" SD_1="3.2" SD_2="4.3" SE="0.3654252873126883" STUDY_ID="STD-Biesma-1990" TOTAL_1="15" TOTAL_2="15" WEIGHT="9.748484497506663"/>
<CONT_DATA CI_END="-3.7799163925878263" CI_START="-4.785322438261804" EFFECT_SIZE="-4.282619415424815" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="3.0" MODIFIED="2014-07-14 22:33:14 +0100" MODIFIED_BY="[Empty name]" ORDER="380" SD_1="0.01" SD_2="0.333" SE="0.2564858470881332" STUDY_ID="STD-Garcia_x002d_Carbonero-2001" TOTAL_1="104" TOTAL_2="99" WEIGHT="10.03306868152967"/>
<CONT_DATA CI_END="-0.17062327540468808" CI_START="-0.7106335211190538" EFFECT_SIZE="-0.4406283982618709" ESTIMABLE="YES" MEAN_1="3.3" MEAN_2="4.3" MODIFIED="2014-07-14 22:33:14 +0100" MODIFIED_BY="[Empty name]" ORDER="382" SD_1="2.0" SD_2="2.5" SE="0.13776024712032914" STUDY_ID="STD-Maher-1994" TOTAL_1="109" TOTAL_2="107" WEIGHT="10.239584969265687"/>
<CONT_DATA CI_END="-0.9261965054835081" CI_START="-2.1284423199057416" EFFECT_SIZE="-1.5273194126946248" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="5.75" MODIFIED="2014-07-14 22:33:14 +0100" MODIFIED_BY="[Empty name]" ORDER="391" SD_1="1.25" SD_2="3.75" SE="0.30670099652478183" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="21" WEIGHT="9.91228143869218">
<FOOTNOTE>G-CSF</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="-0.9184367897784403" CI_START="-2.1014068041701104" EFFECT_SIZE="-1.5099217969742753" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="5.75" MODIFIED="2014-07-14 22:33:14 +0100" MODIFIED_BY="[Empty name]" ORDER="383" SD_1="1.25" SD_2="3.75" SE="0.3017836102404907" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="22" WEIGHT="9.92492330238288">
<FOOTNOTE>GM-CSF</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="-2.492393359241935" CI_START="-3.3212864295189966" EFFECT_SIZE="-2.906839894380466" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="5.0" MODIFIED="2014-07-14 22:33:14 +0100" MODIFIED_BY="[Empty name]" ORDER="384" SD_1="0.5" SD_2="0.833" SE="0.21145619940347488" STUDY_ID="STD-Mitchell-1997" TOTAL_1="94" TOTAL_2="92" WEIGHT="10.1249962287054"/>
<CONT_DATA CI_END="-0.3831713165037638" CI_START="-1.4708786961640392" EFFECT_SIZE="-0.9270250063339015" ESTIMABLE="YES" MEAN_1="4.5" MEAN_2="8.58" MODIFIED="2014-07-14 22:33:14 +0100" MODIFIED_BY="[Empty name]" ORDER="386" SD_1="3.5" SD_2="5.0" SE="0.27748147114946303" STUDY_ID="STD-Riikonen-1994" TOTAL_1="28" TOTAL_2="30" WEIGHT="9.984835648951378"/>
<CONT_DATA CI_END="0.03487441074032699" CI_START="-0.6467558878969464" EFFECT_SIZE="-0.3059407385783097" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="4.0" MODIFIED="2014-07-14 22:33:14 +0100" MODIFIED_BY="[Empty name]" ORDER="388" SD_1="3.25" SD_2="3.25" SE="0.17388847550615374" STUDY_ID="STD-Vellenga-1996" TOTAL_1="65" TOTAL_2="69" WEIGHT="10.189135326046653"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-3.8630621429187046" CI_START="-5.2417012038127035" DF="0" EFFECT_SIZE="-4.552381673365704" ESTIMABLE="YES" I2="0.0" ID="CMP-005.03.02" MODIFIED="2014-07-14 22:34:40 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="2.542795970074239E-38" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="58" WEIGHT="9.788821840496999" Z="12.943930542474307">
<NAME>Hematological malignancies</NAME>
<CONT_DATA CI_END="-3.8630621429187046" CI_START="-5.2417012038127035" EFFECT_SIZE="-4.552381673365704" ESTIMABLE="YES" MEAN_1="7.5" MEAN_2="14.8" MODIFIED="2014-07-14 22:34:40 +0100" MODIFIED_BY="[Empty name]" ORDER="378" SD_1="2.0" SD_2="1.0" SE="0.35170010055504286" STUDY_ID="STD-Aviles-1996" TOTAL_1="61" TOTAL_2="58" WEIGHT="9.788821840496999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.04207115863029898" CI_START="-1.0100926580195093" DF="0" EFFECT_SIZE="-0.5260819083249041" ESTIMABLE="YES" I2="0.0" ID="CMP-005.03.03" MODIFIED="2014-07-14 22:34:43 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.03314455353429892" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="34" WEIGHT="10.053868066422476" Z="2.1303278778116104">
<NAME>Solid tumors</NAME>
<CONT_DATA CI_END="-0.04207115863029898" CI_START="-1.0100926580195093" EFFECT_SIZE="-0.5260819083249041" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="4.2" MODIFIED="2014-07-14 22:34:43 +0100" MODIFIED_BY="[Empty name]" ORDER="385" SD_1="1.75" SD_2="2.0" SE="0.24694879779037784" STUDY_ID="STD-Ravaud-1998" TOTAL_1="34" TOTAL_2="34" WEIGHT="10.053868066422476"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="78.7171868207032" CI_END="-0.0857905777666757" CI_START="-0.8973135166356314" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.49155204720115353" ESTIMABLE="YES" I2="88.56666458304767" I2_Q="52.949830119058035" ID="CMP-005.04" MODIFIED="2014-07-25 20:26:29 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="2.9054536554440347E-13" P_Q="0.11938635956451182" P_Z="0.017579341924318176" Q="4.25078167636992" RANDOM="YES" SCALE="3.86" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.3638736341310851" TOTALS="YES" TOTAL_1="502" TOTAL_2="464" UNITS="" WEIGHT="99.99999999999999" Z="2.3743612482080856">
<NAME>Time to recovering from fever</NAME>
<GROUP_LABEL_1>CSF plus ATB</GROUP_LABEL_1>
<GROUP_LABEL_2>ATB alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors CSF plus ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ATB alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="22.84658280001353" CI_END="3.2679317631217897E-4" CI_START="-0.6219709203233132" DF="6" EFFECT_SIZE="-0.31082206357350056" ESTIMABLE="YES" I2="73.73786682883514" ID="CMP-005.04.01" MODIFIED="2014-07-14 22:37:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="8.495257778022847E-4" P_Z="0.05024110534181823" STUDIES="6" TAU2="0.11968080530809039" TOTAL_1="386" TOTAL_2="353" WEIGHT="70.38767178459167" Z="1.9579054751093727">
<NAME>Mix</NAME>
<CONT_DATA CI_END="0.9573715089499887" CI_START="-0.6458332784416482" EFFECT_SIZE="0.15576911525417028" ESTIMABLE="YES" MEAN_1="2.9" MEAN_2="2.4" MODIFIED="2014-07-14 22:36:16 +0100" MODIFIED_BY="[Empty name]" ORDER="132" SD_1="3.6" SD_2="2.5" SE="0.4089883283666209" STUDY_ID="STD-Biesma-1990" TOTAL_1="12" TOTAL_2="12" WEIGHT="8.06923305013816"/>
<CONT_DATA CI_END="0.26672874944371977" CI_START="-0.26672874944371977" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="3.0" MODIFIED="2014-07-14 22:36:16 +0100" MODIFIED_BY="[Empty name]" ORDER="134" SD_1="3.0" SD_2="4.667" SE="0.1360885973148701" STUDY_ID="STD-Maher-1994" TOTAL_1="109" TOTAL_2="107" WEIGHT="11.208168534227527"/>
<CONT_DATA CI_END="-0.541557311039923" CI_START="-1.6794088928093511" EFFECT_SIZE="-1.110483101924637" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="4.0" MODIFIED="2014-07-14 22:36:16 +0100" MODIFIED_BY="[Empty name]" ORDER="135" SD_1="2.75" SD_2="2.5" SE="0.2902735945008827" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="21" WEIGHT="9.563989456551166">
<FOOTNOTE>G-CSF</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="-0.4744141771913817" CI_START="-1.5858673409668602" EFFECT_SIZE="-1.030140759079121" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="4.0" MODIFIED="2014-07-14 22:36:16 +0100" MODIFIED_BY="[Empty name]" ORDER="352" SD_1="1.5" SD_2="2.5" SE="0.2835391804498652" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="22" WEIGHT="9.64717808893595">
<FOOTNOTE>GM-CSF</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="0.04634806532418545" CI_START="-0.5306797207087747" EFFECT_SIZE="-0.2421658276922946" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="3.0" MODIFIED="2014-07-14 22:36:16 +0100" MODIFIED_BY="[Empty name]" ORDER="136" SD_1="3.0" SD_2="5.0" SE="0.14720367072672805" STUDY_ID="STD-Mitchell-1997" TOTAL_1="94" TOTAL_2="92" WEIGHT="11.116628854499949"/>
<CONT_DATA CI_END="0.4080141339145007" CI_START="-0.6228174197788947" EFFECT_SIZE="-0.10740164293219699" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="2.3" MODIFIED="2014-07-14 22:36:16 +0100" MODIFIED_BY="[Empty name]" ORDER="138" SD_1="1.25" SD_2="2.25" SE="0.2629720652584596" STUDY_ID="STD-Riikonen-1994" TOTAL_1="28" TOTAL_2="30" WEIGHT="9.897591081888455"/>
<CONT_DATA CI_END="0.3387811723135764" CI_START="-0.3387811723135764" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="3.0" MODIFIED="2014-07-14 22:36:16 +0100" MODIFIED_BY="[Empty name]" ORDER="140" SD_1="3.25" SD_2="3.25" SE="0.17285071306709668" STUDY_ID="STD-Vellenga-1996" TOTAL_1="65" TOTAL_2="69" WEIGHT="10.884882718350477"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.657685332469095" CI_END="-0.12043399064076499" CI_START="-2.5271070325758753" DF="1" EFFECT_SIZE="-1.32377051160832" ESTIMABLE="YES" I2="89.64555205958094" ID="CMP-005.04.02" MODIFIED="2014-07-14 22:37:06 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0018856320356165357" P_Z="0.03107399861668039" STUDIES="2" TAU2="0.6768004240353385" TOTAL_1="82" TOTAL_2="77" WEIGHT="19.472838625563494" Z="2.156123811867939">
<NAME>Hematological malignancies</NAME>
<CONT_DATA CI_END="-1.4785229543463472" CI_START="-2.351260966229865" EFFECT_SIZE="-1.914891960288106" ESTIMABLE="YES" MEAN_1="6.1" MEAN_2="11.4" MODIFIED="2014-07-14 22:36:57 +0100" MODIFIED_BY="[Empty name]" ORDER="131" SD_1="2.75" SD_2="2.75" SE="0.22264133901631958" STUDY_ID="STD-Aviles-1996" TOTAL_1="61" TOTAL_2="58" WEIGHT="10.36644848987569"/>
<CONT_DATA CI_END="-0.04563846942141192" CI_START="-1.326546961042164" EFFECT_SIZE="-0.6860927152317879" ESTIMABLE="YES" MEAN_1="5.5" MEAN_2="7.6" MODIFIED="2014-07-14 22:37:06 +0100" MODIFIED_BY="[Empty name]" ORDER="517" SD_1="3.0" SD_2="3.0" SE="0.326768374756984" STUDY_ID="STD-Lopez_x002d_Hernandez-2000" TOTAL_1="21" TOTAL_2="19" WEIGHT="9.106390135687803"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4753610900391237" CI_START="-0.4753610900391237" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-005.04.03" MODIFIED="2014-07-14 22:37:00 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="34" WEIGHT="10.139489589844814" Z="0.0">
<NAME>Solid tumors</NAME>
<CONT_DATA CI_END="0.4753610900391237" CI_START="-0.4753610900391237" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="2.0" MODIFIED="2014-07-14 22:37:00 +0100" MODIFIED_BY="[Empty name]" ORDER="137" SD_1="2.0" SD_2="2.75" SE="0.24253562503633297" STUDY_ID="STD-Ravaud-1998" TOTAL_1="34" TOTAL_2="34" WEIGHT="10.139489589844814"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="9.955338139059913" CI_END="1.1608448029154315" CI_START="0.46920748862943223" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_SIZE="0.7380224079690791" ESTIMABLE="YES" I2="0.0" I2_Q="64.09925041116603" ID="CMP-005.05" LOG_CI_END="0.06477416138992682" LOG_CI_START="-0.3286350650891471" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.1319304518496101" MODIFIED="2014-10-17 17:56:55 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.5344091140711396" P_Q="0.06170092161730978" P_Z="0.18865967102027023" Q="5.570914320468812" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="688" TOTAL_2="647" WEIGHT="100.0" Z="1.314554497887893">
<NAME>Overall mortality</NAME>
<GROUP_LABEL_1>CSF plus ATB</GROUP_LABEL_1>
<GROUP_LABEL_2>ATB alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors CSF plus ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ATB alone</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="4.301764719448483" CI_END="1.7452126968302322" CI_START="0.6029702871893998" DF="8" EFFECT_SIZE="1.0258223047947008" ESTIMABLE="YES" I2="0.0" ID="CMP-005.05.01" LOG_CI_END="0.24184836392012807" LOG_CI_START="-0.21970408823732926" LOG_EFFECT_SIZE="0.0110721378413994" MODIFIED="2014-10-17 17:55:50 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8289227752055986" P_Z="0.9250815295466981" STUDIES="10" TAU2="0.0" TOTAL_1="572" TOTAL_2="536" WEIGHT="72.6518967046816" Z="0.09403477892736951">
<NAME>Mix</NAME>
<IV_DATA CI_END="5.188111442339334" CI_START="0.192748365395385" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.7150092963004789" LOG_CI_START="-0.715009296300479" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-17 17:54:00 +0100" MODIFIED_BY="[Empty name]" ORDER="564" SE="0.84" STUDY_ID="STD-Anaissie-1996" TOTAL_1="50" TOTAL_2="50" WEIGHT="7.568428527215798"/>
<IV_DATA CI_END="403.3997351921896" CI_START="0.1588288662842363" EFFECT_SIZE="8.004468914296353" ESTIMABLE="YES" ESTIMATE="2.08" LOG_CI_END="2.6057356087884753" LOG_CI_START="-0.799070564070948" LOG_EFFECT_SIZE="0.9033325223587638" MODIFIED="2014-10-17 17:54:00 +0100" MODIFIED_BY="[Empty name]" ORDER="566" SE="2.0" STUDY_ID="STD-Arnberg-1998" TOTAL_1="14" TOTAL_2="15" WEIGHT="1.3350707922008667"/>
<IV_DATA CI_END="436.99771623720187" CI_START="0.17205725681918843" EFFECT_SIZE="8.671137658463456" ESTIMABLE="YES" ESTIMATE="2.16" LOG_CI_END="2.6404791673407355" LOG_CI_START="-0.7643270055186878" LOG_EFFECT_SIZE="0.938076080911024" MODIFIED="2014-10-17 17:54:26 +0100" MODIFIED_BY="[Empty name]" ORDER="565" SE="2.0" STUDY_ID="STD-Biesma-1990" TOTAL_1="12" TOTAL_2="14" WEIGHT="1.3350707922008667"/>
<IV_DATA CI_END="3.400684007112884" CI_START="0.2660751237525739" EFFECT_SIZE="0.951229424500714" ESTIMABLE="YES" ESTIMATE="-0.05" LOG_CI_END="0.5315662789944938" LOG_CI_START="-0.574995727184819" LOG_EFFECT_SIZE="-0.021714724095162587" MODIFIED="2014-10-17 17:54:26 +0100" MODIFIED_BY="[Empty name]" ORDER="568" SE="0.65" STUDY_ID="STD-Garcia_x002d_Carbonero-2001" TOTAL_1="104" TOTAL_2="99" WEIGHT="12.639723476457908"/>
<IV_DATA CI_END="1.7050343099339382" CI_START="0.3417809536023755" EFFECT_SIZE="0.7633794943368531" ESTIMABLE="YES" ESTIMATE="-0.27" LOG_CI_END="0.23173312260421292" LOG_CI_START="-0.4662521428319689" LOG_EFFECT_SIZE="-0.11725951011387802" MODIFIED="2014-10-17 17:54:42 +0100" MODIFIED_BY="[Empty name]" ORDER="567" SE="0.41" STUDY_ID="STD-Maher-1994" TOTAL_1="109" TOTAL_2="107" WEIGHT="31.76848999883086"/>
<IV_DATA CI_END="7.382875997309072" CI_START="0.13544857049806638" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.8682255740791531" LOG_CI_START="-0.8682255740791531" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-17 17:54:42 +0100" MODIFIED_BY="[Empty name]" ORDER="559" SE="1.02" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="21" WEIGHT="5.132913464824555"/>
<IV_DATA CI_END="11.779606186931472" CI_START="0.4376351323148584" EFFECT_SIZE="2.2704998375324057" ESTIMABLE="YES" ESTIMATE="0.82" LOG_CI_END="1.0711307714611453" LOG_CI_START="-0.35888782113981255" LOG_EFFECT_SIZE="0.3561214751606665" MODIFIED="2014-10-17 17:54:42 +0100" MODIFIED_BY="[Empty name]" ORDER="558" SE="0.84" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="22" WEIGHT="7.568428527215798"/>
<IV_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-17 17:53:28 +0100" MODIFIED_BY="[Empty name]" ORDER="561" SE="0.0" STUDY_ID="STD-Mitchell-1997" TOTAL_1="94" TOTAL_2="92" WEIGHT="0.0"/>
<IV_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-17 17:53:28 +0100" MODIFIED_BY="[Empty name]" ORDER="560" SE="0.0" STUDY_ID="STD-Riikonen-1994" TOTAL_1="28" TOTAL_2="30" WEIGHT="0.0"/>
<IV_DATA CI_END="174.15191083097233" CI_START="0.06856809299921493" EFFECT_SIZE="3.4556134647626755" ESTIMABLE="YES" ESTIMATE="1.24" LOG_CI_END="2.240928243989744" LOG_CI_START="-1.1638779288696797" LOG_EFFECT_SIZE="0.5385251575600323" MODIFIED="2014-10-17 17:54:56 +0100" MODIFIED_BY="[Empty name]" ORDER="563" SE="2.0" STUDY_ID="STD-Rodriguez-2005" TOTAL_1="18" TOTAL_2="17" WEIGHT="1.3350707922008667"/>
<IV_DATA CI_END="5.225540419472196" CI_START="0.055378811512145895" EFFECT_SIZE="0.5379444375946745" ESTIMABLE="YES" ESTIMATE="-0.62" LOG_CI_END="0.7181312113492166" LOG_CI_START="-1.2566563689092491" LOG_EFFECT_SIZE="-0.26926257878001614" MODIFIED="2014-10-17 17:54:56 +0100" MODIFIED_BY="[Empty name]" ORDER="562" SE="1.16" STUDY_ID="STD-Vellenga-1996" TOTAL_1="65" TOTAL_2="69" WEIGHT="3.968700333534087"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.08265909914261563" CI_END="0.7801130613946217" CI_START="0.13207234026576392" DF="1" EFFECT_SIZE="0.3209849804745968" ESTIMABLE="YES" I2="0.0" ID="CMP-005.05.02" LOG_CI_END="-0.10784245066661086" LOG_CI_START="-0.8791881265772943" LOG_EFFECT_SIZE="-0.49351528862195254" MODIFIED="2014-10-17 17:55:50 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7737257194482554" P_Z="0.012141246735883902" STUDIES="2" TAU2="0.0" TOTAL_1="82" TOTAL_2="77" WEIGHT="26.01303250311753" Z="2.508012222605421">
<NAME>Hematological malignancies</NAME>
<IV_DATA CI_END="0.7948374524378763" CI_START="0.11643962828686279" EFFECT_SIZE="0.3042212640667041" ESTIMABLE="YES" ESTIMATE="-1.19" LOG_CI_END="-0.09972167728959028" LOG_CI_START="-0.933899189640149" LOG_EFFECT_SIZE="-0.5168104334648697" MODIFIED="2014-10-17 17:55:06 +0100" MODIFIED_BY="[Empty name]" ORDER="557" SE="0.49" STUDY_ID="STD-Aviles-1996" TOTAL_1="61" TOTAL_2="58" WEIGHT="22.241912406511734"/>
<IV_DATA CI_END="4.537413525202088" CI_START="0.04275123728826379" EFFECT_SIZE="0.4404316545059993" ESTIMABLE="YES" ESTIMATE="-0.82" LOG_CI_END="0.6568083612650121" LOG_CI_START="-1.369051311586345" LOG_EFFECT_SIZE="-0.35612147516066645" MODIFIED="2014-10-17 17:55:14 +0100" MODIFIED_BY="[Empty name]" ORDER="556" SE="1.19" STUDY_ID="STD-Lopez_x002d_Hernandez-2000" TOTAL_1="21" TOTAL_2="19" WEIGHT="3.771120096605795"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="6.820467167072353" CI_START="0.0026853936013588454" DF="0" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" I2="0.0" ID="CMP-005.05.03" LOG_CI_END="0.8338141226232082" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" MODIFIED="2014-10-17 17:55:50 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.31731052126128756" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="34" WEIGHT="1.3350707922008667" Z="1.0">
<NAME>Solid tumors</NAME>
<IV_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.8338141226232082" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" MODIFIED="2014-10-17 17:55:24 +0100" MODIFIED_BY="[Empty name]" ORDER="555" SE="2.0" STUDY_ID="STD-Ravaud-1998" TOTAL_1="34" TOTAL_2="34" WEIGHT="1.3350707922008667"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2014-10-10 20:38:06 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Sensitivity analysis - Patients hospitalized for more than 10 days by allocation concealment and blinding</NAME>
<DICH_OUTCOME CHI2="22.501324884052927" CI_END="0.9526698015390064" CI_START="0.44480128013234976" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6509598660961993" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="182" I2="68.89072071946741" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="-0.021057601165146364" LOG_CI_START="-0.35183397153028045" LOG_EFFECT_SIZE="-0.18644578634771336" METHOD="MH" MODIFIED="2014-10-10 20:37:44 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.00208092009634131" P_Q="0.5359032684915932" P_Z="0.02713911316396967" Q="0.3831862280661935" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.17640597149618617" TOTALS="YES" TOTAL_1="565" TOTAL_2="522" WEIGHT="100.0" Z="2.209511071830095">
<NAME>Adequacy of allocation concealment</NAME>
<GROUP_LABEL_1>CSF plus ATB</GROUP_LABEL_1>
<GROUP_LABEL_2>ATB alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors CSF plus ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ATB alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="13.217415354089779" CI_END="1.0032644849159555" CI_START="0.3188577354990073" DF="4" EFFECT_SIZE="0.5655958289864588" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="108" I2="69.736897170578" ID="CMP-006.01.01" LOG_CI_END="0.0014154387010750344" LOG_CI_START="-0.4964030425507022" LOG_EFFECT_SIZE="-0.24749380192481363" MODIFIED="2014-07-25 20:01:11 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.010260940912781624" P_Z="0.051317101145673366" STUDIES="4" TAU2="0.2474391172775812" TOTAL_1="385" TOTAL_2="341" WEIGHT="55.76883069284949" Z="1.948818520958809">
<NAME>Adequate allocation concealment</NAME>
<DICH_DATA CI_END="1.63988773696822" CI_START="0.6016672931718803" EFFECT_SIZE="0.9933110367892977" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" LOG_CI_END="0.21481411824036745" LOG_CI_START="-0.22064359625480207" LOG_EFFECT_SIZE="-0.0029147390072172936" MODIFIED="2014-07-25 20:01:11 +0100" MODIFIED_BY="[Empty name]" ORDER="310" O_E="0.0" SE="0.25579001704491355" STUDY_ID="STD-Garcia_x002d_Carbonero-2001" TOTAL_1="104" TOTAL_2="99" VAR="0.06542853281983717" WEIGHT="15.61082638483567"/>
<DICH_DATA CI_END="0.8130748301230439" CI_START="0.3944753449233908" EFFECT_SIZE="0.5663373323923783" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="52" LOG_CI_END="-0.08986948292499009" LOG_CI_START="-0.40398013541611133" LOG_EFFECT_SIZE="-0.2469248091705507" MODIFIED="2014-07-25 20:01:11 +0100" MODIFIED_BY="[Empty name]" ORDER="313" O_E="0.0" SE="0.18451015214609112" STUDY_ID="STD-Maher-1994" TOTAL_1="109" TOTAL_2="107" VAR="0.034043996244973694" WEIGHT="17.938878780839413"/>
<DICH_DATA CI_END="0.606460826035732" CI_START="0.03279392596006056" EFFECT_SIZE="0.14102564102564102" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="-0.21719724687651348" LOG_CI_START="-1.4842065881879973" LOG_EFFECT_SIZE="-0.8507019175322553" MODIFIED="2014-07-25 20:01:11 +0100" MODIFIED_BY="[Empty name]" ORDER="311" O_E="0.0" SE="0.7442475588837554" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="22" VAR="0.5539044289044289" WEIGHT="5.169358753030641"/>
<DICH_DATA CI_END="0.5839566004470578" CI_START="0.010132875899996046" EFFECT_SIZE="0.07692307692307693" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="-0.23361942837859279" LOG_CI_START="-1.9942672762350806" LOG_EFFECT_SIZE="-1.1139433523068367" MODIFIED="2014-07-25 20:01:11 +0100" MODIFIED_BY="[Empty name]" ORDER="314" O_E="0.0" SE="1.0342132611783073" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="21" VAR="1.0695970695970696" WEIGHT="3.029877404976317"/>
<DICH_DATA CI_END="1.679725007800233" CI_START="0.5086682046226763" EFFECT_SIZE="0.9243498817966903" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" LOG_CI_END="0.22523818805306842" LOG_CI_START="-0.29356540801141945" LOG_EFFECT_SIZE="-0.03416360997917553" MODIFIED="2014-07-25 20:01:11 +0100" MODIFIED_BY="[Empty name]" ORDER="312" O_E="0.0" SE="0.3047478004474988" STUDY_ID="STD-Mitchell-1997" TOTAL_1="94" TOTAL_2="92" VAR="0.09287122187758853" WEIGHT="14.019889369167451"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.422573469777796" CI_END="1.3137108904737635" CI_START="0.4083485762202835" DF="2" EFFECT_SIZE="0.7324288168075053" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="74" I2="73.05516734669825" ID="CMP-006.01.02" LOG_CI_END="0.11849980016531358" LOG_CI_START="-0.38896895431755624" LOG_EFFECT_SIZE="-0.13523457707612133" MODIFIED="2014-10-10 20:37:44 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.02444613186902367" P_Z="0.2962006602259277" STUDIES="3" TAU2="0.18642412452585086" TOTAL_1="180" TOTAL_2="181" WEIGHT="44.23116930715051" Z="1.0446156465487415">
<NAME>Inadequate allocation concealment</NAME>
<DICH_DATA CI_END="1.091771683962423" CI_START="0.43900198903207566" EFFECT_SIZE="0.6923076923076923" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="26" LOG_CI_END="0.038131826315114824" LOG_CI_START="-0.3575335120501386" LOG_EFFECT_SIZE="-0.1597008428675119" MODIFIED="2014-07-25 20:01:11 +0100" MODIFIED_BY="[Empty name]" ORDER="308" O_E="0.0" SE="0.23241577833076224" STUDY_ID="STD-Anaissie-1996" TOTAL_1="50" TOTAL_2="50" VAR="0.05401709401709401" WEIGHT="16.38393470866592"/>
<DICH_DATA CI_END="0.8535681487055642" CI_START="0.1494327319987213" EFFECT_SIZE="0.35714285714285715" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="15" LOG_CI_END="-0.06876179918281475" LOG_CI_START="-0.8255542635016236" LOG_EFFECT_SIZE="-0.4471580313422192" MODIFIED="2014-10-10 20:37:44 +0100" MODIFIED_BY="[Empty name]" ORDER="306" O_E="0.0" SE="0.4445436397239844" STUDY_ID="STD-Riikonen-1994" TOTAL_1="28" TOTAL_2="30" VAR="0.19761904761904764" WEIGHT="10.093539917919543"/>
<DICH_DATA CI_END="1.6994623450112405" CI_START="0.8058091452909492" EFFECT_SIZE="1.1702317290552584" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="33" LOG_CI_END="0.23031154636244203" LOG_CI_START="-0.09376780802376854" LOG_EFFECT_SIZE="0.06827186916933672" MODIFIED="2014-07-25 20:01:11 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.19036581698513677" STUDY_ID="STD-Yoshida-1999" TOTAL_1="102" TOTAL_2="101" VAR="0.03623914427641859" WEIGHT="17.75369468056505"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="22.50132488405293" CI_END="0.9526698015390064" CI_START="0.4448012801323497" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6509598660961992" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="182" I2="68.89072071946742" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="-0.021057601165146364" LOG_CI_START="-0.3518339715302805" LOG_EFFECT_SIZE="-0.18644578634771344" METHOD="MH" MODIFIED="2014-10-10 20:38:06 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.002080920096340977" P_Q="0.8573991365418459" P_Z="0.02713911316396967" Q="0.032287055746048184" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.17640597149618625" TOTALS="YES" TOTAL_1="565" TOTAL_2="522" WEIGHT="100.0" Z="2.209511071830095">
<NAME>Blinding</NAME>
<GROUP_LABEL_1>CSF plus ATB</GROUP_LABEL_1>
<GROUP_LABEL_2>ATB alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors CSF plus ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ATB alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.4694094679392604" CI_END="0.9342852256556312" CI_START="0.3923021332932446" DF="2" EFFECT_SIZE="0.6054106764247428" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="85" I2="42.3533019529128" ID="CMP-006.02.01" LOG_CI_END="-0.02952051882543755" LOG_CI_START="-0.40637933022130435" LOG_EFFECT_SIZE="-0.21794992452337092" MODIFIED="2014-10-10 20:38:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1764526080959644" P_Z="0.023388753974667015" STUDIES="3" TAU2="0.06393762873224523" TOTAL_1="231" TOTAL_2="229" WEIGHT="42.05230806792641" Z="2.2670240927460252">
<NAME>Blinded studies</NAME>
<DICH_DATA CI_END="0.8130748301230439" CI_START="0.3944753449233908" EFFECT_SIZE="0.5663373323923783" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="52" LOG_CI_END="-0.08986948292499009" LOG_CI_START="-0.40398013541611133" LOG_EFFECT_SIZE="-0.2469248091705507" MODIFIED="2014-07-25 20:02:01 +0100" MODIFIED_BY="[Empty name]" ORDER="323" O_E="0.0" SE="0.18451015214609112" STUDY_ID="STD-Maher-1994" TOTAL_1="109" TOTAL_2="107" VAR="0.034043996244973694" WEIGHT="17.938878780839413"/>
<DICH_DATA CI_END="1.679725007800233" CI_START="0.5086682046226763" EFFECT_SIZE="0.9243498817966903" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" LOG_CI_END="0.22523818805306842" LOG_CI_START="-0.29356540801141945" LOG_EFFECT_SIZE="-0.03416360997917553" MODIFIED="2014-07-25 20:02:01 +0100" MODIFIED_BY="[Empty name]" ORDER="321" O_E="0.0" SE="0.3047478004474988" STUDY_ID="STD-Mitchell-1997" TOTAL_1="94" TOTAL_2="92" VAR="0.09287122187758853" WEIGHT="14.019889369167453"/>
<DICH_DATA CI_END="0.8535681487055642" CI_START="0.1494327319987213" EFFECT_SIZE="0.35714285714285715" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="15" LOG_CI_END="-0.06876179918281475" LOG_CI_START="-0.8255542635016236" LOG_EFFECT_SIZE="-0.4471580313422192" MODIFIED="2014-10-10 20:38:06 +0100" MODIFIED_BY="[Empty name]" ORDER="320" O_E="0.0" SE="0.4445436397239844" STUDY_ID="STD-Riikonen-1994" TOTAL_1="28" TOTAL_2="30" VAR="0.19761904761904764" WEIGHT="10.093539917919543"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="15.56476425730445" CI_END="1.1571986862002748" CI_START="0.36179007488232806" DF="4" EFFECT_SIZE="0.6470417292061843" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="97" I2="74.3009278272697" ID="CMP-006.02.02" LOG_CI_END="0.06340793190966904" LOG_CI_START="-0.44154335147001744" LOG_EFFECT_SIZE="-0.18906770978017418" MODIFIED="2014-07-25 20:02:01 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0036624245604937045" P_Z="0.14217776322879735" STUDIES="4" TAU2="0.26765972038764796" TOTAL_1="334" TOTAL_2="293" WEIGHT="57.947691932073596" Z="1.467729319661811">
<NAME>Non-Blinded studies</NAME>
<DICH_DATA CI_END="1.091771683962423" CI_START="0.43900198903207566" EFFECT_SIZE="0.6923076923076923" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="26" LOG_CI_END="0.038131826315114824" LOG_CI_START="-0.3575335120501386" LOG_EFFECT_SIZE="-0.1597008428675119" MODIFIED="2014-07-25 20:02:01 +0100" MODIFIED_BY="[Empty name]" ORDER="315" O_E="0.0" SE="0.23241577833076224" STUDY_ID="STD-Anaissie-1996" TOTAL_1="50" TOTAL_2="50" VAR="0.05401709401709401" WEIGHT="16.38393470866592"/>
<DICH_DATA CI_END="1.63988773696822" CI_START="0.6016672931718803" EFFECT_SIZE="0.9933110367892977" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" LOG_CI_END="0.21481411824036745" LOG_CI_START="-0.22064359625480207" LOG_EFFECT_SIZE="-0.0029147390072172936" MODIFIED="2014-07-25 20:02:01 +0100" MODIFIED_BY="[Empty name]" ORDER="316" O_E="0.0" SE="0.25579001704491355" STUDY_ID="STD-Garcia_x002d_Carbonero-2001" TOTAL_1="104" TOTAL_2="99" VAR="0.06542853281983717" WEIGHT="15.610826384835667"/>
<DICH_DATA CI_END="0.5839566004470578" CI_START="0.010132875899996046" EFFECT_SIZE="0.07692307692307693" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="-0.23361942837859279" LOG_CI_START="-1.9942672762350806" LOG_EFFECT_SIZE="-1.1139433523068367" MODIFIED="2014-07-25 20:02:01 +0100" MODIFIED_BY="[Empty name]" ORDER="318" O_E="0.0" SE="1.0342132611783073" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="21" VAR="1.0695970695970696" WEIGHT="3.029877404976317"/>
<DICH_DATA CI_END="0.606460826035732" CI_START="0.03279392596006056" EFFECT_SIZE="0.14102564102564102" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="-0.21719724687651348" LOG_CI_START="-1.4842065881879973" LOG_EFFECT_SIZE="-0.8507019175322553" MODIFIED="2014-07-25 20:02:01 +0100" MODIFIED_BY="[Empty name]" ORDER="317" O_E="0.0" SE="0.7442475588837554" STUDY_ID="STD-Mayordomo-1995" TOTAL_1="39" TOTAL_2="22" VAR="0.5539044289044289" WEIGHT="5.169358753030642"/>
<DICH_DATA CI_END="1.6994623450112405" CI_START="0.8058091452909492" EFFECT_SIZE="1.1702317290552584" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="33" LOG_CI_END="0.23031154636244203" LOG_CI_START="-0.09376780802376854" LOG_EFFECT_SIZE="0.06827186916933672" MODIFIED="2014-07-25 20:02:01 +0100" MODIFIED_BY="[Empty name]" ORDER="319" O_E="0.0" SE="0.19036581698513677" STUDY_ID="STD-Yoshida-1999" TOTAL_1="102" TOTAL_2="101" VAR="0.03623914427641859" WEIGHT="17.753694680565047"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-10-17 18:07:24 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-10-17 18:07:24 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAoIAAAONCAYAAAAS0QF0AACAAElEQVR42uydD2RX3//HvyRJksh8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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-07-18 17:07:12 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAW0AAAL5CAIAAAD0fOK9AAAwDElEQVR42u2dv04kSfa2U0JCGG1g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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2016-07-26 16:12:26 +0100" MODIFIED_BY="Clare Jess">
<APPENDIX ID="APP-01" MODIFIED="2014-05-12 11:36:05 +0100" MODIFIED_BY="Clare Jess" NO="1">
<TITLE MODIFIED="2014-05-05 16:13:29 +0100" MODIFIED_BY="[Empty name]">Search strategy CENTRAL</TITLE>
<APPENDIX_BODY MODIFIED="2014-05-05 16:19:36 +0100" MODIFIED_BY="[Empty name]">
<P>"CSF" AND febrile neutropenia</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-05-12 11:36:05 +0100" MODIFIED_BY="Clare Jess" NO="2">
<TITLE MODIFIED="2014-05-05 16:13:38 +0100" MODIFIED_BY="[Empty name]">Search strategy MEDLINE</TITLE>
<APPENDIX_BODY MODIFIED="2012-11-28 20:29:02 +0000" MODIFIED_BY="[Empty name]">
<P>To the methodological search strategy of each database we add the specific terms pertinent to this review (see below).<BR/>Search strategy:<BR/>#1 (Methodological search strategy)<BR/># 2 explode COLONY-STIMULATING-FACTORS / all subheadings<BR/>#3 CSF<BR/>#4 #2 OR #3<BR/>#5 explode FEVER / all subheadings<BR/>#6 FEVER* OR FEBR*<BR/>#7 #5 OR #6<BR/>#8 #4 AND #7<BR/>#9 #1 AND #8</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2014-05-05 20:38:44 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2014-05-05 16:13:58 +0100" MODIFIED_BY="[Empty name]">Search strategy EMBASE</TITLE>
<APPENDIX_BODY MODIFIED="2014-05-05 20:38:44 +0100" MODIFIED_BY="[Empty name]">
<P>COLONY STIMULATING FACTORS AND febrile neutropenia</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2014-05-05 20:38:51 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2014-05-05 16:21:37 +0100" MODIFIED_BY="[Empty name]">Search strategy CANCERLIT</TITLE>
<APPENDIX_BODY MODIFIED="2014-05-05 20:38:51 +0100" MODIFIED_BY="[Empty name]">
<P>COLONY STIMULATING FACTORS AND febrile neutropenia</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2014-06-09 20:38:33 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2014-06-09 20:36:51 +0100" MODIFIED_BY="[Empty name]">Search strategy LILACS</TITLE>
<APPENDIX_BODY MODIFIED="2014-06-09 20:38:33 +0100" MODIFIED_BY="[Empty name]">
<P>tw:(tw:( (tw:(colony stimulating factors)) AND neutropenia) AND (instance:"regional")) AND (instance:"regional")</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2014-06-09 20:45:21 +0100" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2014-06-09 20:37:27 +0100" MODIFIED_BY="[Empty name]">Search strategy SCI</TITLE>
<APPENDIX_BODY MODIFIED="2014-06-09 20:45:21 +0100" MODIFIED_BY="[Empty name]">
<P>COLONY STIMULATING FACTORS AND febrile neutropenia (Limits: content type: Journal)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2016-07-26 16:12:26 +0100" MODIFIED_BY="Clare Jess" NO="7">
<TITLE MODIFIED="2016-07-26 16:12:26 +0100" MODIFIED_BY="Clare Jess">Economic evaluation search filter</TITLE>
<APPENDIX_BODY MODIFIED="2016-07-26 16:12:16 +0100" MODIFIED_BY="Clare Jess">
<P>1. Economics/<BR/>2. exp "costs and cost analysis"/<BR/>3. Economics, Dental/<BR/>4. exp economics, hospital/<BR/>5. Economics, Medical/<BR/>6. Economics, Nursing/<BR/>7. Economics, Pharmaceutical/<BR/>8. (economic$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$ or cost-effectiveness).ti,ab.<BR/>9. (expenditure$ not energy).ti,ab.<BR/>10. value for money.ti,ab.<BR/>11. budget$.ti,ab.<BR/>12. (fiscal or funding or financial or finance).tw.<BR/>13. (unit adj cost$).mp.<BR/>14. Ec.fs.<BR/>15. or/1-14<BR/>16. ((energy or oxygen) adj cost).ti,ab.<BR/>17. (metabolic adj cost).ti,ab.<BR/>18. ((energy or oxygen) adj expenditure).ti,ab.<BR/>19. or/16-18<BR/>20. 15 not 19<BR/>21. letter.pt.<BR/>22. editorial.pt.<BR/>23. historical article.pt.<BR/>24. or/21-23<BR/>25. 20 not 24<BR/>26. exp animals/ not humans/<BR/>27. 25 not 26</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;Number of studies included in quantitative synthesis (meta-analysis): [N=14 (13 studies from old search and 1 study from new search)]&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;Number of studies included in qualitative synthesis: [N=14 (13 studies from old search and 1 study from new search)]&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;Number of full-text articles assessed for eligibility: (N = 12)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;# of records screened: (N = 1007)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;# of records after duplicates removed: (N = 1007)&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;Records identified through database searching (N = 1007)&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;Number of additional records identified through other sources: (N = 0)&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;Number of records excluded: (N = 995)&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;Number of full-text articles excluded: (N = 11) Non G-CSF/GM-CSF&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
<FLOWCHARTBOX TEXT="&lt;p&gt;We had 13 included studies in our previous review.&lt;/p&gt;"/>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>